

CORPORATE OFFICE :
1st floor, 137 Hubtown Solaris,
N.S. Phadke Road, Opp. Teli Gali,
Near Andheri East West Flyover Bridge,
Andheri East, Mumbai - 400069 (INDIA).
CIN No. L24232MP1989PLC005390
Tel. : 91-22-6863 4200 / 6863 4206
Fax : (91) 022-2206 3929
E-mail : poltd@panchsheelorganics.in
Website : <http://www.panchsheelorganics.com>



**Panchsheel
Organics
Limited**
MFGRS. OF: BULK DRUGS
& FORMULATIONS

September 08, 2026

BSE Limited,
P. J. Tower, Dalal Street,
Fort, Mumbai - 400 001.

Dear Sirs,

Scrip Code: 531726

Sub: Annual Report for the financial year 2025-26

Enclosed is the Annual Report of the Company for the financial year ended March 31, 2026 including the Notice convening the 37th Annual General Meeting of the Members to be held on Wednesday, September 30, 2026.



Kindly take the same on record.

Thanking you,

**For and on behalf of the Board of Director
Panchsheel Organics Limited**


**Kishor A. Turakhia
Managing Director
DIN: 00006236**

Encl.: as above.



PANCHSHEEL ORGANICS LIMITED

ANNUAL REPORT 2025-26



CONTENTS

<u>About Panchsheel</u>	3
-------------------------	---

<u>Board of Directors & Company Info</u>	5
--	---

Statutory Section

<u>Notice</u>	6
---------------	---

<u>Board's Report</u>	35
-----------------------	----

<u>Corporate Governance Report</u>	51
------------------------------------	----

<u>Management Discussion & Analysis</u>	73
---	----

Financial Statements


<u>Independent Auditors' Report</u>	83
-------------------------------------	----

<u>Balance Sheet</u>	100
----------------------	-----

<u>Statement of Profit & Loss</u>	102
---------------------------------------	-----

<u>Cash Flow Statement</u>	104
----------------------------	-----

<u>Notes forming part of Financial Statements</u>	106-137
---	---------



ABOUT PANCHSHEEL

Panchsheel Organics Limited ('the Company'), an **ISO 9001 : 2008 CERTIFIED, GMP approved** public listed company is manufacturer and exporter of Active Pharma Ingredients (APIs), Intermediates & Finished Formulations (both Human & Veterinary), having a wide experience of more than three decades in the healthcare field.

The company was promoted in 1990 by the Turakhia Bros Group, having 40 years of rich experience, expertise and a proven track-record in the field of Pharma Export-Import trading, dealing in a wide range of globally sourced, as well as indigenously manufactured, best-in-their-class life-saving medicines covering APIs, Intermediates, Specialty Chemicals, Hormones, Steroids etc.

Panchsheel is a technology based and market driven company backed by a strong R & D setup aims at innovative production and thus creating a niche market for our products. It complies with all the norms applicable as per Schedule 'M', GMP & WHO standards.

Corporate Mission

Panchsheel's motto: "To manufacture and market Active Pharmaceutical Ingredients of International Standards."


Manufacturing Facilities

The multipurpose manufacturing unit of the Company is situated at **Madhya Pradesh**, in the central province of India at Indore, in B6/ B7, Sector 'C', Sanwer Road Industrial Estate, **Indore** – 452015. It is very well equipped with most modern production facilities and latest equipments capable of undertaking large orders and complex reactions very comfortably with plenty of available land, of which 6,100sq.mts is constructed covering 4 manufacturing blocks. The Company has sufficient Government permission and has maintained all types of licenses for safety and pollution. The Company has also maintained an approved effluent treatment plant.

The Company has two other manufacturing units in the name of **Suneeta Chemicals** and **Paramount Organics**, both located in **Indore**. Every unit has a built-in testing facility which is well-equipped with most modern equipments and testing apparatus like HPLC, GC, IR, UV etc to ensure complete compliance to the set quality standards. They offer a wide range of products under different categories like Cardiovascular, Neuropsychiatry, Anti-fungal, Fluoroquinolones, Antiallergic, Anti-Inflammatory, Gastrointestinal, Osteoporosis, Erectile Dysfunction and many more.

The formulation division of Panchsheel is under the name of **Gene Biotech Pvt Ltd** ("**Gene**"), situated in Poanta Sahib, Himachal Pradesh. This unit is also GMP approved.

Gene has all the facilities to offer customized manufacturing under private label and packaging as per client's need.



Our Promoters

1. Mahendra Turakhia

Mr. Mahendra Turakhia, Chairman and Managing Director of the Company, has established Panchsheel Group. He has completed B.Sc. and is a first generation entrepreneur. He has vast and varied experience in the pharmaceutical industry and over the years, has made a wide network of contacts all over India and abroad. His background and experience makes him a qualified expert in all core areas of the company's operations. Unfortunately, Mr. Mahendra Turakhia is no more with us, On 1st August , 2026 we got the sad news of his demise.


2. Kishor Turakhia

Mr. Kishor Turakhia, an Executive Director of the Company has completed B. Com and has rich experience of more than 40 years in the pharmaceutical industry as well as in finance. He oversees business development and contributes in evolving new growth strategies.

3. Rajesh Turakhia

Mr. Rajesh Turakhia, an Executive Director of the Company, has completed B. Com and has rich experience in the pharmaceutical industry as well as finance.

For more details, please visit our Website: <https://panchsheelorganics.com/>



Board of Directors

Mr. Mahendra A. Turakhia
(Chairman & Managing Director)

Mr. Kishor A. Turakhia
(Executive Director)

Mr. Rajesh Abhechand Turakhia
(Executive Director)

Mr. Basant Shrivastav
(Non-Executive Independent Director)

Mr. Nilesh Bharavi
(Non-Executive Independent Director)

Mrs. Sehal Riddesh Shah
(Non-Executive, Women, Independent
Director)

Chief Financial Officer

Mr. Deepak R. Shah

Company Secretary

Mrs. Sonia Verma

Statutory Auditors

M/S. Jayesh R. Shah & Co.,
Chartered Accountants

Registered Office

B6 & B7, Sector – C, Industrial Area,
Sanwer Road, Indore – 452015, MP.

Corporate Office

137,138, Hubtown Solaris,
Prof. N S Phadke Marg,
Opposite Teli Gali,
Andheri (East), Mumbai – 400 069.

Bankers

Yes Bank
Andhra Pradesh Financial Corporation
ICICI Bank Limited

ISIN: INE316G01019

Secretarial Auditors

M/S. Vijaykumar Tiwari & Ass.,
Practicing Company Secretaries

Plant-I


B6 & B7, Sector – C, Industrial Area,
Sanwer Road, Indore – 452015, MP.

Plant-II

**Plot No 87-88, Sector - 3, Industrial Area,
Pithampur, Dhar 454774**

Share Transfer Agents

Purva Shareregistry (India) Pvt. Ltd.,
Unit No. 9, Shiv Shakti Industrial Estate,
J. R. Boricha Marg, Lower Parel (East),
Mumbai - 400 011.



NOTICE OF THE 37TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the 37th Annual General Meeting of the Members of Panchsheel Organics Limited will be held on Wednesday, September 30, 2026 at 03:00 P.M. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM) to transact the following businesses:-

ORDINARY BUSINESS:

- 1. To consider and adopt the audited Financial Statements of the Company for the financial year ended March 31, 2026, together with the Report of the Board of Directors and the Auditors thereon;**

“RESOLVED THAT the audited financial statements of the Company including the Balance Sheet as at 31st March 2026, Statement of Profit and Loss, cash flow statement for the year ended on that date and noted thereon, Report of the Board of Directors and Auditors thereon be and are hereby received, considered and adopted.”


- 2. To declare final dividend on Equity Shares for the financial year ended March 31, 2026.**

“RESOLVED THAT the Board of Directors of the company has recommended a dividend of Rs.0.80 i.e. 8% per share on their meeting held on 30.05.2026, the shareholders hereby declares the same.”

- 3. To appoint a director in place of Mr. Rajesh Abhaychand Turakhia (DIN: 00006246), who retires by rotation and, being eligible, offered himself for re-appointment.**

To consider and, if thought fit, to pass with or without modification(s), the following Resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013 and rules made thereunder (including any statutory modification and re-enactment thereof) and other applicable provisions, if any of the Companies Act, 2013, Mr Rajesh Abhaychand Turakhia (DIN: 00006246), who is liable to retire by rotation and being eligible, has offered himself for appointment, be and is hereby re-appointed as a Director in the category of executive director of the Company.”



4. To appoint M/s. Harshal Doshi And Associates, Chartered Accountants, (FRN No. 145606W) as Statutory Auditor of the company for a term of five years.

“RESOLVED THAT pursuant to the provisions of Section 139 and other applicable provisions, if any, of the Companies Act, 2013, and the Rules framed there under, as amended from time to time, **M/s. Harshal Doshi And Associates, Chartered Accountants, (FRN No. 145606W)** be and is hereby appointed as Auditor of the Company to hold office from the conclusion of this Annual General Meeting (AGM) till the conclusion of the 42nd AGM of the Company to be held in the year 2031, at such remuneration as may be agreed upon between the Board of Directors and Statutory Auditor.

SPECIAL BUSINESS:-


5. Regularization of Appointment of Additional Non-Executive Director, Mrs. Chandan Mahendra Turakhia (DIN: 11500086) as Director of the company.

“RESOLVED THAT pursuant to the provisions of section 152, 161 and any other applicable provisions of the Companies Act, 2013, and any rules made there under, **Mrs. Chandan Mahendra Turakhia (DIN: 11500086)**, who was appointed as an Additional Director of the Company by the Board of Directors in the Board Meeting held on August 14, 2026 to hold office up to the date of this Annual General meeting be and is hereby elected and appointed as Director of the Company”.

“RESOLVED FURTHER THAT the Board be and is hereby authorized to delegate all or any of the powers to any committee of directors with power to further delegate to any other Officer(s) / Authorized Representative(s) of the Company to do all acts, deeds and things and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

6. Approval Of Material Related Party Transactions for 2026-2027

“RESOLVED THAT pursuant to the provisions of Section 188 and other applicable provisions, if any, of the Companies Act, 2013 (“Act”), read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended from time to time, Regulation 23 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, and the Company’s Policy on Related Party Transactions, and subject to such other approvals, consents, permissions and sanctions as may be necessary, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (“Board”), which term shall include any Committee thereof, to enter into and/or continue with contracts, arrangements and/or transactions with such related parties of the Company, as defined under Section 2(76) of the Act and Regulation 2(1)(zb) of the Listing Regulations, as may be identified by the Board from



time to time, in the ordinary course of business and on an arm's length basis, for the financial year 2026-27, up to the maximum aggregate value as may be specified against each such related party in the explanatory statement to this resolution, on such terms and conditions as the Board may deem fit and appropriate in the interest of the Company.

RESOLVED FURTHER THAT the aforesaid approval shall include, inter alia, transactions relating to purchase or sale of goods or materials, rendering or availing of services, lease or other arrangements, and such other transactions as may fall within the scope of related party transactions under Section 188 of the Act and/or Regulation 2(1)(zc) of the Listing Regulations, as applicable, provided that such transactions shall be undertaken in accordance with the applicable provisions of the Act, the Listing Regulations, the Company's Policy on Related Party Transactions and other applicable laws.

RESOLVED FURTHER THAT in respect of any loan, advance, guarantee, security or other financial transaction with a related party, the Company shall comply separately with the applicable provisions of Sections 185 and 186 and other applicable provisions of the Act, as well as the Listing Regulations and other applicable laws, and the approval accorded pursuant to this resolution shall not be construed as dispensing with any specific approval required under such provisions.


RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to finalise and execute the necessary agreements, contracts, deeds, documents and other writings and to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect to this resolution, including determining the terms and conditions of the transactions, within the approved limits.

RESOLVED FURTHER THAT the Board be and is hereby authorised to delegate all or any of the powers conferred upon it by this resolution to any Committee of Directors, Director(s), Key Managerial Personnel or other officer(s) of the Company, as it may deem appropriate, and to do all such acts, deeds and things as may be necessary or incidental for giving effect to the aforesaid resolution."

7. Appointment of existing whole-time director Mr. Kishor Abhaychand Turakhia (DIN:00006236) as Managing Director of the company for term of Five years.

"**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 203 and other applicable provisions, if any, of the Companies Act, 2013, read with Schedule V to the said Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), approval of the members of the Company be and is hereby accorded to the re-designation and appointment of **Mr. Kishor Abhaychand Turakhia (DIN:00006236)**, who is currently serving as a Whole-time Director, as the **Managing Director** of the Company, for a period of Five (5) years with effect from 30th September 2026, date of AGM, on the terms and conditions including remuneration as set out in the Explanatory Statement annexed to the Notice and as recommended by the Nomination and Remuneration Committee and approved by the Board of Directors, with liberty to the Board of Directors to alter and vary the terms and conditions of the said appointment and/or remuneration in such manner as may be agreed to between the Board and **Mr. Kishor Abhaychand Turakhia (DIN:00006236)**.

RESOLVED FURTHER THAT where in any financial year during the tenure of the Managing Director, the Company has no profits or its profits are inadequate, the Company



shall pay to **Mr. Kishor Abhaychand Turakhia (DIN:00006236)** the remuneration by way of salary, perquisites, and other allowances as approved by the Board/Committee and specified in the Explanatory Statement, as minimum remuneration, subject to the limits and conditions prescribed under Schedule V of the Companies Act, 2013, or any statutory modifications thereof.

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) be and is hereby authorized to do all such acts, deeds, matters, and things as may be considered necessary, desirable, or expedient to give effect to this resolution."

**For and on behalf of the Board`
Panchsheel Organics Limited
Sd/-**

**Sonia Verma
Company Secretary
Membership No: A63984
September 08, 2026**

Corporate Office:


**Unit No. 137, Hubtown Solaris,
N S Phadke Marg,
Opposite Teli Galli,
Andheri (East), Mumbai – 400069.**

Registered Office:


**B-6 & B-7 Sector-C, Industrial Area, Sanwer Road,
Indore – 452015, Madhya Pradesh.**

CIN: L24232MP1989PLC005390

☎ 0731-2721709 ☎ 91-22063929 ✉ www.panchsheelorganics.com

**NOTES:**

1. Pursuant to the General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 (“SEBI Circular”) and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold EGM/AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, EGM/AGM shall be conducted through VC / OAVM.
2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this EGM/AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the EGM/AGM through VC/OAVM and participate there at and cast their votes through e-voting.
3. The Members can join the EGM/AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM/AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM/AGM without restriction on account of first come first served basis.
4. The attendance of the Members attending the EGM/AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secretarial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the EGM/AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the EGM/AGM will be provided by NSDL.



6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the EGM/AGM has been uploaded on the website of the Company at 08th September 2026. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the EGM/AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.
7. EGM/AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time.

8. QUORUM

The Members attending the AGM through VC/OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013

9. BOOK CLOSURE

The Register of Members and Share Transfer Books of the Company will remain closed from September 24, 2026 to September 30, 2026 (both days inclusive).

10. DIVIDEND:

The dividend, as recommended by the Board, if approved at the AGM, will be paid subject to deduction of tax at source, as may be applicable, to those Members:


- a. whose names appear as Beneficial Owners as on **June 12, 2026** in the list of Beneficial Owners to be furnished by National Securities Depository Limited and Central Depository Services (India) Limited in respect of the equity shares held in electronic form; and
- b. whose names appear as Members in the Register of Members of the Company as on **June 12, 2026** in respect of the equity shares held in physical form, after giving effect to valid request(s) received for transmission/ transposition of equity shares.

Pursuant to the Finance Act, 2020, dividend income will be taxable in the hands of Members w.e.f. April 1, 2020 and the Company is required to deduct tax at source from dividend paid to Members at the prescribed rates.

11. UNCLAIMED DIVIDEND

Members are requested to note that dividend which has remained unpaid or unclaimed for 7 consecutive years or more from the date of transfer to the Company's Unpaid Dividend Account will be transferred to the Investor Education and Protection Fund (IEPF) as per Section 124 of the Act.

Accordingly, pursuant to the provisions of the Act and the Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 (IEPF Rules), the



Company has transferred a sum of Rs. 1,97,850.00 to the IEPF for the year 2017-18 (on completion of seven years). Also company has transferred dividend to IEPF on account of shares lying in IEPF for following Corporate actions-March 2025 (Final dividend 2024-25)-Rs.1,25,638, June 2025(interim dividend)-Rs.1,28,198, September 2025(interim dividend)-Rs.1,22,118, December 2025(interim dividend)-Rs.1,25,638 September 2025 and December 2025.

Members are further requested to note that the unpaid or unclaimed dividends and/or the equity shares transferred to the IEPF can be claimed by them by making an on-line/electronic application in Form IEPF-5. Upon submitting duly completed form, applicants are requested to take a print of the same and send the physical copy, duly signed, along with the requisite documents specified in Form IEPF-5, to the Company/ the RTA of the Company, Purva Sharegistry (India) Private Limited (Unit no. 9, Shiv Shakti Industrial Estate, J. R. Boricha Marg, Opposite Kasturba Hospital Lane, Lower Parel (East), Mumbai - 400 011, email: support@purvashare.com. The Rules and the application form (Form IEPF-5), as prescribed by the Ministry of Corporate Affairs (MCA) for claiming the shares/ dividends are available on the website of MCA /IEPF authority – www.iepf.gov.in.

In view of the above, Members who have not claimed /encased the Dividend Warrants for Interim Dividends for quarter viz. June 2025, September 2025. December 2025 or final dividend of March 2025 yet and /or any subsequent years are requested to claim their unpaid dividends within stipulated timeline by writing to the Company /RTA giving the necessary details.

12. GENERAL GUIDANCE TO SHAREHOLDERS

- **NOMINATION FACILITY**


As per the provisions of Section 72 of the Act, the facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. The Members are requested to submit the said form to their Depository Participant (DP) in case the shares are held in electronic form and to Purva Sharegistry (India) Private Limited, the Registrar & Transfer Agent (RTA) of the Company, in case the shares are held in physical form.

- **MODE OF HOLDING SHARES**

As per Regulation 40 of the Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with holding physical shares, the Members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agent of the Company for any support in this regard.

- **UPDATION OF PERSONAL DETAILS**

- Pursuant to SEBI circular dated April 20, 2018, shareholders whose ledger folios having incomplete details with regard to PAN and Bank particulars are required



to compulsorily furnish the same to the Registrar and Transfer Agent (RTA)/ to the Company for registration in the folio.


- Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their

13. DISPATCH OF ANNUAL REPORT IN ELECTRONIC FORM AND PROCESS FOR REGISTRATION OF EMAIL ID FOR OBTAINING COPY OF ANNUAL REPORT BY E-MAIL:

- a. In accordance with the MCA and the SEBI Circulars and owing to the difficulties involved in dispatching of physical copies of the Annual Report for the financial year 2025-26 (including the Financial Statements, Board's Report, Auditor's report or other documents required to be attached thereto), the Annual Report (2025-26) and the Notice of the AGM are being sent in electronic mode to Members and other persons entitled to receive the Notice, whose e-mail address is registered with the Company or the Depository Participant(s).
- b. The Members holding Equity Shares of the Company in Demat Form or Physical Form and who have not yet registered their e-mail address are requested to follow the procedure stated in point no. 14 given below for the purpose of registration.
- c. A copy of the Annual Report 2025-26 along with the Notice of the AGM and Explanatory Statement is available on the website of the Company at www.panchsheelorganics.com, BSE Limited (BSE) at www.bseindia.com and National Securities Depository Limited (NSDL) at www.evoting.nsdl.com.

14. PROCEDURE FOR REGISTRATION OF EMAIL IDS WITH THE DEPOSITORIES FOR PROCURING USER ID AND PASSWORD AND FOR E-VOTING ON THE RESOLUTIONS SET OUT IN THIS NOTICE:

- a. **In case** the shares are held in physical mode, shareholders are requested to provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), self-attested scanned copy of PAN and Aadhar Card by e-mail to the Company at compliance@panchsheelorganics.com.
- b. **In case** the shares are held in demat mode, please provide DPID & CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, self-attested scanned copy of client master or copy of Consolidated Account Statement, PAN Aadhar to the respective Depository Participants.
- c. **If you** are an individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 17(g) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.



- d. **Alternatively**, shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

15. PROCEDURE TO RAISE QUESTIONS / SEEK CLARIFICATIONS WITH RESPECT TO ANNUAL REPORT

- a. **As the AGM is** being conducted through VC /OAVM, the Members are encouraged to express their views /send their queries in advance mentioning their name, demat account number (DP ID & Client ID) /Folio Number, e-mail ID, mobile number at compliance@panchsheelorganics.com.
- b. **Members desirous of** getting any information in respect of the contents of the Annual Report are requested to forward the same to the Company Secretary at least 10 days prior to the AGM so that the required information can be made available. The same will be replied by/on behalf of the Company suitably.
- c. **In order to enable the smooth conduct of AGM**, the Members who would like to express their views during the AGM may register themselves as a Speaker by sending an email to compliance@panchsheelorganics.com, along with your name and DP ID/Client ID on or before Wednesday, September 23, 2026 before 6.00 P.M.

The Company reserves the right to restrict the number of questions and number of speakers, as appropriate for smooth conduct of the AGM.

16. PROCEDURE FOR JOINING THE AGM THROUGH VC/ OAVM:

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-


The remote e-voting period begins on 27th September, 2026 at 09:00 A.M. and ends on 29th September, 2026 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. 23rd September 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 23rd September 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:

Step 1: Access to NSDL e-Voting system

Type of shareholders	Login Method
----------------------	--------------



Individual Shareholders holding securities in demat mode with NSDL.


For OTP based login you can click on <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Existing IDeAS user can visit the e-Services website of NSDL Viz. <https://eservices.nsdl.com> either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

If you are not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com>. Select “Register Online for IDeAS Portal” or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>

Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

	Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on  App Store  Google Play  
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.



Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
--	--

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode


In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911




B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the ‘initial password’ which was communicated to you. Once you retrieve your ‘initial password’, you need to enter the ‘initial password’ and the system will force




- you to change your password.
- c) How to retrieve your 'initial password'?
- (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
- (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
- a) Click on "**Forgot User Details/Password?**" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
- b) **Physical User Reset Password?** (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
- c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
- d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.




7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to viju2209@gmail.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to Mr. Shubham Manethiya at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to compliance@panchsheelorganics.com.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to compliance@panchsheelorganics.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.




Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:


1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of “VC/OAVM” placed under “**Join meeting**” menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at compliance@panchsheelorganics.com. The same will be replied by the company suitably.



6. Registration of Speaker – Any shareholder interested in becoming speaker at the event has to apply to the company on registered mail id compliance@panchsheelorganics.com along with the following details on or before 23rd September, 2026, after such date registration could not be done.(Name, DP-id, Folio no., PAN, Mobile number, number of shares held, questions/queries to be asked in AGM.)

1. GENERAL INFORMATION FOR SHAREHOLDERS

- i. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the —Forget User Details/Password? or —Physical User Reset Password? option available on www.evoting.nsdl.com to reset the password.
- ii. The Statutory Registers under the Act and documents, if any, referred to in the Notice and Explanatory Statement pursuant to Section 102 of the Act will be available electronically for inspection by the Members during the AGM. Documents, if any, referred to in the Notice will also be available for electronic inspection by the Members from the date of circulation of this Notice up to the date of AGM. Members seeking to inspect such documents can send an email to compliance@panchsheelorganics.com.
- iii. The Board of Directors of the Company has appointed CS Vijay S. Tiwari, Proprietor of M/s. Vijay Tiwari & Associates, Practicing Company Secretaries, as the Scrutinizer to scrutinize the voting and remote e-voting process in a fair and transparent manner. The Scrutinizer's decision on the e-voting shall be final.
- iv. The Scrutinizer shall, after the conclusion of voting at the AGM, count the votes cast at the meeting, and the votes cast through remote e-voting and make, within two working days from the conclusion of the AGM, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- v. The results declared along with the report of the Scrutinizer shall be placed on the website of the Company www.panchsheelorganics.com and on the website of NSDL e-voting viz. www.evoting.nsdl.com after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be forwarded to BSE.
- vi. In case of any queries regarding the Annual Report, the Members may write to compliance@panchsheelorganics.com to receive an email response.



2. PROCEDURE FOR REGISTRATION OF E-MAIL ADDRESS AND BANK DETAILS BY SHAREHOLDERS:-

i. For Temporary Registration of e-mail id for shareholders holding shares in Demat form and Registration of email id for shareholders holding shares in physical form:

The Members of the Company holding Equity Shares of the Company in physical form and Members holding shares in Demat Form who have not registered their e-mail addresses may temporarily get their e-mail addresses registered with Purva Shareregistry (India) Pvt. Ltd. by clicking the link: <http://www.purvashare.com/email-and-phone-updation/> and follow the registration process as guided therein. The members are requested to provide details such as Name, DP ID, Client ID/ PAN, mobile number and e-mail id. In case of any query, members may send an e-mail to the RTA of the Company at support@purvashare.com.

On submission of the shareholders details, an OTP will be received, which needs to be entered in the link for verification.

ii. For Permanent Registration of e-mail id for shareholders holding shares in demat form:


It is clarified that for permanent registration of e-mail address, the Members are requested to register their e-mail addresses, in respect of demat holdings with their respective Depository Participants (DP) by following the procedure prescribed by their Depository Participants.

iii. Registration of Bank Details for shareholders holding shares in physical form:

The Members of the Company holding Equity Shares of the Company in physical Form and who have not registered their bank details can get the same registered with Purva Shareregistry (India) Pvt. Ltd. by sending an E-mail at support@purvashare.com. The members are requested to provide details such as Name, Folio Number, Certificate number, PAN, e – mail id on a covering letter requesting them to update the bank details. The covering letter should be signed by the shareholder(s) and the same should be accompanied with self-attested PAN card and address proof, along with a copy of the cheque leaf with the first named shareholder's name printed on the face of the cheque leaf containing bank name and branch, type of account, bank account number, MICR details and IFSC code in PDF or JPEG format. In case of any query, members may send an e-mail to the RTA at support@purvashare.com.

iv. Registration of Bank Details for Demat shareholders:

It is clarified that for registration of bank details, the Members are requested to register their bank details, in respect of demat holdings with their respective Depository Participants (DP) by following the procedure prescribed by the Depository Participants.

**ANNEXURE TO THE NOTICE****EXPLANATORY STATEMENT PURSUANT TO THE PROVISIONS OF SECTION 102 OF THE COMPANIES ACT, 2013.**

The relevant details, pursuant to Regulations 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (—SEBI Listing Regulations) and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Directors seeking appointment/re-appointment at this Annual General Meeting (—AGM) are as follow-

Item No. 3

Mr. Rajesh Abhaychand Turakhia (DIN: 00006246), joined the Company's Board in December 08, 2021.


In terms of section 152 of the Companies Act 2013 and the Articles of Association of the Company, Mr. Rajesh Abhaychand Turakhia (DIN: 00006246), is due to retire by rotation at this meeting.

However, he has offered himself for re-election, as he is not disqualified, being eligible for reappointment offered himself for being re-appointed; and, the Board has resolved, subject to approval of shareholders, that the vacancy in the Board shall be filled by his re-appointment.

The Board recommends the resolution for approval by the shareholders. None of the Directors has any concern or interest in this resolution.

In pursuance of Regulations and Secretarial Standards in respect of appointment/Re-appointment of directors-

<u>Name of the Director</u>	Rajesh Abhechand Turakhia
<u>Date of Birth</u>	<u>08/02/1958</u>
<u>Date of First appointment on Board</u>	<u>08-12-2021</u>
<u>Date of current appointment (at current term)</u>	NA
<u>DIN</u>	00006246
<u>Directorship of other companies</u>	1. Planet Pharmaceutical Private Limited 2. Gene Biotech Private



	Limited 3. Pan -India Drugs & Chemicals Limited
<u>Expertise</u>	More than 35 years of rich experience in finance. He oversees marketing strategies and practices. He oversees business development and contributes in evolving new growth strategies.
<u>Memberships /Chairmanships of committees of other public companies</u>	NIL
<u>Qualification</u>	has completed B.com. and has rich experience in the pharmaceutical industry and finance
<u>Inter-se Relationship with other Directors</u>	Brother of Late Mr. Mahendra Turakhia and Mr. Kishor Turakhia
<u>No. of shares held</u>	2385324


EXPLANATORY STATEMENT

(PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013)

Item no.5:

Regularization of Additional Director Ms. Chandan Mahendra Turakhia as non-executive director of the company.

Particulars	Mrs. Chandan Mahendra Turakhia
DIN	11500086
Age	77 years
Date of first Appointment	August 14, 2026



Qualifications	B.Com
Experience in specific functional areas	Mrs. Chandan Mahendra Turakhia has completed graduation from Malaya University. Mrs. Chandan Mahendra Turakhia has a vast experience of over 35 years in extending training related to HRA and motivational sessions to human resources. She has 35years of experience in the field of HRA. She has excelled in both the levels of Principles of accounts held by Pittmans institute , UK. Other than mothertongue Gujarati , She has proficiency in speaking English ,Hindi and Malay.
Terms and Conditions of Appointment/ Reappointment	As per Board discussion
Directorships held in other public/private companies (excluding Section 8 companies and foreign companies)	1.Pan -India Drugs & Chemicals Limited
Memberships/ Chairmanships of committees of other public companies (includes only Audit Committee and Stakeholders' Relationship Committee)	Nil
Relationship with other Directors inter-se and with Key Managerial Personnel of the Company	Wife of Late Mr. Mahendra Turakhia, and sister-in-law of Mr. Kishor Turakhia and Mr. Rajesh Turakhia.
No. of shares held in the Company	NIL
No. of Board Meetings attended during 2025-2026	NA

EXPLANATORY STATEMENT

(PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013)

Item No. 6:

To approve Material Related Party Transactions for the year 2026-27.

The Company proposes to enter into and/or continue with Related Party Transactions during the financial year 2026-27 in the ordinary course of business and on an arm's length basis, in accordance with Section 188 of the Companies Act, 2013 ("Act"), Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, Regulation 23 of the SEBI (Listing Obligations and Disclosure



Requirements) Regulations, 2015 (“Listing Regulations”) and the Company’s Policy on Related Party Transactions.

The proposed transactions may include purchase/sale of goods or materials, rendering or availing of services, lease arrangements and other transactions as may be required for the day-to-day business operations of the Company, up to the limits specified in the Notice.

The Audit Committee has reviewed and approved the proposed transactions and recommended the same to the Board. The Board has approved the proposal and recommends the resolution for approval of the Members.

The transactions shall be undertaken on an arm’s length basis, in the ordinary course of business and on such terms and conditions as may be considered appropriate in the interest of the Company.

In case of any loan, advance, guarantee or security involving a Related Party, the Company shall separately comply with the applicable provisions of Sections 185 and 186 of the Act and other applicable laws.

Except to the extent of their respective interest, if any, in the Related Party, none of the Directors, Key Managerial Personnel or their respective relatives is concerned or interested, financially or otherwise, in the proposed resolution.

The Board recommends the Special Resolution for approval of the Members.

The Related Parties shall abstain from voting on the resolution to the extent required under the applicable provisions of the Act and Listing Regulations.

The transactions with related parties are at arm’s length price and are within the thresholds specified under section-188 of the companies act 2013, with regard to sale, purchase or supply of goods or materials, selling or otherwise disposing off or buying property of any kind, leasing of property of any kind, and availing or rendering any services.

S.NO	NAME OF RELATED PARTY	NATURE OF TRANSACTION	AMOUNT(in Rupees)
1	Invochem Laboratory	services or any other transaction	20,00,000.00
2	Invochem Laboratory	Purchase of fixed assets	-
	Invochem Laboratory	Sale of goods or services	-
3	Suneeta Chemicals	services	10,00,00,000.00
3	Suneeta Chemicals	Purchase of goods	5,00,00,000.00
4	Suneeta Chemicals	Sale of goods or services	5,00,00,000.00
5	Turakhia Bros	services	19,80,000.00
	Turakhia Bros	Purchase of goods	2,50,00,000.00
6	Turakhia Bros	Sale of goods or services	2,50,00,000.00
7	Gene Biotech Private Limited	Purchase of fixed assets	2,00,00,000.00
7	Gene Biotech Private Limited	Purchase of goods	2,00,00,000.00
	Gene Biotech Private Limited	services	20,00,000.00
8	Gene Biotech Private Limited	Sale of goods or services	2,00,00,000.00
9	Paramount Organics	Service	25,00,000.00
9	Paramount Organics	Purchase of goods or	1,00,00,000.00
10	Paramount Organics	Sale of goods or services	1,00,00,000.00
11	Synodrug & Intermediates	Rendering /availing of services	25,00,000.00
	Synodrug & Intermediates	Purchase of goods	50,00,000.00



12	Synodrug & Intermediates	Sale of goods	50,00,000.00
13	Pan India Drug and chemicals Limited	Purchase of goods	4,00,00,000.00
14	Pan India Drug and chemicals Limited	Sale of goods or services	4,00,00,000.00


EXPLANATORY STATEMENT

(PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013)

Item No. 7:

To appoint whole-time director Mr. Kishor Abhaychand Turakhia as Managing Director of the company.

Particulars	Mr. Kishor Turakhia
DIN	00006236
Age	70 years
Date of first Appointment	August 2, 1989
Qualifications	B.Com
Experience in specific functional areas	More than 40 years of rich experience in finance. He oversees business development and contributes to evolving new growth strategies.
Terms and Conditions of Appointment/ Reappointment	Currently holds position of whole-time director of the company. Being executive director of the company the designation to be changed to Managing director.
Directorships held in other public/private companies (excluding Section 8 companies and foreign companies)	1.Gene Biotech Private Limited 2.Pan -India Drugs & Chemicals Limited
Memberships/ Chairmanships of committees of other public companies (includes only Audit Committee and Stakeholders' Relationship Committee)	Nil
Relationship with other Directors inter-se and with Key Managerial Personnel of the Company	Mr. Mahendra Turakhia, Managing Director of the Company is brother of Mr. Kishor Turakhia.
No. of shares held in the Company	2279116



No. of Board Meetings attended during 2025-2026	5
--	---

**For and on behalf of the Board
Panchsheel Organics Limited**

Sd/-

Sonia Verma

Company Secretary

Membership No: A63984

Indore, September 08, 2026

Corporate Office:


Unit No. 137, Hubtown Solaris,
N S Phadke Marg, Opposite Teli
Galli, Andheri (East), Mumbai –
400 069.

Registered Office:

B-6 & B-7 Sector-C, Industrial Area, Sanwer Road,
Indore – 452015, Madhya Pradesh.

CIN: L24232MP1989PLC005390

☎ 0731-2721709 91-22063929 ✉ www.panchsheelorganics.com



CFO CERTIFICATION

To,
The Board of Directors
Panchsheel Organics Limited

This is to certify with reference to the Annual Accounts of the Company for the year ended 31st March, 2026 that:-


- a. I have reviewed financial statements and the cash flow statement for the year ended on 31st March, 2026 and that to the best of my knowledge and belief:
 - i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - ii. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b. There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or that may violate the Company's code of conduct.
- c. I accept responsibility for establishing and maintaining internal controls for financial reporting and that I have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. I have not come across any reportable deficiencies in the design or operation of such internal controls.
- d. I have indicated to the Auditors and the Audit committee:
 - i. That there is no significant changes in internal control over financial reporting during the year;
 - ii. That there are no significant changes in accounting policies during the year except implementation of Ind AS ; and
 - iii. That there is no instance of any fraud which we have become aware of.

For Panchsheel Organics Limited

Sd/-

Place: Mumbai
Date: September 08, 2026

Mr. Deepak R. Shah
(Chief Financial Officer)




CERTIFICATE BY MANAGING DIRECTOR

[Pursuant to Regulation 17 (8) of SEBI Listing Obligation and Disclosure Requirements) Regulations, 2015 read with Schedule II]

To,
The Board of Directors,
Panchsheel Organics Limited.

I, Mahendra Turakhia, Managing Director of Panchsheel Organics Limited, to the best of my knowledge and belief, certify that:

1. I have reviewed the Balance Sheet as on March 31, 2025 and Profit and Loss Account for the year ended as on that date along with all its schedules and notes on accounts as well as the cash flow statements and the Board's Report;
 2. Based on my knowledge and information, these statements do not contain any untrue statement of a material fact or omit any material fact, in light of the circumstances under which such statements were made, not misleading anyone with respect to the statements made;
 3. Based on my knowledge and information, the financial statements and other financial information included in this Report, present in all the material aspects, a true and fair view of the Company's affairs, the financial condition, results of operations and Cash Flows of the Company as of, and for, the periods presented in this Report, and are in compliance with the existing accounting standards and / or applicable laws and regulations;
 4. To the best of my knowledge and belief, no transactions entered into by the Company during the year are fraudulent, illegal or violative of the Company's Code of Conduct;
- I.** I am responsible for establishing and maintaining disclosure controls and procedures and internal controls over financial reporting for the Company, and I have:
- a) Designed such disclosure controls and procedures to ensure that material information relating to the Company, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the Company's disclosure, controls and procedures; and
 - d) Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal year that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting;




- II.** I have disclosed based on our most recent evaluation, wherever applicable, to the Company's auditors and the Audit Committee of the Company (and persons performing the equivalent functions):
- a) All deficiencies in the design or operation of internal controls, which could adversely affect the Company's ability to record, process, summarize and report financial data, and have identified for the Company's auditors, any material weaknesses in internal controls over financial reporting including any corrective actions with regard to deficiencies;
 - b) Significant changes, if any, in internal controls during the year covered by this report;
 - c) All significant changes in accounting policies during the year, if any, and that the same have been disclosed in the notes to the financial statements;
 - d) Instances of significant fraud of which I am aware, that involves management or other employees who have a significant role in the Company's internal control system;
- 1. I affirm that I have not denied any personnel, access to the Audit Committee of the Company (in respect of matters involving alleged misconduct) and I have provided protection to whistle blowers' from unfair termination and other unfair or prejudicial employment practices; and
 - 2. I further declare that all board members and senior managerial personnel have affirmed compliance with the code of conduct for the current year.

For Panchsheel Organics Limited
Sd/-

Kishor Abhaychand
Turakhia

Managing Director
DIN: 00006236

Date: September 08, 2026

**CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS**

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Board of Directors
PANCHSHEEL ORGANICS LIMITED
B-6 & B-7 Sector-C, Industrial Area,
Sanwer Road, Indore, Madhya Pradesh- 452015

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **PANCHSHEEL ORGANICS LIMITED** and having registered office B-6 & B-7 Sector-C, Industrial Area, Sanwer Road, Indore, Madhya Pradesh, India, 452015, produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub-clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in as considered necessary and explanations furnished to us by the Company & its Directors, we hereby certify that none of the Directors on the Board of the Company as on March 31, 2026 as stated below, have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority(ies):

S. No	Name of Directors	DIN	Date of appointment in Company
1.	MAHENDRA ABHAYCHAND TURAKHIA	00006222	01/04/2012
2.	KISHOR ABHAYCHAND TURAKHIA	00006236	02/08/1989
3.	RAJESH ABHECHAND TURAKHIA	00006246	08/12/2021
4.	BASANT SHRIVASTAVA	02581255	08/09/2025
5.	NILESH RAMESHCHANDRA SHAH	00368422	08/09/2025
6.	SEJAL RIDDHESH SHAH	11269204	08/09/2025




Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company.

Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Vijay S. Tiwari & Associates
Practicing Company Secretary

Sd/-
CS Vijaykumar Tiwari
Proprietor
Membership No.: 33084
CP No.: 12220
Peer Review Certificate No. 1679/2022
UDIN: A033084H001410768

Date: 08-09-26
Place: Mumbai

**BOARD'S REPORT**

To the Members of Panchsheel Organics Limited,

The Directors hereby present their 37th Annual Report on the business, operations and the state of affairs of the Company together with the audited financial statements for the year ended March 31, 2026:-

FINANCIAL PERFORMANCE

(Amt in Rupees)


Particulars	2025-26	2024-25
Total Income	1,10,30,24,624.20	1,10,25,13,224.18
Total Expenditure	95,83,55,898.19	92,15,43,376.69
Profit Before Tax	14,46,68,726.01	18,09,69,847.49
Tax Expenses	3,63,64,970.90	4,30,24,804.88
Profit for the year	10,83,03,755.11	13,79,45,042.61
Other Comprehensive Income/ (Loss)	35,49,283.00	-75,24,968.00
Total Comprehensive Income	11,18,53,038.11	13,04,20,074.61
Earnings Per Share (Rs.) (Face Value of Re. 1/- each)		
Basic	8.22	10.47
Diluted	8.22	10.47

EQUITY SHARE CAPITAL

During the year under review, Company has not issued or allotted any Equity Shares on preferential basis.

The Company has not issued equity shares with differential rights as to dividend, voting or otherwise.

The Company has not issued ESOP or sweat equity shares to Directors or employees.

**DIVIDEND**

During the year under review, the Company declared 3 interim dividend of Rs. 0.80/-, Rs 0.80/-, Rs 0.80/- and Rs 0.08/- per Equity Share of the face value of Rs. 10/- each in its Board Meeting held on August 14, 2025, November 14, 2025 and February 14, 2026 respectively.

The Board at its meeting held on May 30, 2025, recommended a final dividend of Rs. 0.80/- per Equity Share of the face value of Rs. 10/- each, which was approved by the Members of the company at the Annual General Meeting (_AGM) of the Company held on 30th September, 2025.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

The Company does not have subsidiaries, joint ventures and associate Companies.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

The particulars of loans given, Investments made, guarantees made and securities provided are reported in the financial statements.

MANAGEMENT DISCUSSION AND ANALYSIS

A report on Management Discussion and Analysis covering industry structure and developments, financial and operational performance of the Company, risks, concerns, opportunities, threats and outlook forms a part of this Report.

TRANSFER TO RESERVES


The Company has transferred an amount of Rs. 697.04 lakhs to the General Reserve.

INTERNAL FINANCIAL CONTROLS AND RISK MANAGEMENT

The Company has in place adequate internal financial controls with reference to the financial statements. The Company's internal control system is designed to ensure operational efficiency, protection and conservation of resources, accuracy and promptness in financial reporting and compliance with the applicable laws and regulations.

The Company has a robust Business Risk Management framework to identify and evaluate business risks and opportunities. This framework seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company's competitive advantage. The business risk framework defines the risk management approach across the enterprise at various levels including documentation and reporting. The framework has different risk models which help in identifying risks

trend, exposure and potential impact analysis at a Company level as also separately for business. The Company has adopted a Risk Management Policy.



HUMAN RESOURCES

The key to the Company's agility and success is, of course, its highly dedicated people. The focus of the Company is on attracting, engaging and developing talented people who share their vision and values. Therefore, the Company offers innovative programs, benefits and resources that address the diverse needs of employees, reward their efforts, help them build their best careers at Panchsheel.

CORPORATE GOVERNANCE

Corporate Governance Report and Certificate from the Statutory Auditors of the Company on compliance with the conditions of Corporate Governance pursuant to the requirements of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, form a part of this Report.


PUBLIC DEPOSITS

The company has not accepted any deposits covered under Chapter V of the Companies Act, 2013 ("the Act"). Accordingly, there is no disclosure or reporting required in respect of details relating to deposits.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to section 134 of the Companies Act, 2013, the Board of Directors confirm that:-

- (i) in the preparation of the annual accounts, the applicable accounting standards have been followed;
- (ii) such accounting policies have been selected and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2026 and the profits of the Company for the financial year ended on that date;
- (iii) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (iv) the annual accounts have been prepared on a going concern basis;
- (v) internal financial controls have been laid down and the same are adequate and were operating effectively; and
- (vi) proper systems have been devised to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

**DIRECTORS AND KEY MANAGERIAL PERSONNEL**

The Board of Directors of the Company, as on 31st March, 2026, comprise of six Directors of which one is Managing Director, two are Executive Directors and three are Non-executive and Independent Directors. There is one Woman Director on the Board.

i. Directors

The board of the company comprises of six directors as on 31st March 2026, namely Mahendra Abhaychand Turakhia (DIN: 00006222), Kishor Abhaychand Turakhia (DIN:00006236), Rajesh Abhechand Turakhia (DIN:00006246), Mr. Basant Shrivastav (DIN: 02581255), Mr. Nilesh Rameshchandra Shah (DIN: 00368422) and Mrs. Sejal Riddhesh Shah (DIN: 11269204).

ii. Independent Directors

Mr. Basant Shrivastav(DIN: 02581255), Mr. Nilesh Rameshchandra Shah(DIN: 00368422) and Mrs. Sejal Riddhesh Shah (DIN: 11269204) are the independent directors of the company, and will not continue to be the Independent Directors of the Company.

In accordance with the provisions of Section 149 of the Companies Act, 2013, the Independent Directors have given a declaration that they meet the criteria of independence as provided in the said Section and also in terms of the Listing Regulations. In the opinion of the Board, the Independent Directors are persons of integrity and possess relevant expertise, experience and proficiency as per the Act.

iii. Retirement by rotation

In terms of Section 152 of the Companies Act, 2013, Mr. Mahendra Abhaychand Turakhia (DIN: 00006222) Rajesh Abhechand Turakhia (DIN:00006246),, retires by rotation at the forthcoming AGM and, being eligible, has offered himself for re-appointment. Brief resume of Rajesh Abhechand Turakhia (DIN:00006246), as required under Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is covered in the notes of the Notice of 37th AGM of the Company.


iv. Key Managerial Personnel

Ms. Sonia Verma was appointed as the Company Secretary and Compliance Officer of the company with effect from May 29, 2024, since then there is no such change in the appointment.

BOARD MEETINGS HELD DURING THE YEAR

During the year under review, 5 (Five) Board Meetings were held on the following dates:-

30th April 2025, 14th August 2025, 08th September 2025, 14th November 2025 and 14th February 2026.



FAMILIARIZATION PROGRAMME FOR THE INDEPENDENT DIRECTORS

The Board of Directors have adopted a Familiarization Program for Independent Directors of the Company. The same is available on the website of the Company at <https://panchsheelorganics.com>.

Besides that, expositions are made to the Directors on various topics covering the pharmaceutical industry. Updates on relevant statutory changes and judicial pronouncements around industry related laws are regularly circulated to the directors. Each director has complete access to any of the company's information and full freedom to interact with senior management.

MEETING OF INDEPENDENT DIRECTORS DURING THE YEAR

During the year the non-executive independent directors met to evaluate the working, performance, and conflict of interest of executive directors on February 14, 2026.

COMMITTEES OF THE COMPANY

- NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee comprises of Mrs. Darshana Shah, Non-Executive - Independent Director, Mr. Diwakar Tripathi, Non-Executive - Independent Director and Mr. Sambhunath Chakravarti, Non-Executive - Independent Director, however with change in the independent directors the composition and constitution of the committee changed. And the same has been reconstituted with following directors as members- Nilesh Rameshchandra Shah- Non-Executive - Independent Director and Basant Shrivastav- Non-Executive - Independent Director and Mrs. Sejal Riddhesh Shah- Non-Executive - Independent Director.

The Company has formulated a Remuneration Policy pursuant to Section 178 of the Act and the Listing Regulations. The Policy is provided as —[Annexure II](#) to this Report.


- AUDIT COMMITTEE

The Audit Committee comprises of Mr. Mahendra Turakhia, Managing Director and Executive Director, Mr. Diwakar Tripathi, Non-Executive - Independent Director and Mrs. Darshana Vishal Shah, Non-Executive - Independent Director, however with change in the independent directors, the composition and constitution of the committee changed and the Audit Committee reconstituted with the Mr. Mahendra Turakhia, Managing Director and Executive Director, Nilesh Rameshchandra Shah- Non-Executive - Independent Director and Basant Shrivastav- Non-Executive - Independent Director.

Further details of the Audit Committee are provided in the Corporate Governance Report forming a part of this Report.

AUDITORS

Pursuant to the provisions of section 139 of the Act, the members at the annual general meeting of the Company held on 30th September 2021 appointed M/s. Jayesh R. Shah & Associates, Chartered Accountants (Firm Registration No. 104182W) as statutory auditors of the Company from the conclusion of 32nd Annual general meeting till the conclusion of 37th annual general meeting.



The statutory audit report for the financial year 2025-26 does not contain any qualification, reservation or adverse remark or disclaimer made by statutory auditor.

SECRETARIAL AUDIT REPORT

Pursuant to the provisions of section 204 of the Act and Rules made thereunder, the Company has appointed, M/s. Vijay Tiwari & Associates Practicing Company Secretaries (Membership No.33084, CP No. 12220) to undertake the secretarial audit of the Company. Secretarial audit report for the financial year ended March 31, 2026 issued by him in the prescribed form MR-3.

In addition to the above, pursuant to regulation 24A(2) of the Listing Regulations, 2015, a report on secretarial compliance for the financial year ended March 31, 2026 has been issued by M/s. Vijay Tiwari & Associates, Practicing Company Secretaries and the same will be submitted with the stock exchanges within the given timeframe. The report will be made available on the website of the Company. The Secretarial Audit Report is provided as —[Annexure I](#) to this Report.

There are no observations, reservations or qualifications or adverse remark in any of the aforesaid reports.

- CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

In accordance with the provisions of Section 135 of the Companies Act, 2013 (the Act) and the Rules made thereunder, the Board of Directors of the Company have constituted the Corporate Social Responsibility (CSR) Committee. The CSR Committee comprises of Mr. Mahendra Turakhia, Managing Director; Mr. Kishor Turakhia, Executive Director and Mrs. Darshana Shah, Non-executive Director, however with change in the independent directors the composition and constitution of the committee changed. And the same has been reconstituted with following directors- Mr. Mahendra Turakhia, Managing Director; Mr. Kishor Turakhia, Executive Director and Mrs. Sejal Riddhesh Shah- Non-Executive - Independent Director.

The report on CSR activities undertaken during the year is provided as —[Annexure III](#) to this Report. During the year ended March 31, 2026, the Committee met once.


- STAKEHOLDERS RELATIONSHIP COMMITTEE

The Audit Committee comprises of Mr. Kishor Turakhia, Executive Director, Mr. Diwakar Tripathi, Non-Executive - Independent Director and Mrs. Darshana Shah, Non-Executive - Independent Director, Mrs. Darshana Shah, Non-Executive - Independent Director is the Chairperson of the committee, however with change in the independent directors the composition and constitution of the committee changed. And the same has been reconstituted with following directors- Mr. Kishor Turakhia, Executive Director, Nilesh Rameshchandra Shah- Non-Executive - Independent Director and Basant Shrivastav- Non-Executive - Independent Director.

PERFORMANCE EVALUATION OF THE BOARD, COMMITTEES OF THE BOARD AND DIRECTORS

In compliance with the provisions of the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the performance evaluation was carried out as under:

Based on recommendation of the Nomination and Remuneration Committee, a mechanism and criteria are set for evaluation of the Board, Committees of the Board and Directors, including Independent Directors. The Board and Board Committees evaluation is done by the Board through self-assessment and group discussions. Parameters for evaluation of the Board include structure and composition of the Board, frequency and number of meetings, devotion of time for important



business matters-financials, monitoring Internal Controls/ Code of Conduct/Insider Trading.

Policy/Risk Management Framework and Emerging Risks/Governance and compliance issues, adequate access to information for effective decision making, strategic guidance to management through regular interactions and cohesiveness in the overall working that facilitates open discussion.

Parameters for evaluation of the Committee include structure and composition of the committees, adequacy of charter and working procedure, frequency of meetings, if the Committee is functioning as per the charter and if the Committee recommendations contribute effectively to the Board decision making.

Evaluation of the Directors is done by the Board (excluding the Director whose evaluation is being done). Parameters for evaluation of the Directors include skill set, knowledge, attendance, effective participation at Board/Committee Meetings, their contribution at the Meetings, leveraging on his/ her experience to provide the necessary insights/guidance on Board discussions and display of candor in expressing views even when they are in divergence with the rest of the Board, etc.

EMPLOYEES

The particulars of ratio of remuneration of each director to median remuneration of the employees of the Company for the financial year under report, percentage increase in remuneration of each Director and KMP, etc, more particularly described under Section 197(12) of the Companies Act, 2013 and Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are given in —[Annexure IV](#) to this Report.

The statement showing particulars of employees as required under Section 197(12) of the Companies Act, 2013, read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in this report in the above stated annexure.

RELATED PARTY TRANSACTIONS


All the Related Party Transactions entered by the Company during the financial year are on arm's length and in the ordinary course of business.

In accordance with the provisions of the Listing Regulations, the Company has formulated the Related Party Transactions Policy, which is available on the Company's website at www.panchsheelorganics.com.

The details of the Related Party Transactions are discussed in notes to the financial statements. The Audit Committee has granted omnibus (ad hoc) approval for the Related Party Transactions as per the provisions and restrictions contained in the policy framed as per Regulation 23 of the SEBI (LODR) Regulations, 2015 and provision of Companies Act, 2013 are also adhered

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The required information under the provisions of Section 134(3)(m) of the Companies Act, 2013 in respect of Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo, etc, are provided as —[Annexure V](#).



PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE

Pursuant to the legislation, The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has a policy on Prevention of Sexual Harassment at Workplace. During the year under review, no complaint has been received from employees. There was no other case reported during the year under review under the said policy.

Entire staff is working in the most congenial manner and there were no occurrences of incidences of sexual harassment during the year.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

The Company has adopted a Whistle Blower Policy to report genuine concerns/ grievances. The Policy is available on the website of the Company at www.panchsheelorganics.com.

The Policy provides for adequate safeguards against victimization of persons who use such mechanism. The mechanism is overseen by the Audit Committee.

ANNUAL RETURN

Pursuant to Sections 92 and 134 of the Companies Act, 2013, the Annual Return as on March 31, 2025 in Form MGT-7 is available on the website of the Company at www.panchsheelorganics.com and as on March 31, 2026 will be made available within 60 days of the Annual General Meeting (AGM for 2025-2026)

ACKNOWLEDGEMENTS


The Board of Directors acknowledge the valuable guidance and continued support and co-operation extended by the Securities and Exchange Board of India, Stock Exchanges, Ministry of Corporate Affairs, other Government Authorities, Banks, and other Stakeholders.

**For and on behalf of the Board of Directors
Panchsheel Organics Limited**

Sd/-

**Kishor A. Turakhia
Managing Director
DIN: 00006236**

Mumbai, September 08, 2026




Form No. MR-3
Annexure A to Board's Report
Secretarial Audit Report
For the period April 1, 2025 to March 31, 2026
[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Board of Directors
Panchsheel Organics Limited
B-6 & B-7 Sector-C, Industrial Area,
Sanwer Road, Indore, Madhya Pradesh- 452015

We have conducted the secretarial audit of the compliance with applicable statutory provisions and the adherence to good corporate practices by **Panchsheel Organics Limited** (hereinafter called "the Company"). The Secretarial audit was conducted in a manner that provided us with a reasonable basis for evaluating corporate conduct and statutory compliance and for expressing our opinion thereon.

Based on our verification of the books, papers, minutes books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period ended on March 31, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

- i. We have examined the books, papers, minute books, forms and returns filed and other records maintained by **Panchsheel Organics Limited** ("The Company") for the period ended on March 31, 2026 according to the provisions of:
- I. The Companies Act, 2013 (the Act) and the Rules made thereunder;
 - II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;
 - III. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
 - IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not Applicable to the Company during Audit Period).
 - V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') to the extent applicable to the Company:
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
 - c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - d) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not Applicable to the Company during Audit Period)
 - e) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (Not Applicable to the Company during the Audit Period)



- f) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (Not Applicable to the Company during the Audit Period);
- g) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021; (Not applicable to the Company during the Audit Period)
- h) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; (Not applicable to the Company during the Audit Period)

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreement entered into by the Company with Bombay Stock Exchanges.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above except the following:


No	Particulars
1.	<i>All the Independent Directors of the Company has not registered their names in the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs (IICA) pursuant to Section 150 of the Companies Act, 2013, read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014 and applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</i>
2.	<i>The Company was not in compliance with Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 relating to the disclosure of related party transactions, BSE Limited imposed a penalty of Rs. 5900/- on the Company for non-compliance with the said regulation.</i>
3.	<i>The Company was not in compliance with Regulation 17(2A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for March, 2025 relating to the non-compliance with the requirements pertaining to quorum of Board meetings. BSE Limited imposed a penalty of Rs. 11800/- on the Company for non-compliance with the said regulation.</i>
4.	<i>The listed entity has not maintained and disclosed all the required details on the website as per Regulation 46 of SEBI (LODR), 2015.</i>

We further report that during the audit period; there were no instances of:

- Public/Right/Preferential Issue of Shares/Debentures/Sweat Equity, etc
- Redemption/Buy Back of Securities.
- Merger/Amalgamation/Reconstruction. etc
- Foreign technical Collaborations

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

This report is to be read with our letter of even date, which is annexed as 'Annexure-A-1' and forms an integral part of this report.



We further report that.

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors.

Adequate notice is given to all directors to schedule the Board Meetings; the agenda and detailed notes on the agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.


We further report that:

- There are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- There were no such specific events/actions in pursuance of the above-referred laws, rules, regulations, etc., having a major bearing on the Company's affairs.

For Vijay S. Tiwari & Associates
Practicing Company Secretary

Sd/-
CS Vijaykumar Tiwari
Proprietor
Membership No.: 33084
CP No.: 12220
Peer Review Certificate No. 1679/2022
UDIN: A033084H001410768

Date: 08-09-26
Place: Mumbai



Annexure A

To,
The Members
Panchsheel Organics Limited
B-6 & B-7 Sector-C, Industrial Area,
Sanwer Road, Indore, Madhya Pradesh- 452015

Our report of even date is to be read along with this letter.

Managerial Responsibility

1. Maintenance of Secretarial Records is the responsibility of the Management of the Company. Our Responsibility is to express an opinion on these Secretarial records based on our audit.

Auditors Responsibility

1. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verifications were done on a test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices I followed provide a reasonable basis for our opinion.
2. I have not verified the correctness and appropriateness of the financial records and Books of Accounts of the company
3. Wherever required, I have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.
4. The compliance with the Provisions of Corporate and other applicable Laws, Rules, Regulations, and standards is the responsibility of the Management. My examination was limited to the verification of procedures on a test basis.


Disclaimer

5. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For Vijay S. Tiwari & Associates
Practicing Company Secretary

Sd/-
CS Vijaykumar Tiwari
Proprietor
Membership No.: 33084
CP No.: 12220
Peer Review Certificate No. 1679/2022
UDIN: A033084H001410768

Date: 08-09-2026
Place: Mumbai



Annexure to Board's Report

Annexure II

NOMINATION AND REMUNERATION POLICY

The Board of Directors of Panchsheel Organics Limited (—the Company) has constituted the Nomination and Remuneration Committee (—the Committee) in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The Committee had framed Nomination and Remuneration Policy (—the Policy) and recommended to the Board in accordance with the requirements of the Companies Act, 2013 and the Listing Regulations. The Board had approved and adopted the Policy w.e.f. 14th February, 2020.

1. OBJECTIVE

The Committee and the Policy is in compliance with Section 178 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 19 read with Part D of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Key Objectives of the Committee would be:

- a) to guide the Board in relation to appointment and removal of Directors, Key Managerial Personnel and Senior Management Employees.
- b) to evaluate the performance of the members of the Board and provide necessary report to the Board for further evaluation of the Board (as and when required).
- c) to recommend to the Board, the Remuneration payable to the Directors, Key Managerial Personnel and Senior Management.


2. DEFINITIONS

(a) Key Managerial Personnel: Key Managerial Personnel means—

- i) Chief Executive Officer or the Managing Director or the Manager;
- ii) Company Secretary,
- iii) Chief Financial Officer; and
- iv) Such other officers as may be prescribed.

(b) Senior Management:

Senior Management means personnel of the Company who are members of its core management team excluding the Board of Directors. This will also include all the members of management one level below the executive directors including all functional heads.



3. MEMBERSHIP

- a) The Committee shall consist of minimum 3 non-executive directors, out of whom not less than one half shall be independent.
- b) Minimum two (2) members, of whom one must be Independent Director, shall constitute the quorum for the Committee meeting.
- c) Membership of the Committee shall be disclosed in the Annual Report.
- d) Term of the Committee shall be continued unless terminated by the Board of Directors.

4. CHAIRPERSON


- a) Chairperson of the Committee shall be an Independent Director.
- b) Chairperson of the Company may be appointed as a member of the Committee but shall not be a Chairperson of the Committee.
- c) In the absence of the Chairperson, the members of the Committee present at the meeting shall choose one amongst them to act as Chairperson.
- d) Chairperson of the Committee meeting may be present at the Annual General Meeting or may nominate some other member to answer the shareholders' queries, if any.

5. ROLE OF COMMITTEE

a) NOMINATION DUTIES

The duties of the Committee in relation to nomination matters include:

- a) To identify persons who are qualified (i) to become directors and (ii) for appointment in Senior Management Cadre;
- b) To formulate criteria for determining qualifications, positive attributes and independence of a Director;
- c) To recommend to the Board, the appointment and removal of Senior Management Employees;
- d) To carry out evaluation of Directors' performance and recommend to the Board, their appointment/removal/ suspension based on his/her performance;
- e) To recommend the Board, a policy relating to remuneration for Directors, Key Managerial Personnel and other Senior Management employees;
- f) To devise a policy on Board diversity;
- g) Ensure that there is an appropriate induction & training program in place for new Directors and members of Senior Management and review its effectiveness;



- h) Ensure that on appointment on the Board, Independent Directors receive a formal letter of appointment in accordance with the Guidelines provided under the Companies Act, 2013;
- i) Determine the appropriate size, diversity and composition of the Board;
- j) Set a formal and transparent procedure for selecting new Directors on the Board
- k) Develop a succession plan for the Board and Senior Management and regularly reviewing the plan;
- l) Delegate any of its powers to one or more of its members;
- m) Recommend necessary changes to the Board;
- n) Consider any other matters as may be requested by the Board.


b) REMUNERATION DUTIES

The duties of the Committee in relation to remuneration matters include:

- ☐ to consider and determine the Remuneration Policy, based on the performance and also bearing in mind that the remuneration is reasonable and sufficient to attract, retain and motivate members of the Board and such other factors as the Committee shall deem appropriate with regard to the remuneration of the members of the Board;
- ☐ to approve the remuneration of the Directors, Senior Management including key managerial personnel of the Company, maintaining a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company;
- ☐ to delegate any of its powers to one or more of its members;
- ☐ to consider any other matters as may be requested by the Board.

6. BOARD DIVERSITY

- a) The Board shall consist of such number of Directors, including at least one woman Director and not less than fifty percent of the Board of Directors comprising of non-executive directors, as is necessary to effectively manage the Company of its size.
- b) When the Chairperson of the Board is a non-executive director, at least one-third of the Board should comprise of independent directors and in case the Company does not have a regular non-executive Chairperson or in case the regular non-executive Chairperson is a promoter of the Company, at least half of the Board should comprise of independent directors.
- c) The Committee will lead the process for Board appointments. All Board appointments will be based on the skills, diverse experience, independence and knowledge which the Board as a whole requires to be effective. The Committee shall seek to address Board vacancies by actively considering candidates that bring a diversity of background and opinion from



amongst those candidates with appropriate background and industry or related expertise and experience. The candidates will be considered against objective criteria, having due regard to the benefits of diversity of the Board.

- d) Additionally, the Board may consider appointment of experts from various specialized fields such as finance, law, information technology, corporate strategy, marketing and business development, international business, operations management etc. so as to bring diversified skill sets on board or succeed any outgoing director with the same expertise.

7. FREQUENCY OF MEETINGS

The meeting of the Committee shall be held at such regular intervals as may be required.

8. COMMITTEE MEMBERS' INTERESTS


- a) A member of the Committee is not entitled to be present when his or her own remuneration is discussed at a meeting or when his or her performance is being evaluated.
- b) The Committee may invite such executives, as it considers appropriate, to be present at the meetings of the Committee.

9. VOTING

- a) Matters arising for determination at Committee meetings shall be decided by a majority of votes of Members present and voting and any such decision shall for all purposes be deemed a decision of the Committee.
- b) In case of equality of votes, the Chairman of the meeting will have a casting vote.

10. MINUTES OF COMMITTEE MEETING

Proceedings of all meetings must be recorded in minutes book and signed by the Chairperson of the Committee. Minutes of the Committee meetings will be tabled at the subsequent Board meeting.

**REPORT ON CORPORATE SOCIAL RESPONSIBILITY****Annual Report on Corporate Social Responsibility Activities**


[As prescribed under Section 135 of the Companies Act, 2013 and Companies(Corporate Social Responsibility Policy) Rules, 2014]

1. Brief outline on CSR Policy of the Company:

To leverage the capacity and capital to equip and enable the social sector to achieve the greatest impact on the lives of the poor in India.

Sr. No.	Name of Director	Designation/Nature of Directorship	Number of meetings held during the year	Number of meetings attended during the year
1	Mr. Mahendra Turakhia	Managing Director (Chairman of the Committee)	1	1
2	Mr. Kishor Turakhia	Executive director(member)	1	1
3	Mrs. Darshana Shah(upto 30th Sept. 2025)	Independent director(member)	1	0
4	Mrs. Sejal Shah (w.e.f. 30th Sept. 2025)	Independent director(member)	1	1

- Web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the Company at www.panchsheelorganics.com.
- Details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report): Not Applicable
- Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any: NIL
- Average net profit of the Company of the last three financial years as per section 135(5):
Rs. 1,914 lakhs.
- (a) Two percent of average net profit of the Company as per section 135(5): Rs. 38.28 lacs



- (b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years: NIL
- (c) Amount required to be set off for the financial year, if any: NIL
- (d) Amount unspent for previous years, if any: 43.89lacs(2024-25)
- (e) Total CSR obligation for the financial year (7a+7b-7c+7d): Rs. 82.17lacs

7. (a) CSR amount spent or unspent for the financial year:

	CSR Amount spent	Amount Unspent				
Particulars	Total Amount Spent for the Financial Year	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
		Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
During the year 2025-26	50,00,000	16,00,000	-	-	-	-
after closure of financial year and before Annual report date i.e. 30 th June 2026	16,50,000	-	-	-	-	-

***transferred Rs. 16.00lakhs to Unspent CSR account on 08th September 2026, actual obligation was 15.67lakhs.**

- (b) Details of CSR amount spent against ongoing projects for the financial year: NA
- (c) Details of CSR amount spent against other than ongoing projects for the financial year: 66.50lacs
- (d) Amount spent in Administrative Overheads: NIL
- (e) Amount spent on Impact Assessment, if applicable: Not applicable
- (f) Total amount spent for the financial year (8b+8c+8d+8e): 66.50lacs
- (g) Excess amount for set off, if any:-NIL
- (h) Excess amount paid during the year mentioned in point-g, is to be adjusted against next year's obligations.



9.(a) Details of Unspent CSR amount for the preceding three financial years:

Sr . No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under section 135 (6) (amount in lacs)	Amount spent in the reporting Financial Year (amount in lacs)	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any	Amount remaining to be spent in succeeding financial years (amount in lacs)
-----------------	---------------------------------	---	--	--	--


Name of the Fund (amount in lacs) Date of transfer

1	FY 2022-23	NIL	Nil	-	-	-	Nil
2	FY 2023-24	Nil	Nil	-	-	-	NIL
3	FY 2024-25	43.89	66.50	-	-	-	NIL

(c) Details of CSR amount spent in the financial year for ongoing projects of the preceeding financial year(s): Nil

Sl. No.	Project ID	Name of the Project	Financial Year in which the project was commenced	Project duration	Total amount allocated for the project (in Rs.)	Amount spent on the project in the reporting Financial Year (in Rs.)	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project - Completed/ Ongoing
----------------	-------------------	----------------------------	--	-------------------------	--	---	---	---


Nil



10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year (asset-wise details):
- a) Date of creation or acquisition of the capital asset(s): None
 - b) Amount of CSR spent for creation or acquisition of capital asset: Nil
 - c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.: Not Applicable
 - d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset): Not Applicable
11. Specify the reason(s), if the Company has failed to spend two per cent of the average net profit as per section 135(5): **Company has spent the remaining amount after closing of financial year i.e. Rs. 16.50lakhs on 30th June 2026 for CSR and also transferred the amount Rs. 15.60lakhs to Unspent CSR account on 08 September 2026relating to 2025-2026.**

Sd/-
Kishor Turakhia
Managing Director
(Chairman of CSR Committee)

Sd/-
Rajesh Turakhia
Executive Director
(Member of CSR Committee)



Annexure to Board's Report


Annexure IV

Statement of disclosure of remuneration

[Pursuant to Section 197 of the Companies Act, 2013 ("the Act") and Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

Part-1: Disclosure of Ratio of Remuneration of each Director to the Median Employee's Remuneration, the Percentage increase in Remuneration of each Director, Chief Executive Officer, Company Secretary and Chief Financial Officer, etc., for the Financial Year ended 31st March, 2026.

1. Ratio of remuneration of each Director to whom remuneration is paid to the median remuneration of employees:
 - a. Mr. Mahendra A. Turakhia, Managing Director: 46.255:1
 - b. Mr. Kishor A. Turakhia, Executive Director: 45.45:1
 - c. Mr. Rajesh A. Turakhia, Executive Director: 45.45:1
2. Percentage increase in remuneration of Directors and Key Managerial Personnel to whom remuneration is paid in the financial year ended 31' March, 2026:
 - a. Mr. Mahendra A. Turakhia, Managing Director: Nil
 - b. Mr. Kishor A. Turakhia, Executive Director: Nil
 - c. Mr. Rajesh A Turakhia:, Executive Director: Nil
 - d. Mr., Deepak R. Shah, Chief Financial Officer : 10%
 - e. Ms. Sonia Verma, Company Secretary : 10%
3. Percentage increase in the median remuneration of employees in the financial year ended March 31, 2026 in comparison to the financial year ended March 31, 2025: 10%
4. Number of permanent employees as on 31st March, 2025: 191
 - a. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year:10 %
 - b. Percentile increase in the managerial remuneration in the last financial year:
 - i. Mr. Mahendra A. Turakhia, Managing Director: 0.53
 - ii. Mr. Kishor A. Turakhia, Executive Director: 0.55
 - iii. Mr. Rajesh A. Turakhia, Executive Director: 0.55
 - iv. Mr. Deepak R. Shah Chief Financial Officer: 0.10



v. Ms. Sonia Verma: NA

- c. Justification of the above: Remuneration is based on individual performance
- a. Any exceptional circumstances for increase in the managerial remuneration: None
- 1. The remuneration of all the Directors, Key Managerial Personnel and other employees are as per the remuneration policy of the Company.

Part-2: Statement of particulars of top ten employees in terms of remuneration pursuant to provisions of Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

There is no employee employed during the year drawing remuneration exceeding the limits prescribed under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.


For and on behalf of the Board
Panchsheel Organics Limited

Sd/-

Kishor Abhaychand Turakhia
Managing Director
DIN: 00006236

Place: Mumbai

Dated: September 08, 2026



Annexure to Board's Report

Annexure V

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

*[Pursuant to Section 134(3)(m) of the Companies Act, 2013 read with
Rule 8 of the Companies (Accounts) Rules, 2014]*

A. CONSERVATION OF ENERGY


i. Energy conservation measures:

The manufacturing units of the Company have continued their efforts to reduce their energy consumption year on year. Some of the key measures undertaken by the manufacturing plants are as below:

- Elimination of idle running of Air Handling Unit for energy reduction.
- Use of Energy Efficient aluminum Air piping solution to reduce friction losses.
- LED lighting for all plants
- Sharing of best practices at each plant started for easy replication of applicable ideas
- Use of Energy efficient motors for all new projects. **The total power consumption by the Company is as below:-Power**

Fuel Consumption: RS. 8611498.74/-.

Sr. No.	Particulars	Current Year 25-26	Previous Year 24-25
1.	Electricity		
	Total Units	566043.00	587667.00
	Amount (Rs. In Lacs)	54.63	53.44
	Rate per unit (Rs.)	9.65	9.09
	Consumption per unit of Production (in unit)/Kg	4.84	5.11
2.	Gas/Furnace Oil (Diesel)		
	Total units (liter)	417506.55	503862.58
	Amount (Rs. In Lacs)	31.49	39.24
	Rate per Unit (Rs.)	7.54	7.79
	Consumption per unit of production (in unit) Kg	3.57	4.38




- ii. The steps taken by the Company for utilizing alternate sources of energy – Nil
- iii. The Capital Investment on Energy Conservation Equipment - None

B. TECHNOLOGY ABSORPTION

- i. The efforts made towards technology absorption - The Company extensively uses the information technology in its operations and has absorbed the technology required in this regard.
- ii. The benefits derived like product improvement, cost reduction, product development or import substitution - The Company has leveraged the technology to reach out to its customer in the difficult times of pandemic.
- iii. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year:
 - (a) The details of technology imported: Not Applicable
 - (b) The year of import: Not Applicable
 - (c) Whether the technology has been fully absorbed: Not Applicable
 - (d) If not fully absorbed, areas where absorption has not taken place, and the reasons thereof: Not Applicable
- iv. The expenditure incurred on Research and Development: Not Applicable.

C. FOREIGN EXCHANGE EARNINGS AND OUTGO

During the year under review, the Company earned foreign exchange of Rs. 105.43 lakhs (previous year: Rs. 207.37 lakhs) and there was outgo of foreign exchange of Rs. 3.73 lakhs (previous year: Rs. 4.31 lakhs)



Corporate Governance Report

Company's Philosophy on Corporate Governance

At Panchsheel, we strongly uphold good governance practices to promote fairness, transparency, accountability and integrity. In line with this philosophy, Guiding Principles have been articulated and these forms an integral part of Company's Corporate Governance practices. Processes have been designed to run the businesses responsibly and harmonize the diversified interests of various stakeholders, thereby enhancing stakeholder value.

Board of Directors


Composition, Meeting and Attendance

The Board of Directors (the Board) of the Company comprises of Executive and Non-Executive Directors and the same is in conformity with the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations) and the Companies Act, 2013 (the Act).

The agenda for the Board Meetings is circulated in advance and is backed by comprehensive background information to enable the Board to take informed decisions. During the financial year 2025-26, the Board met 5 (five) times i.e. on:

The names and categories of the Directors on the Board, their attendance at the Board Meetings held during the financial year 2025-26 and at the last Annual General Meeting (AGM), the number of directorships and committee positions held by them in other public limited companies and the name of the other listed entities where he/she is a Director and category of directorships as on March 31, 2026, are as under:

Name and DIN of the Directors	Category	No. of Board Meetings Attended	Attendance at the last AGM held on September 30, 2025	No. of directorships in other Public Limited Companies	Name of other Listed entities where person is Director - Category of Directorship	Committee Position*
						Member/ Chairman
Mr. Mahendra Turakhia {Chairman} (DIN: 00006222)	Executive (Promoter)		YES	NIL		Chairman/ Member - 1
Mr. Kishor Turakhia (DIN: 00006236)	Executive (Promoter)		YES	NIL		Chairman/ Member - 2
Mr. Rajesh Turakhia (DIN: 00006246)	Executive (Promoter)		YES	NIL		Chairman/ Member
Mrs. Darshana Shah	Non-Executive,		YES	NIL		Chairman-2/ Member



(DIN:0736092)	Independent					- 1
Mr. Diwakar Tripathi (DIN: 06912629)	Non-Executive, Independent		YES	NIL		Chairman-1/ Member - 2
Mr. Shambhunath Chakravarti (DIN: 06924557)	Non-Executive, Independent		YES	NIL		Chairman/ Member - 1
Mr. Basant Shrivastav (DIN: 02581255)	Non-Executive, Independent		YES	NIL		Chairman-1/ Member - 2
Mr. Nilesh Rameshchandra Shah (DIN: 00368422)	Non-Executive, Independent		YES	NIL		Chairman-2/ Member -1
Ms. Sejal Riddhesh Shah (DIN: 11269204)	Non-Executive, Independent		YES	NIL		Chairman/ Member - 1

*Only Directorships of public limited companies incorporated in India have been considered and excludes private limited companies, section 8 companies and foreign companies.


*Only Audit Committee and Stakeholders' Relationship Committee, in other public limited companies, have been considered for the Committee position.

Except for Mr. Mahendra Turakhia, Mr. Rajesh Turakhia and Mr. Kishor Turakhia, none of the Directors are related to each other.

None of the Directors hold office in more than 10 public companies as prescribed under the Act. No Director holds Directorships in more than 7 listed companies. Further, none of the Non-executive Directors serve as Independent Director in more than 7 listed companies as required under the Listing Regulations. The Managing Director does not serve as an Independent Director in any listed company. None of the Directors on the Board is a member of more than 10 Committees and Chairperson of more than 5 Committees, across all public limited companies in which he/she is a Director. Independent Directors are Non-executive Directors as defined under the Listing Regulations and the Act along with Rules framed thereunder. In terms of the Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact their ability to discharge their duties.

Based on the declarations received from the Independent Directors, the Board has confirmed that they meet the criteria of independence as prescribed under the Listing Regulations and that they are independent of the management. In the opinion of the Board, the Independent Directors are persons of integrity and possess relevant expertise, experience and proficiency as per the Act.

All the directors of the Company have confirmed that they are not disqualified for being appointed as directors pursuant to Section 164 of the Companies Act, 2013.



M/s.Vijay Tiwari & Associates, Company Secretaries, have issued a certificate certifying that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India (SEBI), the Ministry of Corporate Affairs and any such statutory authority.

Committees of the Board:

A) Audit Committee

Meetings held:

During the Financial Year 2025-26, the Committee met 4(four) times i.e. on: 30 May 2025, 14 Aug 2025, 14 Nov 2025, and 14 Feb 2026.


The composition as on March 31, 2026 and attendance during the year ended March 31, 2026:

Name of the Members	No. of Meetings Attended
Mr.Diwakar Mani Tripathi	2
Mr. Mahendra Abhaychand Turakhia	4
Mrs. Darshana Vishal Shah	2
Mr. Basant Shrivastav	2
Mr.Nilesh Rameshchandra Shah	2

All the members have financial management expertise. The constitution and terms of reference of the Committee are in compliance with the requirements of the Act and the Listing Regulations.

Brief description of the terms of reference of the Audit Committee inter alia include:

1. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible
2. Recommendation for appointment, remuneration and terms of appointment of auditors of the Company
3. Approval of payment to the statutory auditors for any other service rendered by the statutory auditors
4. Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the Board for approval with particular reference to:
 - a. matters required to be included in the director's responsibility statement to be included in the Board's report in terms of clause (c) of sub section 3 of the section 134 of the Companies Act, 2013
 - b. changes if any, in the accounting policies and practices and reasons for the same



- c. major accounting entries involving estimates based on the exercise of judgement by management.
 - d. significant adjustments made in the financial statements arising out of audit findings
 - e. compliance with the listing and other legal requirements relating to financial statements
 - f. disclosure of any related party transactions
 - g. qualifications in the draft audit report.
5. Reviewing, with the management, the quarterly financial statements before submission to the Board for approval
 6. Evaluation of internal financial controls and risk management systems
 7. Reviewing, with the management, performance of statutory auditors, adequacy of the internal control systems
 8. Discussion with internal auditors of any significant findings and follow up thereon
 9. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post audit discussion to ascertain any area of concern
 10. To review the functioning of the Whistle Blower/Vigil mechanism
 11. Carrying out any other function as is mentioned in the terms of reference of the Audit Committee.


The Auditors and the Chief Financial Officer are invited to attend the meetings of the Committee. The Company Secretary acts as the Secretary to the Committee.

B) Nomination and Remuneration Committee Meetings held:

During the Financial Year 2025-26, the Committee met thrice on May 30, 2025, September 08, 2025 and February 14, 2026.

The Committee comprises of the Independent Directors only. The composition as on March 31, 2026 and attendance during the year ended March 31, 2026:

Name of the Members	No. of Meetings Attended
Mr. Diwakar Mani Tripathi	2
Mrs. Darshana Vishal Shah	2
Mr. Shambhunath	2
Mr. Basant Shrivastav	1
Mr. Nilesh Rameshchandra Shah	1
Ms. Sejal Riddhesh Shah	1



Brief description of the terms of reference of the Nomination and Remuneration Committee inter alia includes:

1. Identifying the persons who can become Directors
2. Formulating the criteria for determining the qualifications, positive attributes etc. and independence of a Director
3. Recommending to the Board a policy relating to the remuneration for the Directors & Key Managerial Personnel
4. Recommend to the Board, all remuneration, in whatever form, payable to senior management
5. Specify the manner for effective annual evaluation of performance of the Board, its Committees and individual Directors.

The Company has formulated a Remuneration Policy which is annexed to the Board's Report.

C) Stakeholder' Relationship Committee

Meetings Held:


During the Financial Year 2025-26, the Committee met twice on May 30, 2025 and February 14, 2026.

The composition as on March 31, 2026 and attendance during the year ended March 31, 2026:

Name of the Members	No. of Meetings Attended
Mr.Diwakar Mani Tripathi	1
Mr. Kishor Abhaychand Turakhia	2
Mrs. Darshana Vishal Shah	1
Mr. Basant Shrivastav	1
Mr.Nilesh Rameshchandra Shah	1

As on date of this Report, Ms. Sonia Verma is the Company Secretary & Compliance Officer of the Company.

Based on the report received from the Registrar & Share Transfer Agents, the Company did not receive any requests/complaints during the year ended March 31, 2026.



Board Evaluation


During the year, in accordance with the Board Evaluation Policy and the Guidance Note on Board Evaluation issued by SEBI, an annual evaluation of its own performance and that of the Committees and Directors pursuant to the provisions of the Act and the Listing Regulations was carried out by the Board on various parameters which inter alia included composition, diversity, effectiveness, quality of discussion, contribution at the meetings, business acumen, strategic thinking, time commitment, relationship with the stakeholders, corporate governance practices, contribution of the Committees etc.

A separate meeting of the Independent Directors was held wherein the performance of the Non-Independent Directors, performance of the Board as a whole (including the Committees) and also that of the Chairman in terms of the provisions of the Act, the Listing Regulations and the Guidance Note issued by SEBI in this regard was discuss.

General Body Meetings

The date, time and venue of the last four AGMs are given below:

Financial Year	Date	Time	Venue
2024-25	September 30, 2025	3.00 p.m.	Held through Video Conferencing (B-6 & B-7 Sector-C, Industrial Area, Sanwer Road, Indore – 452015, Madhya Pradesh.)
2023-2024	September 30, 2024	3.00 p.m.	Held through Video Conferencing (B-6 & B-7 Sector-C, Industrial Area, Sanwer Road, Indore – 452015, Madhya Pradesh.)
2022-2023	September 29, 2023	4.00 p.m.	Held through Video Conferencing (B-6 & B-7 Sector-C, Industrial Area, Sanwer Road, Indore – 452015, Madhya Pradesh.)
2021-2022	September 30, 2022	4.00 p.m.	Held through Video Conferencing (B-6 & B-7 Sector-C, Industrial Area, Sanwer Road, Indore – 452015, Madhya Pradesh.)

**Means of Communication**

The financial results are submitted to the Stock Exchanges and also uploaded on the website of the Company at www.panchsheelorganics.com. The financial results are also published in the newspapers.

I. General Shareholder Information


- | | | |
|------|---------------------------------|---|
| i. | AGM: Date, time and venue/mode: | Wednesday, September 30, 2026 at 03.00 P.M. through Video Conferencing/Other Audio Visual Means (VC/OAVM) |
| ii. | Financial Year: | April 1, 2025 to March 31, 2026 |
| | Book Closure dates: | September 24, 2026 to September 30, 2026 (both days inclusive) |
| iii. | Dividend payment date: | October 5, 2026 to October 30, 2026 |

I. Listing of Securities on Stock Exchanges:**Equity Shares**

The Equity Shares of the Company are listed on:

Name of the Stock Exchange	Address of the Stock Exchange	Trading Symbol
BSE Limited (BSE)	P J Towers, Dalal Street, Fort, Mumbai - 400 001.	531726

The Company has paid the listing fees to the Stock Exchanges for the financial year 2026-27. ISIN with National Securities Depository Limited and Central Depository Services (India) Limited: INE316G01019.

**II. Market Price Data**


Stock Market price data for the financial year 2025-26 and high/low of market price of the Company's shares traded at BSE during each month in the financial year ended March 31, 2026 are as under:

Month	Open Price	High Price	Low Price	Close Price
Apr 25	133.60	155.00	130.20	142.05
May 25	144.00	155.00	129.60	151.55
Jun 25	148.05	158.20	135.00	151.40
Jul 25	154.95	180.00	142.00	179.00
Aug 25	184.00	184.00	146.50	151.05
Sep 25	151.55	156.70	134.00	135.55
Oct 25	139.90	146.00	131.00	140.05
Nov 25	145.00	145.45	135.00	138.15
Dec 25	140.20	140.20	123.60	129.90
Jan 26	133.90	133.90	101.00	105.10
Feb 26	107.95	122.00	101.25	108.55
Mar 26	101.30	111.00	86.10	90.20

III. Registrar & Share Transfer Agent:**Equity Shares**

Purva Share Registry (India) Private Limited

Address: Unit No. 9, Shiv Shakti Ind. Estate, J. R. Boricha Marg, Opp. Kasturba Hospital Lane, Lower Parel (East), Mumbai - 400011
Ph. No. 022- 23012517 / 8261



VI. Distribution of shareholding as on March 31, 2026.


S N	Category	No. of Shareholders	% of Shareholders	Amount	% Amount
1	1 to 100	5272	63.76	168466	1.28
2	101 to 200	953	11.53	155701	1.18
3	201 to 500	941	11.38	334240	2.54
4	501 to 1000	526	6.36	413191	3.14
5	1001 to 5000	427	5.16	951273	7.22
6	5001 to 10000	53	0.64	389835	2.96
7	10001 to 100000	82	0.99	2437164	18.5
8	100001 to Above	14	0.17	8321880	63.18
		Total	8268	99.99	13171750

Shareholding Pattern as at 31st March, 2026:

Sr. No.	Category of Shareholder	No. of Shareholders	Number of Shares	% of Equity
1.	RESIDENT INDIVIDUALS	7963	4401481	33.42
2.	IEPF	1	165688	1.26
3.	LLP	2	11	0.00
4.	BODIES CORPORATE	36	426636	3.24
5.	CLEARING MEMBERS	1	300	0.00
6.	PROMOTER	6	6370368	48.36
7.	PROMOTER RELATIVES	4	1022144	7.76
8.	N.R.I. (NON-REPAT)	31	31270	0.24
9.	N.R.I. (REPAT)	52	405756	3.08
10.	TRUST	1	8400	0.06
11.	HINDU UNDIVIDED FAMILY	171	339696	2.58
Total		8268	13171750	100

VII. Dematerialisation of shares:

As on March 31, 2026, 1,30,19,350 equity shares representing 98.843% of the equity shares of the Company were held in dematerialised form and 1,52,400 equity shares representing 1.157% of the outstanding equity shares of the Company were held in physical form. At the end of each quarter, reconciliation of share capital audit is conducted by a Practicing Company Secretary to reconcile the total issued capital, listed capital and capital held by the Depositories in dematerialised form and is submitted to the stock exchanges.

**VIII. Outstanding GDRs/ADRs/Warrants or any convertible instruments, conversion date and likely impact on equity:**

The Company has not issued GDRs/ADRs/Warrants or any other instrument convertible into equity.

IX. Details of equity shares lying in the suspense account pursuant to the Listing Regulations: Nil

Sr. No.	Particulars	No. of Shareholders	No. of equity shares
1	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the beginning of the year	-	-
2	Number of shareholders who approached the Company for transfer of shares from the suspense account during the year	-	-
3	Number of shareholders to whom shares were transferred from the suspense account during the year	-	-
4	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of the year	-	-

The voting rights on the above shares shall remain frozen till the rightful owner of such shares claims the same.

XI. Plant location(s):

PLANT-I	Panchsheel Organics Limited, B6 - B7, Sector C, Sanwer Road, Industrial Estate, Indore (MP) 452015
PLANT-II	Panchsheel Organics Limited, Plot No 87-88, Sector - 3, Industrial Area, Pithampur, DHAR 454774


Other Disclosures

i. The Company did not enter into any materially significant related party transactions having a potential conflict with the interest of the Company at large.

Transactions with the related parties are disclosed in the financial statements.

ii. The financial statements have been prepared in accordance with the applicable Accounting Standards.

iii. The Company has a Whistle Blower Policy/Vigil Mechanism to report concerns



about unethical behaviour, actual or suspected fraud or violation of our code of conduct and confirms that no personnel have been denied access to the Audit Committee.

iv. Code for Prohibition of Insider Trading of the Company, the Policy for determining Material Subsidiaries and the Policy on Related Party Transactions are available at:

www.panchsheelorganics.com.

v. There have been no instances where the Board has not accepted recommendation of any Committee of the Board, during the financial year.

vi. The statutory auditors of the Company, M/s. Jayesh R. Shah & Co, the Auditors were paid an amount of Rs. 4.50 lakh (Amount in lakh) by the Company for all the services provided by them.

vii. Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

- a) Number of complaints filed during the Financial Year: Nil
- b) Number of complaints disposed of during the Financial Year: Nil
- c) Number of complaints pending as on end of the Financial Year: Nil.

ix. The Company has complied with the corporate governance requirements as prescribed in Regulations 17 to 27, 46(2) (b) to (i) and Schedule V of Chapter IV of the Listing Regulations.

viii. The Company has adopted the discretionary requirements as specified in Part E of Schedule II - The financial statements are accompanied with an unmodified audit report.

ix. CEO/CFO Certification

The CEO and the CFO have certified to the Board, the requirements of the Listing Regulations, with regard to financial statements.


x. Compliance Certificate

Pursuant to the Listing Regulations, a certificate issued by M/s. Vijay Tiwari & Associates, Company Secretaries, certifying the compliance by the Company with the provisions of the Corporate Governance forms part of this Report.

Address for correspondence:

For any assistance, request or instruction regarding transfer or transmission of securities, dematerialisation of securities, change of address, non-receipt of annual report, dividend warrant and any other query relating to the securities of the Company, the investors may write to:

The Company Secretary
Panchsheel Organics Limited




Panchsheel Organics Limited

Annual Report 2025-26

B-6 & B-7 Sector-C, Industrial Area, Sanwer Road,
Indore - 452015,
Madhya Pradesh.
Ph. No. 0731-2721709, 91-22063929
Email: compliance@panchsheelorganics.com

Purva Share Registry (India) Pvt. Ltd
Unit No. 9, Shiv Shakti Ind. Estate,
J.R. Boricha Marg,
Opp. Kasturba Hospital Lane,
Lower Parel (East),
Mumbai-400011
Website: www.panchsheelorganics.com
Ph. No. 022- 23012517 / 8261.
Email: support@purvashare.com
Website: www.purvashare.com



Declaration by the Chairman & Managing Director under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 regarding adherence to the Company's Code of Conduct

In accordance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, it is hereby confirmed that for the financial year ended March 31, 2026, the Directors and the Senior Management Personnel of the Company have affirmed compliance with Panchsheel's Code of Conduct.


For Panchsheel Organics Limited

Sd/-

Kishor Turakhia

(Chairman & Managing Director)

DIN: 00006236



AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE

TO THE MEMBERS,
PANCHSHEEL ORGANICS LIMITED.

We have examined the compliance of conditions of Corporate Governance by Panchsheel Organics Limited (the Company) for the year ended on March 31, 2026 as stipulated in SEBI Listing Regulations, 2015 of the Company with the Stock exchanges.

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-referred Listing Regulation.

We have been explained that no investor grievances are pending for a period exceeding one month against the Company as per the records maintained by the Company.


We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Jayesh R Shah & Co.
Chartered Accountants
Firm Registration No.104182W

Kruti Doshi
Partner
Membership No.605915

Place: Mumbai
Date: 30.05.2026

UDIN: 26605915QVNEUR8155



MANAGEMENT DISCUSSION AND ANALYSIS REPORT

INTRODUCTION AND OVERVIEW OF PHARMACEUTICAL INDUSTRY

India being the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, supplying 62% of Global Vaccine demand is a prominent and rapidly growing presence in the global pharmaceuticals industry. India ranks 3rd worldwide for production by volume and 14th by value. India is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities offering over 60,000 generic brands across 60 therapeutic categories. India has the highest number of US-FDA compliant Pharma plants outside of USA and its API industry is third largest in the world, with 57% of APIs on the WHO.

- The Indian pharmaceutical industry is the 3rd-largest globally by volume and the 11th largest by value.
- The domestic market size is USD 60 billion, projected to reach USD 130 billion by 2030.
- The annual turnover of the Pharma sector reached Rs. 4.72 lakh crore in FY25.
- India currently ranks 11th globally by value in pharmaceutical exports, with exports to 191 countries in 2024-25.
- Pharma exports stood at USD 30.5 billion, a nearly 16-fold increase from USD 1.9 billion in 2000-01.
- FDI inflows Rs. 13,193 Crore for the current financial year 2025-26 (up to September).
- In the Union Budget 2026-27, Biopharma SHAKTI has been proposed to position India as a global biopharmaceutical manufacturing hub with a total outlay of Rs. 10,000 Crore over the next five years.


India's pharmaceutical industry in 2026 is valued at approximately \$60 billion, maintaining its position as the third-largest globally by volume and the primary provider of global generic medicines and vaccines.

Market Size and Projections

- **Current Valuation:** Valued around \$60 billion in 2026, with domestic market turnover reaching high growth trajectories.
- **Future Outlook:** As of 2026, the sector is projected to reach approximately \$130 billion by 2030, with a robust CAGR of 8–11% over the next 2-3 years.
- **Global Standing:** Occupies a 20% share in global generic medicine supply by volume and supplies over 60% of global vaccine demand.

Introduction - Linking Public Health with Economic Progress

Health functions both as a driver and an outcome of economic development, and the pharmaceutical industry occupies a unique position at this intersection. By ensuring the availability of essential medicines and vaccines, the industry plays a critical role in advancing public health outcomes and societal welfare, while concurrently generating employment, reinforcing supply-chain resilience, and contributing to broader socio-economic development. Over time, the Indian pharmaceutical industry has emerged as one



of the world's most distinctive and socially significant sectors, positioning India among the largest and most technologically advanced pharmaceutical producers globally.

India in the Global Pharmaceuticals Market

India's standing as the Pharmacy of the World is rooted in the unique combination of affordable pricing and assured quality, which has made Indian medicines widely preferred across global markets. Cost-efficient manufacturing, supported by a strong scientific workforce and scale, has enabled the consistent supply of essential drugs without compromising standards.

The Indian pharmaceutical industry ranks 3rd globally by volume and 11th by value, with more than 3,000 companies and 10,500 manufacturing units. The domestic pharmaceutical market, valued at USD 60 billion, is projected to reach USD 130 billion by 2030. As per Economic Survey 2025-26, in FY25, the sector's annual turnover reached Rs. 4.72 lakh crore, with exports growing at a CAGR of 7 per cent over the last decade (FY15 to FY25). India is the largest global supplier of generic medicines, accounting for around 20 per cent of global supply, manufacturing about 60,000 generic brands across 60 therapeutic categories. By expanding access to affordable HIV treatment and emerging as a leading global supplier of cost-effective vaccines, the pharmaceutical industry continues to advance public health outcomes domestically and internationally while generating economic opportunities. India hosts the highest number of manufacturing plants approved by the United States Food and Drug Administration (USFDA) outside the United States of America, reinforcing international confidence in the safety and quality of Indian pharmaceuticals. There are about 500 active pharmaceutical ingredient (API) manufacturers, accounting for nearly 8 per cent of the global API industry.

Pharmaceutical Exports - Global Reach and Investment Growth


India is the global leader in the supply of Diphtheria, Tetanus, and Pertussis (DPT), Bacillus CalmetteGuerin (BCG), and measles vaccines. Indian manufacturers provide about 60 percent of vaccine supplies to the United Nations International Children's Emergency Fund (UNICEF), meet 40-70 per cent of global demand for DPT and BCG vaccines, and account for 90 per cent of the World Health Organization's (WHO) measles vaccine demand. This highlights the robustness of Indian pharmaceutical exports and their substantial integration within global healthcare supply networks.

Export Performance

As per the Economic Survey 2025-26, India currently ranks 11th globally in pharmaceutical exports by value, with exports to 191 countries in 2024-25, of which 50 percent are directed to highly regulated markets such as the United States and Europe, reflecting wide international acceptance of Indian medicines. In 2024-25, pharmaceutical exports stood at USD 30.5 billion, a nearly 16-fold increase from USD 1.9 billion in 2000-01. Export momentum has also remained strong every month, with Drugs and Pharmaceuticals exports rising by approximately 2.70 per cent from USD 2.59 billion in January 2025 to USD 2.66 billion in January 2026.

Further, medical device exports have grown significantly from USD 2.5 billion in 2020-21 to USD 4.1 billion in 2024-25, with exports to 187 countries in FY25.

India's pharmaceutical sector has expanded its global presence through rising exports and steady foreign investment, signalling strong international confidence in its manufacturing and regulatory standards. Collectively, these strengths position India as a dependable supplier of quality, affordable medicines and underpin its continued export-driven growth. Indian pharmaceutical exporters have strategically diversified their export portfolio by expanding shipments to emerging and non-traditional destinations, including Nigeria,



Mexico, the United Republic of Tanzania, the Netherlands, France, Brazil, Sri Lanka, Saudi Arabia, and Spain, across bulk drugs, surgical products, and formulations. This targeted market diversification has enhanced export resilience by mitigating exposure to tariff-related risks concentrated in individual markets.

SEGMENT-WISE PERFORMANCE

The operation of the Company consists of a single segment. Our Company deals in bulk drugs. Hence, Accounting Standard (AS-17) on Segment Reporting issued by the Institute of Chartered Accountants of India does not apply.

OUTLOOK

The likely duration, intensity and spread of the corona virus has brought in a lot of uncertainty into the global and domestic economic outlook. The concerns have transformed from the initial impact of imports from China on the domestic supply chains to the domestic and external demand shock.


The duration of the same remains uncertain with social distancing and lockdowns raising the prospects of production shutdowns and job losses in some sectors. A revival in domestic investment is likely to be hindered, given the increased risk aversion on a global scale, and renewed concerns about resilience of the financial sector.

In the near term, the negative impact of the Covid-19 outbreak on economic growth and sentiment may be modestly mitigated by higher government spending, a brighter outlook for crop yields and emergency stockpiling of essential items. Furthermore, the fall in commodity prices would provide mild cushioning to earnings in the near term, which provides some comfort.

FACTORS THAT MAY AFFECT OUR RESULT OF OPERATIONS

Our financial conditions and results of operations are affected by numerous factors inter alia—

- Growth of unorganized sector and threat from local regional players;
- Change in freight and forwarding charges;
- General economic and business conditions;
- Our Company's ability to successfully implement our growth strategy;



- Fluctuation in Exchange rates;
- Prices of raw materials we consume and the products we manufacture;
- Changes in laws and regulations relating to the industry in which we operate;
- Changes in political and social conditions in India.

PANCHSHEEL ORGANICS SWOT ANALYSIS

- STRENGTHS

- Extensive experience in specialty chemicals and pharmaceutical intermediates;
- Stronger sustainability and compliance framework with thrusts to continuously improving and adding on to it;
- Export sales in more than 15 countries;
- Sound manufacturing capability of APIs;
- Strategic location of manufacturing units with easy access to raw materials and utilities.

- WEAKNESS

- Products are highly dependent on the availability of raw materials;
- Macro factors may expose various risks impacting the growth;
- Global nature of operations like unfavorable currency movements, etc, expose the business to losses.


- OPPORTUNITIES

• Domestic Markets

The Company has a wide range of pharmaceutical products in its portfolio. The Company tries and taps every lawful opportunity coming its way and follows a focused approach and increases marketing efforts. All these have resulted in increased growth of the Company in the recent years. In the coming years, it shall strive hard to build a strong reputation for themselves and carve a niche for our products.

• International Markets

The Company is continuously trying to build a large overseas business and revenue from export business accounts for a sizeable component of Company's total turnover. The Company is continuously tapping potentially new markets and exporting a wide range of products to these countries.



- THREATS

- Due to emergence of corona virus, API production has been hampered in China, which has impacted the Company's supply chain;
- Other low-cost countries such as China and Israel are affecting outsourcing demand for Indian pharmaceutical products;
- Entry of foreign players (well-equipped technology-based products) into the Indian market;
- Drug Pricing: The domestic pharmaceutical industry is very much dependent on the government's Drug Pricing Policy. It is important for the Government to introduce free and fair competition rather than arbitrary drug control measures to decide prices of essential drugs.

This will ensure that Companies like us can manufacture and market all the vital life-saving drugs at economical prices;

- Rising Costs and Availability of Materials;
- The prices of many API's and intermediates have risen significantly due to restriction in production by various Chinese manufacturers. Other factors contributing to such price hike are rise in price of petroleum-based products, frequent shortages and general inflationary conditions.

All these adversely affect the production schedules and overall margins of our Company's products.

REPORT ON NEW FERMENTATION PLANT ESTABLISHED BY THE COMPANY

FERMENTATION PLANT – PROGRESS & DEVELOPMENT REPORT

Fermentation-Based Antibiotics, Probiotics & Enzymes Manufacturing Division

Financial Year: 2025–26

1. Overview

Panchsheel Organics Ltd. has established a dedicated Fermentation-Based Manufacturing Division focused on the development, scale-up and commercial manufacturing of high-value fermentation-derived pharmaceutical APIs/intermediates, probiotics, enzymes and other specialty microbial products.

The manufacturing platform encompasses the complete microbial production cycle, including:

- Microbial strain development and preservation
- Seed-train development
- Upstream fermentation
- Biomass and product recovery
- Downstream processing
- Purification and concentration
- Drying and formulation
- Quality control and product release



- GMP documentation and complete batch traceability.

The Company is developing a flexible manufacturing platform capable of supporting multiple microbial products through campaign-based manufacturing.

2. R&D and Technology Development

The Company's R&D facility at Indore has successfully completed the development and pilot-scale scale-up of several important fermentation-based products.

The major products developed include:

Antibiotics / APIs

- Mupirocin
- Bacitracin
- Polymyxin
- Fusidic Acid
- Clavulanic Acid
- Other selected fermentation-based pharmaceutical products

Probiotics

- Bacillus-based probiotic products
- Lactobacillus-based products
- Other microbial probiotic products


Enzymes

- Serratio Peptidase
- Other specialty enzymes under development

The successful completion of R&D development and pilot-plant scale-up demonstrates the robustness, reproducibility and scalability of the developed manufacturing processes.

3. Product Portfolio

Segment	Representative Products	Applications
Antibiotics / APIs	Clavulanic Acid, Bacitracin, Nystatin, Fusidic Acid, Mupirocin, Polymyxin, Minocycline, etc.	Pharmaceutical
Probiotics	Bacillus spp., Lactobacillus spp., Saccharomyces spp.	Human, Animal Health & Aquaculture
Enzymes	Serratio Peptidase, Protease, Amylase, Lipase, Cellulase and Specialty Enzymes	Pharmaceutical, Food, Feed & Industrial
Specialty Fermentation Products	Organic Acids, Biopolymers and Microbial Metabolites	Food & Pharmaceutical



4. Scale-Up and Commercial Manufacturing

Following successful laboratory and pilot-scale development, the Company is progressing towards commercial-scale manufacturing at its Pithampur manufacturing facility.

Almost 60 percent of the work is completed till date, balance machinery procurement and plant development activities are currently in progress.

The facility is planned to be commissioned progressively, enabling the Company to commence large-scale commercial production of the developed products in next 4-5 months.

5. Strategic Growth Opportunities


The Fermentation Division is expected to provide a strong platform for future business growth through:

- Commercialization of successfully developed R&D products
- Expansion of fermentation manufacturing capacity
- Addition of new antibiotics, probiotics and enzymes
- Development of high-value specialty microbial products
- Improvement in fermentation yields and process efficiency
- Expansion into pharmaceutical, animal health, aquaculture, food and industrial markets
- Development of domestic and export markets
- Greater utilization of manufacturing infrastructure through multi-product campaign production.

6. Future Outlook


Panchsheel Organics Ltd. intends to continue investing in R&D, process optimization, fermentation technology, manufacturing infrastructure and product commercialization.

With the combination of R&D capability, pilot-scale experience, fermentation technology and planned commercial manufacturing infrastructure, the Fermentation Division is expected to become an important contributor to the Company's long-term growth and expansion.

**a. RESULTS OF OPERATIONS:**

The break-up of Revenue and Costs of the Company is as given below:

PARTICULARS	Financial year ended March 31, 2026	Financial year ended March 31, 2025
INCOME(A)		
Sales & income from Operations:		
Domestic	1,05,63,75,701.18	1,05,79,68,286.75
Export	1,04,79,419.00	1,29,49,881.40
Total Sales	1,06,68,55,120.18	1,07,09,18,168.15
<i>Less : Excise Duty</i>	-	-
<i>Other operating Income</i>	9,70,729.96	8,66,200.96
Add: Other Income:	3,51,98,774.06	3,07,28,855.07



TOTAL INCOME	1,10,30,24,624.20	1,10,25,13,224.18
EXPENDITURE(B)		
Operating Expenditure	79,15,65,079.21	83,32,15,460.30
Administrative and other expenditure	12,13,82,545.24	12,48,02, 769.75
Finance Charges	24,35,322.81	37,42,395.30
(Increase)/ Decrease in stocks	1,96,32,939.31	-6,21,79,684.00
Depreciation for the Year	2,33,40,011.62	2,19,62,435.34
TOTAL	95,83,55,898.19	92,15,43,376.69
Profit Before Tax	14,46,68,726.01	18,09,69,847.49
Less: Current tax	3,65,69,025.00	4,65,61,162.17
Excess or short income tax provision	-	-
Deferred Tax	-2,04,054.10	-35,36,357.29
Profit after Tax	10,83,03,755.11	13,79,45,042.61

(1) Total Income:


Our revenue has Increased from **Rs 1,10,25,13,224.18** to **Rs.1,10,30,24,624.20** as compared to previous year 2024-25. Sales in the domestic market have increased, however it has increased in the export market. The overall sales have however decreased.

(2) Operating Expenditure:

The operating expenditure has decreased from **Rs. 83,32,15,460.30** to **Rs. 79,15,65,079.21** as compared to previous financial year 2024-25.

(3)Administrative and other Expenditures:

The administrative expenses have decreased from **Rs. 12,48,02,769.75** to **Rs. 12,13,82,545.24** as compared to previous financial year 2024-25.

**(3) Depreciation:**

The Depreciation cost has increased from Rs. 2,19,62,435.34 in Financial Year 2024-25 to Rs. 2,33,40,011.62 current year.

(4) Net Profit:

Net profit for the financial year 2025-26 is Rs. **10,83,03,755.11**

b. OTHER FACTORS:**(1) Known trends or uncertainties**

The world economy has witnessed an unprecedented economic crisis causing severe recessionary trends in various countries, but Indian pharmaceutical industry remained less affected compared to other sectors.

(2) Future relationship between costs and revenues

The Company doesn't see substantial increase in labor cost or other costs related to the product, except that raw material prices may go up in the near future due to rise in commodity prices. However, any increase in raw material prices would be duly covered in the sales price of the product.

(3) Dependence on Single or few suppliers / Customers

The Customer base of the Company is very strong it does not deal with a single customer or supplier. The Company has a very cordial relationship with all the customers and suppliers with whom they have been dealing since a very long time.

(4) Significant developments subsequent to the last financial year

In the opinion of the Directors, there are no significant changes since the date of the last financial statements, which could materially affect the operations, and profitability of the Company.


TRANSACTION(S) IN WHICH THE MANAGEMENT IS INTERESTED IN THEIR PERSONAL CAPACITY

During the year, there are no materially significant related party transactions entered into with the management that may have potential conflict with the interest of the Company.

For more details, refer Notes to the Financial Statements.

CAUTIONARY STATEMENT

Statements in this Management Discussion and Analysis Report describing the Company's objectives, projections, estimates and expectations, may be forward looking statements and are within the meaning of the applicable laws and regulations. Actual results might differ substantially or materially from those expressed and implied. Important developments that could affect the Company's operations include a downtrend in the international market, fall in onsite, offshore rate and significant changes in political and economic environment, environment standards, tax laws, litigations and labor relations.



INDEPENDENT AUDITOR'S REPORT

To the Members of
Panchsheel Organics Limited
Report on the Audit of the Standalone Financial Statements

1. Opinion

We have audited the standalone financial statements of Panchsheel Organics Limited ("the Company"), which comprise the balance sheet as at 31st March 2026, and the statement of Profit and Loss, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.


In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the Ind AS and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

2. Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

3. Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



Processing Charges

Processing charges represent a significant expense for the Company, accounting for approximately 6% of the total expenses. Approximately 95% of the Company's chemical processing activities are carried out through its related party, Panchsheel Bio Tech.

Our procedures included obtaining an understanding of the Company's process for determining processing charges payable to the related party and assessing the relevant internal controls. It was explained that the pricing is done on arms length basis the prevalent market rates for the same. We tested, on a sample basis, the processing charges by verifying invoices with supporting documents. We compared the rates charged by the related party with those charged by independent parties for similar processing activities and noted no material exceptions. We also tested the accuracy and completeness of the expenses recorded and evaluated the adequacy of the related party disclosures in the financial statements.


4. Emphasis of Matter

We draw attention to point (i)(a)(A) of annexure B of our report. The records of fixed assets as per requirements of clause I of Companies (Auditor's Report) Order, 2020 ("the Order"), are not maintained as required by the Companies Act, 2013. Our opinion on financial statement is not modified due to such.

5. Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the



Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

6. Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.**
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.**
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the**



standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- d. Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Statements.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

7. Other Matter

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the company's annual report, but does not include the financial statements and auditor's report thereon. The Company's annual report is expected to be made available to us



after the date of this auditor's report. Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. When we read the company's annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

8. Report on Other Legal and Regulatory Requirements


As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

Audit Trail (Edit Log)

Based on our examination, the company has used Flash accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility *except in respect of maintenance of fixed asset records which is not maintained by the Company in the format as require by the Companies Act, 2013.* Further, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

9. As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid standalone financial statements comply with the



Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.


(e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”. Our Report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company’s internal financial control over financial reporting. We would also like to mention that company has not appointed internal auditor as required by Companies Act 2013.

(g) With respect to the other matter to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Companies Act, 2013, as amended, in our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the year exceeds the limits prescribed under Section 197 of the Act by Rs 22.96 lakhs. Management has represented that the excess remuneration arose on account of a decline in the Company's profits during the fourth quarter of the financial year. Management has informed us that it is taking appropriate steps to regularize the excess remuneration in accordance with the provisions of the Companies Act, 2013.

(h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- a) The standalone financial statements disclose the impact of pending litigations as at 31 March 2026. Refer Note 25 for the same.
- b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- c) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company Except for dividend for FY 2015-16 and 2016-17 and FY 17-18 amounting to Rs. 197096/- , Rs. 187153/- and Rs 197850/- respectively due for transfer in the year under report not yet transferred till the date of this report in accordance with Section 125(1) of Companies Act,2013.
- d) The interim dividend declared and paid by the Company during the year and until the date of this audit report is in compliance accordance with Section 123 of the Act. The final dividend declared is in compliance with Section 123 of



the Act.


e) (i) The respective Managements of the Company which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, other than as disclosed in the notes to accounts, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company or any of such subsidiaries to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company or any of such subsidiaries ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The respective Managements of the Company have represented to us that, to the best of their knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company or any of such entity shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us on the Company incorporated in India, whose financial statements have been audited under the Act, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

For Jayesh R Shah & Co.
Chartered Accountants
Firm Registration No. 104182W

Kruti Doshi
partner
Membership No.605915
Place: Mumbai
Date: 30.05.2026
UDIN: 26605915QVNEUR8155



Annexure-A to the Independent Auditors Report.

Referred to in paragraph 9(f) of the Independent Auditors' Report of even date to the members of Panchsheel Organics Limited on the Ind AS financial statements for the year ended March 31, 2026.

Report on the Internal Financial Controls over financial reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Panchsheel Organics Limited ("the Company") as of March 31, 2026 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.


Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI)". These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial control, both applicable to an audit of internal financial control and both issued by ICAI. Those Standards and the Guidance Note require that I comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their



operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

\We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the Ind AS financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion


In our opinion, subject to clause xiv a and b of CARO report, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were



operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company - commensurate with the size of the company and nature of its business considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Jayesh R Shah & Co.
Chartered Accountants
Firm Registration No.104182W**

**Kruti Doshi
Partner
Membership No.605915
Place: Mumbai
Date: 30.05.2026
UDIN: 26605915QVNEUR8155**



Annexure-B to the Independent Auditors Report.

Referred to in paragraph (8) of the Independent Auditors Report of even date to the members of Panchsheel Organics Limited on the Ind AS financial statements for the year ended March 31, 2026

(i) In respect of the Company's Property, Plant and Equipment and Intangible Assets

(a) (A) The Company has not maintained proper records showing full particulars including quantitative details and situation of Property, Plant and Equipment. The management explained that the records were maintained but has been misplaced and the new records are under preparation.

(B) The Company does not have any intangible assets hence no records required.


(b) The management explained that they are required to submit details of plant every five years with FDA and a list of plant and equipments is prepared and physically verified by the management once in a year. Due to proper internal control in the factory there are no chance of any discrepancies. As per the management there were no discrepancies noticed but, in absence of proper records, in our opinion, it is difficult to report whether any material discrepancies have been noticed and dealt with properly in books of accounts.

(c) According to information and explanation given to us and on the basis of our examination of the records of the Company, we are of the opinion that the title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee and self constructed properties) disclosed in the financial statements are held in the name of the company;

(d) As per the information furnished and verification of the records the company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year;

(e) As per the information provided by the management and from verification of the records, in our opinion, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under, if so, whether the company has appropriately disclosed the details in its financial statements;

(ii) (a) As per information furnished, the physical verification of inventory is conducted once in a year by the management, in our opinion, the coverage and procedure of such verification by the management is appropriate; minor discrepancies were noticed and have been properly dealt with in the books of accounts



(b) According to information and from verification of the records the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets; The details of Inventories and debtors as per quarterly statement filed with the bank and books of accounts are as under:

As per Books	June'25	Sept'25	Dec'25	Mar'26
Inventory	4474.95	4680.29	4499.87	4507.53
Debtors	4570.94	4793.55	5394.14	4511.38
As per bank statement				
Inventory	4473.79	4679.13	4498.72	4507.53
Debtors	4570.94	4217.08	5008.34	4530.15


(iii) According to the information and explanation provided and from the verification of records, in our opinion, during the year, The Company has not made investments or granted unsecured loans to any companies, firms, Limited Liability Partnerships, or other parties. Hence sub clause a, b, c, d, e and f of clause (iii) are not applicable.

(iv) In our opinion and according to the information and explanations given to us and from verification of the records, the Company has not granted any loans or made any investments or provided any guarantees, and security, to the companies covered under section 185. Further the Company has complied with the provisions of Section 186 of the Companies Act, 2013;

(v) From verification of the records, in our opinion, the Company has not accepted any deposits during the year from the public within the meaning of the provisions of section 73 to 76 of the Companies act, 2013 and rules framed there under;

(vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under sub-section (1) of Section 148 of the Companies Act, 2013, and are of the opinion that, *prima facie*, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records.


(vii) (a) According to the information and explanation given to us and the records of the Company examined by us, in our opinion, the company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. and if not, the extent of the arrears of outstanding statutory dues as on




the last day of the financial year concerned for a period of more than six months from the date they became payable, shall be indicated;

(b) According to the information and explanation provided to us and the records of the Company verified by us, the outstanding dues of Sales Tax, VAT, Income tax and excise duty which have not been deposited on account of dispute with the appropriate authorities are Rs 1,18,62,158/-:

Name of the Statute	Nature of Dues	Amt Due	FY pertaining to demand	Forum where dispute is pending
Income Tax Act, 1961	80HHC/80IA/MAT/Regular Demand	384874	FY 2005-06	Rectification request filed
Income Tax Act, 1961	80HHC/80IA/MAT/Regular Demand	1184628	FY 2016-17	Rectification request filed
Income Tax Act, 1961	80HHC/80IA/MAT	12078	FY 2017-18	Rectification request filed
Income Tax Act, 1961	80HHC/80IA/MAT	1033882	FY 2019-20	The Income Tax Appellate Tribunal, Indore.
Income Tax Act, 1961	80HHC/80IA/MAT	103046	FY 2021-22	The Income Tax Appellate Tribunal, Indore.
Income Tax Act, 1961	80HHC/80IA/MAT	39449	FY 2023-24	The Income Tax Appellate Tribunal, Indore.
Income Tax Act, 1961	80HHC/80IA/MAT	1970043	FY 2024-25	The Income Tax Appellate Tribunal, Indore.
Central Sales Tax & VAT	Sales Tax & Interest Penalty	452310	FY 2005-06	The Hon'ble Registrat, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	273138	FY 2006-07	The Hon'ble Registrat, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	591395	FY 2007-08	The Hon'ble Registrat, MP Commercial Tax



				Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	276114	FY 2008-09	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	688545	FY 2008-09	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	426311	FY 2009-10	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	851350	FY 2010-11	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	497963	FY 2011-12	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	2234783	FY 2012-13	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	57999	FY 2013-14	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
Central Sales Tax & VAT	Sales Tax & Interest Penalty	451780	FY 2014-15	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)



Central Sales Tax & VAT	Sales Tax & Interest Penalty	332470	FY 2016-17	The Hon'ble Registrar, MP Commercial Tax Appellate Board, Bhopal (MP)
-------------------------	------------------------------	--------	------------	---

(viii) According to information and explanation given to us by the management and from the verification of the records, in our opinion, there are no transactions, not recorded in the books of accounts which have been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961 (43 of 1961);

(ix) (a) Based on our audit procedures and the information and explanation given by the management, we are of the opinion that the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender; There are no loans taken by company.

(b) As per the information, we are of the opinion that the company is not a declared willful defaulter by any bank or financial institution or other lender;

(c) As per the information and verification of records, in our opinion the Company has not availed any term loans during the year;

(d) In our opinion, the funds raised on short term basis have not been utilised for long term purposes;


(e) From verification of the records, in our opinion the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;

(f) From verification of the records, in our opinion, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies;

(x) (a) From verification of the records, in our opinion, the Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) during the year;

(b) From verification of the records, in our opinion the company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year;

(xi) (a) During the course of our examination of the books and records of the Company carried out in accordance with the generally accepted auditing practice and according to information and explanations given to us, we have neither come across



any instances of material fraud by the or on the Company has been noticed or reported during the year;

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;

(c) As per the information and explanation furnished, there are no whistle-blower complaints received during the year by the company;

(xii) (a) As the Company is not a Nidhi company sub clause a, b and c of clause xii of the order are not applicable to the Company;

(xiii) As per the information and explanation provided by the company and from the verification of the records, in our opinion, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable and the details have been disclosed properly in the Ind AS financial statements as required under Ind AS 24, Related Party Disclosures specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014;

(xiv) (a) In our opinion and according to the information and explanations given to us, though the Company is required to have an internal audit system commensurate with its size and the nature of its business under Section 138 of the Act, no internal auditor was appointed by the Company during the year under audit.


(b) In the absence of an appointed internal auditor, no internal audit reports were available for the period under audit; consequently, we were unable to consider any such reports as required under this clause.

(xv) The company has not entered into any non-cash transactions with directors or persons connected with him accordingly the provisions of section 192 of Companies Act are not applicable to the company;

(xvi) (a) We have been informed by the management and from the verification of the books of accounts, in our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934);

(b) On verification of the books of accounts, we are of the opinion that the company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934;

(c) On verification of the books of accounts, we are of the opinion that the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India;



(d) In our opinion, company does not have any CIC as part of the group;

(xvii) From verification of the books and records, in our opinion, the company has not incurred cash losses in the financial year and in the immediately preceding financial year;

(xviii) There has been no resignation of the statutory auditors of the Company during the year;

(xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report, and that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date; We however state that this is not an assurance as to the future viability of the Company, We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx) (a) In respect of other than ongoing projects, the Company had an unspent Corporate Social Responsibility (CSR) amount of ₹43,89,040/- as at the end of the financial year, 2025, out of which Rs 33,89,040/- was required to be transferred to a Fund specified in Schedule VII to the Companies Act, 2013 within six months from the expiry of the financial year in accordance with the second proviso to Section 135(5) of the Act. The Company had not transferred the said amount within the prescribed time. Although the Company subsequently utilized Rs 50,00,000/- towards CSR activities during the FY 25-26, such utilization does not constitute compliance with the requirements of Section 135(5) of the Act.

(xxi) The Company do not have any subsidiary or holding company hence reporting under this clause is not applicable

**For Jayesh R Shah & Co.
Chartered Accountants
Firm Registration No.104182W**

**Kruti Doshi
Partner
Membership No.605915
Place: Mumbai
Date: 30.05.2026
UDIN: 26605915QVNEUR8155**



PANCHSHEEL ORGANICS LIMITED

BALANCE SHEET AS AT MARCH 31, 2026

(Rs. in Lakhs)

	Note	As at March 31, 2026	As at March 31, 2025
ASSETS			
Non-Current Assets			
Property, plant and equipment and Intangible assets	3	2,019.36	1,790.41
Capital work-in-progress	4	1,712.31	1,483.28
Intangible assets			
Financial assets			
i. Non current investments	5	0.06	0.06
ii. Loans			
iii. Other financial assets	6	3,807.96	3,572.09
Deferred tax assets (net)	7	112.54	110.50
Other Non-Current Assets	8	586.41	498.80
Total Non-Current Assets		8,238.63	7,455.13
Current Assets			
Inventories	9	4,507.53	4,589.79
Financial assets			
i. Trade receivables	10	3,924.96	3,479.71
ii. Cash and cash equivalents	11	351.64	415.20
iii. Bank balances other than (ii) above	12	31.12	25.92
iii. Loans	13	22.87	18.18
Other current assets	14	116.39	344.12
Total Current Assets		8,954.51	8,872.92
Total Assets		17,193.14	16,328.05
EQUITY AND LIABILITIES			
Equity			
Equity share capital	15	1,317.18	1,317.18
Other equity		12,766.05	12,069.01
Total Equity		14,083.22	13,386.19
Liabilities			



Non-Current Liabilities			
Financial liabilities			
i. Borrowings	16	6.49	17.82
ii. Trade payables	17	195.12	227.97
Deferred tax liabilities (net)			
Employee benefit obligations	18	272.30	268.43
Other non-current liabilities			-
Total Non-Current Liabilities		473.92	514.22
Current Liabilities			
Financial liabilities			
i. Borrowings	19	558.23	525.84
ii. Trade payables	20		
a. Total outstanding dues of micro enterprises and small enterprises		104.37	336.14
b. Total outstanding dues of creditors other than (a) above		1,656.08	1,302.73
iii. Other financial liabilities	21	111.69	83.22
Short Term Provisions	22	32.36	-
Employee benefit obligations	23	141.70	135.65
Other current liabilities	24	31.58	44.05
Total Current Liabilities		2,636.00	2,427.64
Total Equity & Liabilities		17,193.14	16,328.05
The notes are an integral part of these financial statements		1 to 44	

For Jayesh R Shah & Co
Chartered Accountants
Firm Registration No. : 104182W

Mahendra Turakhia
Chairman &
Managing Director
DIN: 00006222

Kishore Turakhia
Director
DIN: 00006236

Kruti H Doshi
Partner
Membership No.: 605915

Rajesh Turakhia
Director
DIN: 00006246

Deepak Shah
Chief Financial
Officer

Sonia Verma
Company Secretary

Place: Mumbai
Date: May 30, 2026

Place: Mumbai
Date: May 30, 2026




PANCHSHEEL ORGANICS LIMITED

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026

(Rs. in Lakhs)

	Note	Year ended March 31, 2026	Year ended March 31, 2025
Revenue from operations	26	10,678.26	10,717.84
Other income	27	351.99	307.29
Total Income		11,030.25	11,025.13
Expenses			
Cost of materials consumed	28	4,787.61	5,856.22
Purchase of stock in trade		2,182.20	1,584.44
Changes in inventories of finished goods and work-in-progress	29	196.33	(621.80)
Employees benefit expenses	30	856.31	794.61
Finance costs	31	24.35	37.42
Depreciation and amortisation expenses	32	233.40	219.62
Power and fuel		89.53	96.88
Other expenses	33	1,213.83	1,248.03
Total Expenses		9,583.56	9,215.43
Profit before tax		1,446.69	1,809.70
Income tax expense			
Current tax	22A	365.69	465.61
Excess or short income tax provision		-	
Deferred tax	7A	(2.04)	(35.36)
Total tax expenses		363.65	430.25
Profit for the year		1,083.04	1,379.45
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Remeasurements of post employment benefit obligations		35.49	(101.44)
Income tax relating to above	7B		26.19
Other comprehensive income for the year, net of tax		35.49	(75.25)



Total comprehensive income for the year		1,118.53	1,304.20
Earnings per equity share (in Rs.) (Nominal value per share Rs.10)	40		
Basic earning per share (In Rs.)		8.22	10.47
Diluted earning per share (In Rs.)		8.22	10.47
The notes are an integral part of these financial statements	1 to 44		

In terms of our report of even date

For Panchsheel Organics Limited

For Jayesh R Shah & Co
Chartered Accountants
Firm Registration No. : 104182W

Mahendra Turakhia
Chairman &
Managing Director
DIN: 00006222


Kishore Turakhia
Director
DIN: 00006236

Kruti H Doshi
Partner
Membership No.: 605915
Place: Mumbai
Date: May 30, 2026

Rajesh Turakhia
Director
DIN: 00006246

Deepak Shah
Chief Financial Officer


Sonia Verma
Company Secretary
Place: Mumbai
Date: May 30, 2026




PANCHSHEEL ORGANICS LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026

(Rs. in
Lakhs)

	PARTICULARS	Year ended March 31, 2026	Year ended March 31, 2025
A.	CASH FLOW FROM OPERATING ACTIVITIES		
	Profit before tax	1,446.69	1,809.70
	Adjustments for:		
	Depreciation and amortisation	233.40	219.62
	Interest income	(257.29)	(307.29)
	Interest and finance charges	24.35	37.42
	Loss on sale of Investment	-	0.42
	Other Comprehensive Income	35.49	
	Operating profit before working capital changes	1,482.65	1,759.88
	Adjustments for:		
	Increase / (Decrease) in trade payables, current	121.57	(494.13)
	Increase / (Decrease) in trade payables, non current	(32.84)	(20.78)
	Increase / (Decrease) in other financial liabilities, current	28.47	(38.07)
	Increase / (Decrease) in employee benefit obligation, current	6.05	(50.65)
	Increase / (Decrease) in employee benefit obligation, non current	3.87	90.24
	Increase / (Decrease) in other current liabilities	(12.48)	13.15
	Increase / (Decrease) in other non current liabilities	-	
	(Increase) / Decrease in trade receivables, current	(445.26)	467.18
	(Increase) / Decrease in trade receivables, non current	(87.61)	(44.30)
	(Increase) / Decrease in inventories	82.26	(637.54)
	(Increase) / Decrease in loans, current	(4.68)	17.49
	(Increase) / Decrease in Short term Provision	32.36	
	(Increase) / Decrease in other bank balances	(5.19)	(1.51)
	(Increase) / Decrease in other current assets	227.73	(213.41)
	(Increase) / Decrease in other non-current financial assets		1.50
	Cash generated from operations	1,396.89	849.06



	Taxes paid (net of refunds)	(365.69)	(465.61)
	Net cash generated from operating activities	1,031.20	383.45
B.	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of tangible/intangible assets	(691.37)	(1,555.59)
	Sale proceeds of property plant and equipments	-	
	Investment in Mutual Funds	-	
	Sale proceeds of Mutual Funds	-	305.90
	Interest received	257.29	307.29
	Movement in term deposit with bank (net)	(235.87)	(690.31)
	Net cash (used in) investing activities	(669.95)	(1,632.71)
C.	CASH FLOW FROM FINANCING ACTIVITIES		
	Issue of shares	-	-
	Issue of Share warrants	-	-
	Repayment of borrowings (non current)	(11.33)	(9.37)
	Repayment of borrowings (current)	32.37	(77.87)
	Interest paid	(24.35)	(37.42)
	Dividend paid (Incl. Dividend Distribution Tax)	(421.50)	(395.57)
	Dividend distribution tax paid	-	-
	Net cash (used in) financing activities	(424.81)	(520.24)
	Net increase in cash and cash equivalents (A+B+C)	(63.56)	(1,769.50)
	Cash and cash equivalents at the beginning of the year	415.20	2,184.70
	Cash and cash equivalents at the end of the year	351.64	415.20
	Cash and cash equivalents comprise:		
	Cash on hand	2.87	6.37
	Balances with banks	348.76	408.83
	Demand deposits (less than 3 months maturity)		-
	Total	351.64	415.20



Note: The above cash flow statement has been prepared under "Indirect Method" specified in Ind AS 7 on "Cash Flow Statements".

In terms of our report of even date

For Panchsheel Organics Limited

Mahendra Turakhia
Chairman &
Managing Director
DIN: 00006222

Place: Mumbai
Date: May 30, 2026

PANCHSHEEL ORGANICS LIMITED

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2026


A Equity Share Capital

Balance ss at April 1, 2025	Changes in equity share capital due to prior period errors	Restated balance as at April 1, 2025	Changes in equity share capital during the year	Balance as at March 31, 2026
1,317.18	-	1,317.18		1,317.18

Balance ss at April 1, 2024	Changes in equity share capital due to prior period errors	Restated balance as at April 1, 2024	Changes in equity share capital during the year	Balance as at March 31, 2025
1,178.18	-	1,178.18	139.00	1,317.18

B Other Equity

	Share application money pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instrument through Other Comprehensive Income	Equity Instruments through Other Comprehensive Income	Effective portion of Cash Flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of a foreign operation	Other items of Other Comprehensive Income (specify nature)	Money received against share warrants	Total
			Capital Reserve	Securities Premium Reserve	Other Reserves (General Reserve)	Retained Earnings								
Balance as at April 1, 2025	-	-	-	5,468.55	220.60	6,379.86	-	-	-	-	-	-	-	12,069.01
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	5,468.55	220.60	6,379.86	-	-	-	-	-	-	-	12,069.01
Other comprehensive income	-	-	-	-	-	35.48	-	-	-	-	-	-	-	35.48
Dividends paid (Including dividend distribution tax)	-	-	-	-	-	-421.50	-	-	-	-	-	-	-	-421.50
Transfer to retained earnings (Profit of Current Year)	-	-	-	-	-	1,063.04	-	-	-	-	-	-	-	1,063.04
Issue of bonus shares														
Issue of shares														
Issue of Share warrants														
Any other change (Adj. of MAT entitlement)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2026	-	-	-	5,468.55	220.60	7,078.89	-	-	-	-	-	-	-	12,768.05



			Reserves and Surplus				Debt instruments through Other Comprehe nsive Income	Equity instruments through Other Comprehen sive Income	Effective portion of Cash Flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of a foreign operation	Other items of Other Comprehensive Income (specify nature)	Money received against share warrants	Total
	Share application money pending allotment	Equity component of compound financial instruments	Capital Reserve	Securities Premium Reserve	Other Reserves (General Reserve)	Retained Earnings								
Balance as at April 1, 2024	-	-	-	5,468.95	220.60	5,497.15	-	-	-	-	-	-	-	11,186.30
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	5,468.95	220.60	5,497.15	-	-	-	-	-	-	-	11,186.30
Other comprehensive income	-	-	-	-	-	-75.25	-	-	-	-	-	-	-	-75.25
Dividends paid (Including dividend distribution tax)	-	-	-	-	-	-421.50	-	-	-	-	-	-	-	-421.50
Transfer to retained earnings (Profit of Current Year)	-	-	-	-	-	1,379.45	-	-	-	-	-	-	-	1,379.45
Issue of bonus shares														
Issue of shares														-
Issue of Share warrants														-
Any other change (Adj. of MAT entitlement)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2025	-	-	-	5,468.95	220.60	6,379.06	-	-	-	-	-	-	-	12,069.01

Directors of the Company propose dividend @ 8% amounting to Rs. 105.37 Lakhs as at March 31, 2026

(Rs. 105.37 as at March 31, 2025)

In terms of our report of even date

For Panchsheel Organics Limited

For Jayesh R Shah & Co
Chartered Accountants
Firm Registration No.: 104182W

Mahendra Turakhia
Chairman &
Managing Director
DIN: 00006222

Kishore Turakhia
Director
DIN: 00006236


Kruti H Doshi
Partner
Membership No.: 605915
Place: Mumbai
Date: May 30, 2026

Rajesh Turakhia
Director
DIN: 00006246


Deepak Shah
Chief Financial Officer

Sonia Verma
Company Secretary

Place: Mumbai
Date: May 30, 2026

**PANCHSHEEL ORGANICS LIMITED****NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026**

- 1 Company Overview**
Panchsheel Organics Limited (the 'Company') is a public limited Company domiciled in India with its registered office address being B6 & B7, Sector C, Industrial Estate, Sanwer Road, Indor, M. P. 452015. The company is listed on the Bombay Stock Exchange (BSE). The company's principal business is manufacturing and trading of Bulk Drug and Intermediate.
- The Standalone financial statements of the Company for the year ended 31 March 2026 were approved for issue by the Board of Directors at its meeting held on 30th May 2026. The Company's shareholders have the power to adopt the financial statements in the ensuing Annual General Meeting, but they do not have the power to amend the financial statements after they have been approved for issue by the Board of Directors.
- 2(A) Summary of significant accounting policies**
- 2.01 Basis of preparation**
- a) Compliance with Indian Accounting Standards (Ind AS)**
The financial statements comply in all material aspects with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] and other relevant provisions of the Act.
- b) Historical cost convention**
The financial statements have been prepared on a historical cost basis, except for following items:
- | Items | Measurement Basis |
|--|---|
| Certain financial assets and liabilities | Fair Value |
| Net defined benefit (asset)/ liability | Fair Value of plan assets less present value of defined benefit |
- Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions, regardless of whether that price is directly observable or estimated using another valuation technique. In determining the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
- c) Current versus non-current classification**
All the assets and liabilities have been classified as current or non-current as per the company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of the products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.
- The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.
- An asset is treated as current when it is:**
- Expected to be realized or intended to be sold or consumed in normal operating cycle
 - Held primarily for the purpose of trading
 - Expected to be realized within twelve months after the reporting period, or
 - Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.
- All other assets are classified as non-current.
- A liability is current when:**
- It is expected to be settled in normal operating cycle
 - It is held primarily for the purpose of trading
 - It is due to be settled within twelve months after the reporting period, or
 - There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period
- All other liabilities are classified as non-current.
- Deferred tax assets and liabilities are classified as non-current assets and liabilities.
- Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.
- 2.02 Segment reporting**
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM). Chairman and Managing Director of the Company has been identified as CODM who assesses the financial performance and position of the company, and makes strategic decisions.
- 2.03 Foreign Currency Transactions**
- a) Functional and presentation currency**




The financial statements are presented in Indian Rupees (INR), which is the Company's functional and presentation currency.

b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of profit and loss.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Non-monetary items that are measured at historical cost in foreign currency are translated using the exchange rate at the date of the transaction.

*****THIS SPACE IS INTENSIONALLY LEFT BLANK*****

**2.04 Revenue Recognition****a) Sale of goods :**

Revenue from sale of goods is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company assesses promises in the contract that are separate performance obligations to which a portion of transaction price is allocated.

Revenue is measured based on the transaction price as specified in the contract with the customer. It excludes discounts, incentives, volume rebates, goods & services tax and amounts collected on behalf of third parties. In determining the transaction price, the Company considers below, if any:

Variable consideration :

This includes discounts, incentives, volume rebates, etc. It is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved. It is reassessed at end of each reporting period.

Consideration payable to a customer :

Such amounts are accounted as reduction of transaction price and therefore, of revenue unless the payment to the customer is in exchange for a distinct good that the customer transfers to the Company

Further, in accordance with Ind AS 37, the Company recognises a provision for onerous contract when the unavoidable costs of meeting the obligations under a contract exceed the economic benefits to be received.

Contract balances :

Trade receivables that do not contain a significant financing component are measured at transaction price.

Contract liabilities :

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration (or an amount of consideration is due) from the customer. Contract liabilities are recognised as revenue when the Company performs under the contract.

Significant payment terms :

Generally, the Company provides credit period of 90 days to 120 days to customers.

b) Export incentives

Benefits on account of entitlement of export incentives are recognized as and when the right to receive is established.

c) Interest income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the amortised cost and at the effective interest rate applicable.

d) Dividend income

Dividend income is recognized when the right to receive is established.

2.05 Borrowing costs

General and specific borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalised as part of the cost of such asset till such time the asset is ready for its intended use or sale and borrowing costs are being incurred. Qualifying assets are assets that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.


2.06 Leasing - As a lessee**Ind AS 116 – Leases:**

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A Contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the site on which it is located, less any lease incentives received. Certain lease arrangements include the option to extend or terminate the lease before the end of the lease term.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using incremental borrowing rate. For leases with reasonably similar characteristics, the Company, on a lease by lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole.



Lease payments included in the measurement of the lease liability comprises of fixed payments, including in-substance fixed payments, amounts expected to be payable under a residual value guarantee and the exercise price under a purchase option that the Company is reasonably certain to exercise, lease payments in an optional renewal period if the Company is reasonably certain to exercise an extension option.

The lease liability is subsequently remeasured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if Company changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

Lease liability and the right of use asset have been separately presented in the balance sheet and lease payments have been classified as financing activities.

The Company has elected not to recognise right-of-use assets and lease liabilities for short term leases that have a lease term of less than or equal to 12 months with no purchase option and assets with low value leases. The Company recognises the lease payments associated with these leases as an expense in statement of profit and loss over the lease term. The related cash flows are classified as operating activities.

2.07 Employee benefits

a) Short-term obligations

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

b) Post employee obligations

The Company operates the following post-employment schemes:

- defined benefit plans such as gratuity
- defined contribution plans such as provident fund

i) Gratuity obligations

The liability or asset recognised in the balance sheet in respect of defined benefit gratuity plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is determined at the year end by independent actuary using the projected unit credit method.

The present value of the defined benefit obligation denominated in Indian Rupees is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss.

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity. Remeasurements are not reclassified to profit and loss in the subsequent periods.

ii) Defined contribution plans

Provident fund

The Company pays contributions toward provident fund to the regulatory authorities as per local regulations where the Company has

c) Bonus plans

The Company recognise a liability and an expense for bonuses. The Company recognise a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

2.08 Current and deferred tax


Income tax expense or credit represents the sum of the current tax and deferred tax.

Current and deferred tax is recognised in the Statement of Profit and Loss except to the extent it relates to items recognised in 'Other comprehensive income' or directly in equity, in which case it is recognised in 'Other comprehensive income' or directly in equity, respectively.

Current tax

Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the Statement of profit and loss because some items of income or expense are taxable or deductible in different years or may never be taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Current tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority. The Company periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

**Deferred tax**

Deferred tax is the tax expected to be payable or recoverable in the future arising from temporary differences between the carrying amounts of assets and liabilities in the balance sheet and the corresponding tax bases used in the computation of taxable profit. It is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset realised, based on tax rates that have been enacted or substantively enacted by the reporting date.

A deferred tax asset shall be recognised for the carry-forward of unused tax losses and unused tax credits to the extent that it is probable that future taxable profit will be available against which the unused tax losses and unused tax credits can be utilised.

Deferred income tax assets and liabilities are off-set against each other and the resultant net amount is presented in the Balance sheet, if and only when, (a) the Company currently has a legally enforceable right to set-off the current income tax assets and liabilities, and (b) when the Deferred income tax assets and liabilities relate to income tax levied by the same taxation authority.

Deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting profit nor taxable profit (tax loss).

The carrying amount of deferred tax assets is reviewed at each reporting date and adjusted to reflect changes in probability that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

2.09 Property, plant and equipment

All items of property, plant and equipment ("PPE") are stated at historical cost less accumulated depreciation less accumulated impairment losses. The cost of property, plant and equipment includes purchase price including import duties, non-refundable taxes and expenditure that is directly attributable to acquisition and installation, cost of dismantling and removing the item and restoring the site on which it is located.

Capital work in progress is carried at cost, less any recognised impairment loss. Depreciation of these assets commences when the assets are substantially ready for their intended use. Advances given towards acquisition or construction of PPE outstanding at each reporting date are disclosed as Capital Advances under "Other non-current Assets".

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to the statement of profit and loss during the reporting period in which they are incurred.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in statement of profit and loss.

Depreciation methods, estimated useful lives and residual value


Depreciation is provided on a pro-rata basis on the written down value method (WDV) to allocate their cost, net of their residual values, over their estimated useful lives as per technical evaluation. Estimated useful lives of the assets thereof are as under:

Assets class	Useful life in years
Building	30
Plant and Equipment	15
Laboratory / Testing	15
Furniture and Fixtures	10
Office Equipments	5
Vehicles	8
Computers	3

Estimated useful lives, residual values and depreciation methods are reviewed annually, taking into account commercial and technological obsolescence as well as normal wear and tear and adjusted prospectively, if appropriate.

2.10 Impairment of non-financial assets

Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or group of assets (cash-generating units). Non-financial assets that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

**2.11 Government grants**

Government grant is recognized only when there is a reasonable assurance that the entity will comply with the conditions attaching to them and the grants will be received. Government grant related to assets is recognized as deferred income which is recognized in the statement of profit & loss on systematic basis over the useful life of the assets.

2.12 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost of raw materials, packing materials and fuels comprises cost of purchases. Cost of work-in progress and finished goods comprises direct materials, direct labour, other direct costs and related production overheads. Cost of inventories also include all other costs incurred in bringing the inventories to their present location and condition. Cost is determined using the first in first out (FIFO). Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

However, these items are considered to be realizable at cost if the finished products, in which they will be used, are expected to be sold at or above cost.

2.13 Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, demand deposits with banks, short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

2.14 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a. Initial recognition and measurement:

All financial assets are recognized initially at fair value. In the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset are added to the initial cost of such asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place [regular way trades] are recognized on the settlement date, trade date, i.e., the date that the Company commits to purchase or sell the asset.

b. Subsequent measurement:

For purposes of subsequent measurement, financial assets are classified in four categories:

Effective Interest Method

The effective interest method is a method of calculating the amortised cost of a financial instrument and of allocating interest income or expenses over the relevant period. The effective interest rate is the rate that exactly discounts future cash receipts or payments through the expected life of the financial instrument, or where appropriate, a shorter period.

Financial Assets**i) Classification**

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit or loss),
- those measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in statement of profit or loss or other comprehensive income.

For investments in debt instruments, this will depend on the business model in which the investment is held.

The Company reclassifies debt investments when and only when its business model for managing those assets changes.


Debt instruments

Subsequent measurement of debt instruments depends on the Company's business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Company classifies its debt instruments:

Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost is recognised in statement of profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

Fair value through other comprehensive income (FVOCI): Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognised in profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to statement of profit or loss and recognised in other income. Interest income from these financial assets is included in other income using the effective interest rate method.

Fair value through statement of statement of profit or loss (FVTPL): Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through statement of profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through statement of profit or loss is recognised in statement of profit or loss in the period in which it arises. Interest income from these financial assets is included in other income.

**iii) Impairment of financial assets**

The Company recognizes loss allowances using the expected credit loss (ECL) model for the financial assets which are not fair valued through statement of profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all other financial assets, credit risk is considered to be low.

For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognized from initial recognition of the receivables. As a practical expedient, the company uses a provision matrix to determine impairment loss of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward looking estimates. The ECL loss allowance (or reversal) during the year is recognized in the statement of profit and loss.

iv) De-recognition of financial assets

A financial asset is derecognised only when:

- the Company has transferred the rights to receive cash flows from the financial asset or
- retains the contractual rights to receive the cash flows of the financial asset, but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognised. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not derecognised.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is derecognised if the Company has not retained control of the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

v) Trade Receivable

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment.

Financial Liabilities**i) Classification**

Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definition of a financial liability and an equity instrument.

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognised at the proceeds received, net of direct issue costs.

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, it is a derivative or it is designated as such on initial recognition.

ii) Measurement

Financial liabilities are initially recognised at fair value, reduced by transaction costs (in case of financial liability not at fair value through statement of profit or loss), that are directly attributable to the issue of financial liability. After initial recognition, financial liabilities are measured at amortised cost using effective interest method. The effective interest rate is the rate that exactly discounts estimated future cash outflow (including all fees paid, transaction cost, and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. At the time of initial recognition, there is no financial liability irrevocably designated as measured at fair value through statement of profit or loss.


iii) Derecognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

iv) Borrowings

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in statement of profit or loss over the period of the borrowings using the effective interest method.

Borrowings are removed from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in statement of profit or loss.

**v) Trade and other payables**

Trade and other payables represent liabilities for goods and services provided to the company prior to the end of financial year which are unpaid. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

Offsetting financial instruments

Financial assets and liabilities are offset and the net amount is reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

Dividend distribution to equity shareholders of the Company

The Company recognises a liability to make dividend distributions to its equity holders when the distribution is authorised and the distribution is no longer at its discretion. A corresponding amount is recognised directly in equity

Cash Flow Statement

Cash flows are reported using the indirect method, where by profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

Operating Cycle

Considering the nature of business activities, the operating cycle has been assumed to have a duration of 12 months. Accordingly, all assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in Ind AS 1 'Presentation of Financial Statements' and Schedule III to the Companies Act, 2013.

2.15 Provisions and contingent liabilities**Provision**

Provisions are recognised when the company has a present legal or constructive obligation as a result of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and amount of the obligation can be reliably estimated. Provisions are not recognised for future operating losses.

Provisions are measured at the management's best estimate of the expenditure required to settle the present obligation at the Balance sheet date. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as an interest expense.

Contingent liabilities

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

Contingent Assets

A contingent asset is disclosed, where an inflow of economic benefits is probable.

2.16 Earnings per share

Basic earnings per share is calculated by dividing the profit or loss attributable to owners of the Company by the weighted average number of equity shares outstanding during the financial year. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources.

Diluted earnings per share, adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential equity shares, and the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

2.17 Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Schedule III, unless otherwise stated.


2(B)

Critical estimates and judgements

The preparation of financial statements requires the use of accounting estimates. Management also needs to exercise judgement in applying the Company's accounting policies. This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be different than those originally assessed. The areas involving critical estimates or judgements are:

a) Estimation of Provisions & Contingent Liabilities

The Company exercises judgement in measuring and recognising provisions and the exposures to contingent liabilities which is related to pending litigation or other outstanding claims. If a loss arising from these litigations and/or claims is probable and can be reasonably estimated, the management record the amount of the estimated loss. If a loss is reasonably possible, but not probable, the management discloses the nature of the significant contingency and, if quantifiable, the possible loss that could result from the resolution of the matter. As additional information becomes available, the management reassess any potential liability related to these litigations and claims and may need to revise the estimates. Such revisions or ultimate resolution of these matters could materially impact the results of operations, cash flows or financial statements of the company. (Refer Note 25)

**b) Estimation of current tax expense and deferred tax**

The calculation of the Company's tax charge necessarily involves a degree of estimation and judgement in respect of certain items whose tax treatment cannot be finally determined," until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. "The final resolution of some of these items may give rise to material adjustment to taxable profits/losses (Refer note 7, 22A)

Recognition of deferred tax assets/ liabilities

The recognition of deferred tax assets/ liabilities is based upon whether it is more likely than not that sufficient taxable profits will be available in the future against which the reversal of temporary differences will be offset. To determine the future taxable profits, the management considers the nature of the deferred tax assets, recent operating results, future market growth, forecasted earnings and future taxable income in the jurisdictions in which the company operate. (Refer Note 7).

c) Useful lives of property, plant and equipment

The Company reviews the estimated useful lives of property, plant and equipment at the end of each reporting period or even earlier in case, circumstances change such that the recorded value of an asset may not be recoverable. The estimate of useful life requires significant management judgment and requires assumptions that can include: planned use of equipments, future volume trends, revenue and expense growth rates and annual operating plans, and in addition, external factors such as changes in macroeconomic trends which are developed in connection with the Company's long-term strategic planning.

d) Employee benefit plans

The Company's obligation on account of gratuity and compensated absences is determined based on actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, these liabilities are highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases are based on expected future inflation rates. Further details about gratuity obligations are given in note 30A.

2(C) Recent Accounting Pronouncements

The new and amended standards that are notified by the Ministry of Corporate Affairs (MCA), but not yet effective, up to the date of issuance of the Company's financial statements are disclosed below. The Company will adopt these new and amended standards, when they become effective.

Amendments to Ind AS 1 - Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants and Ind AS 10 Events after the Reporting Period, Ind AS 7 and Ind AS 107 ; Ind AS 12; Ind As 21

Ind AS 1 and Ind AS 10 has been amended to remove the previous treatment under which a lender's post reporting date waiver granted before the financial statements were approved for issue of a breach of a material covenant in a long term loan arrangement that occurred on or before the end of the reporting period, resulting in the liability becoming payable on demand at the reporting date, was regarded as an adjusting event.

For annual reporting periods beginning on or after April 1, 2026, any breach of a covenant whether material or immaterial occurring on or before the reporting date will, in accordance with Ind AS 1, require the related liability to be classified as current, unless the lender has granted a waiver of the breach on or before the reporting date and has agreed not to demand repayment for at least 12 months after the reporting date as a consequence of the breach. Such a waiver shall be treated as an adjusting event.

The amendments are effective for annual reporting periods beginning on or after April 1, 2026 retrospectively in accordance with Ind AS 8. **The Company has evaluated this amendment and does not expect any material impact on its financial statements.**

Ind AS 7 & Ind AS 107 – Supplier Finance Arrangements

The amendments introduce explicit disclosure requirements regarding an entity's supplier finance (reverse factoring) arrangements. Entities are now required to disclose the terms and conditions, the carrying amounts of financial liabilities part of such schemes, and the associated liquidity risk profile. The Company does not expect these amendments to have any significant impact on its financial statements

Ind AS 12 – International Tax Reform (Pillar Two Model Rules)

The amendments introduce a mandatory temporary exception to the accounting for deferred taxes arising from the jurisdictional implementation of the OECD's Pillar Two global minimum tax rules. The Company has applied this exception and is monitoring tax developments in relevant operational jurisdictions. The Company does not expect these amendments to have any significant impact on its financial statements.


Ind AS 21 – Lack of Exchangeability

The amendments introduce specific criteria to determine if a foreign currency is exchangeable into another currency. If a currency lacks exchangeability (due to government controls, sanctions, or market breakdowns), the entity is required to estimate the spot exchange rate at the measurement date. The Company has evaluated this amendment and does not expect any material impact on its financial statements.


PANCHSHEEL ORGANICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026
3 PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

(Rs. in Lakhs)

Sr. No.	Particulars	Gross Carrying Amount				Accumulated Depreciation				Net Carrying Amount
		Opening as at April 01, 2025	Additions	Disposals	Closing as at March 31, 2026	Opening as at April 01, 2025	For the Year	Disposals	Closing as at March 31, 2026	As at March 31, 2026
	Own Assets									
1	Land Leasehold	2.33	-	-	2.33	-	-	-	-	2.33
2	Land Freehold	25.78	-	-	25.78	-	-	-	-	25.78
3	Building	673.20	55.31	-	728.51	158.73	48.75	-	207.48	521.03
4	Plant and Equipment	1,511.76	366.28	-	1,878.04	801.07	137.68	-	938.75	939.29
5	Laboratory / Testing	129.93	32.30	-	162.24	80.08	18.61	-	98.70	63.54
6	Furniture and Fixtures	17.61	4.66	-	22.27	15.38	0.66	-	16.04	6.23
7	Office Equipments	4.49	2.68	-	7.17	4.10	0.40	-	4.50	2.67
8	Vehicles	310.78	-	-	310.78	218.63	25.58	-	244.21	66.58
9	Computers	10.59	1.11	-	11.70	8.02	1.70	-	9.71	1.98
10	LAND PITHAMPUR SIP	389.94	-	-	389.94	-	-	-	-	389.94
	TOTAL	3,076.42	462.34	-	3,538.76	1,286.01	233.40	-	1,519.40	2,019.36

(Rs. in Lakhs)

Sr. No.	Particulars	Gross Carrying Amount				Accumulated Depreciation				Net Carrying
		Opening as at	Addition	Disposals	Closing as at	Opening as at	For the Year	Dispo	Closing as at	As at March 31,
	Own Assets									
1	Land Leasehold	0.54	1.79	-	2.33	-	-	-	-	2.33
2	Land Freehold	25.78	-	-	25.78	-	-	-	-	25.78
3	Building	643.32	29.88	-	673.20	108.50	50.23	-	158.73	514.47
4	Plant and Equipment	1,280.90	230.87	-	1,511.76	683.61	117.47	-	801.07	710.69
5	Laboratory / Testing	126.19	3.75	-	129.93	65.26	14.82	-	80.08	49.85
6	Furniture and Fixtures	17.21	0.41	-	17.61	14.78	0.60	-	15.38	2.23
7	Office Equipments	4.49	-	-	4.49	3.86	0.24	-	4.10	0.39
8	Vehicles	310.78	-	-	310.78	183.21	35.41	-	218.63	92.16
9	Computers	8.41	2.18	-	10.59	7.18	0.85	-	8.02	2.57
10	LAND PITHAMPUR SIP		389.94	-	389.94			-	-	389.94
	TOTAL	2,417.61	658.81	-	3,076.42	1,066.39	219.62	-	1,286.01	1,790.41



PANCHSHEEL ORGANICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026

4 CAPITAL WORKING PROGRESS

(Rs.)

Particulars	Factory Building	Plant & Machinery	Advance for Land	Total
Carring amount as on March 31, 2023	80.46	189.40	83.17	353.02
Additions	56.96	259.68	(83.17)	233.47
Carring amount as on March 31, 2024	137.42	449.07	-	586.49
Additions	47.71	849.07	-	896.78
Carring amount as on March 31, 2025	185.13	1,298.15	-	1,483.28
Additions	74.75	154.28	-	229.04
Carring amount as on March 31, 2026	259.88	1,452.43	-	1,712.31

CAPITAL WORK -IN- PROGRESS AGING

Ageing for capital work-in-process as at March 2026 is as follows :

(Rs.)

CWIP	Amount in CWIP for a period of				Total
	Less than 1	1-2 year	2-3 year	more then 3 year	
Project in process	229.04	896.78	233.47	353.02	1,712.31
Project temporarily suspended	-	-	-	-	-
Total	229.04	896.78	233.47	353.02	1,712.31


Ageing for capital work-in-process as at March 2025 is as follows :

(Rs. in lakhs)

CWIP	Amount in CWIP for a period of				Total
	Less than 1	1-2 year	2-3 year	more then 3 year	
Project in process	896.78	233.47	353.02	-	1,483.28
Project temporarily suspended	-	-	-	-	-
Total	896.78	233.47	353.02	-	1,483.28

Title deeds of immoveable properties not held in the name of the Company

Releavent line items in the Balance Sheet	Description of items of property	Gross carrying Value	Title deeds held in the name of	Whether the deed holder/promotor/director/relative of promotor/director or employee of company	Property held since which date	Reason for not being held in the name of the company
N/A	N/A	NIL	N/A	N/A	N/A	N/A



PANCHSHEEL ORGANICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026

(Rs. in Lakhs)

5	INVESTMENTS (NON-CURRENT)	As at March 31, 2026	As at March 31, 2025
	Investments in equity Instruments (fully paid up)		
	<u>Unquoted</u>		
	10 Shares in Gujrat Mercantile Credit Co Op Soc Ltd of Rs. 100 each	0.01	0.01
	<u>Quoted</u>		
	Mutual Funds (carried at fair value through profit or loss)	-	-
	Investment in debt instruments		
	<u>Unquoted</u>		
	Indira Vikas Patra	0.05	0.05
	TOTAL	0.06	0.06

Note:

Aggregate amount of Quoted Investments	-	-
Market Value of Quoted Investments (Quoted Price)	-	-
Aggregate amount of Unquoted Investments	0.06	0.06
Aggregate amount of impairment in the value of the investments	-	-


(Rs. in Lakhs)

6	OTHER NON-CURRENT FINANCIAL ASSETS	As at March 31, 2026	As at March 31, 2025
	unsecured considered good		
	Deposit with bank with maturity period of more than 12 months		
	- In fixed deposit accounts	3,790.24	3,554.38
	- In margin money deposit accounts	-	-
		17.71	17.71
	<i>*All the above deposits are refundable deposits placed with statutory and government authorities in the ordinary course of business.</i>		
	TOTAL	3,807.96	3,572.09

(Rs. in Lakhs)

7	DEFERRED TAX ASSETS (NET)	As at March 31, 2026	As at March 31, 2025
	Deferred tax assets (Net)	112.54	110.50
	TOTAL	112.54	110.50
	The balance comprises temporary		
	Deferred Tax Liability		
	Depreciation	2.24	-
	Borrowing Cost		-
	Less : Deferred Tax Assets		
	Provision for gratuity	104.20	101.71
	Provision for bonus	10.57	8.71
	Depreciation		0.08
	Net Deferred Tax Asset (Refer note below)	112.54	110.50

Note: Deferred tax assets and deferred tax liability have been offset as they relate to same governing taxation laws.



(Rs. in Lakhs)						
7A	MOVEMENT IN DEFERRED TAX ASSETS/LIABILITIES	As at March 31, 2025	(Charged)/ Credited to Profit and Loss	(Charged)/ Credited to OCI	(Charged)/ Credited to Equity	As at March 31, 2026
	Deferred Tax Liability					
	Depreciation	-	(2.24)	-	-	2.24
	Borrowing Cost	-	-	-	-	-
	Total Deferred Tax Liability	-	(2.24)	-	-	2.24
	Less : Deferred Tax Assets					
	Provision for gratuity	101.71	2.50	-	-	104.20
	Provision for bonus	8.71	1.86	-	-	10.57
	Depreciation	0.08	(0.08)	-	-	-
	Total Deferred Tax Assets	110.50	4.28	-	-	114.78
	Net Deferred Tax Assets	110.50	2.04	-	-	112.54

7B	MOVEMENT IN DEFERRED TAX ASSETS/LIABILITIES	As at March 31, 2024	(Charged)/ Credited to Profit and Loss	(Charged)/ Credited to OCI	(Charged)/ Credited to Equity	As at March 31, 2025
	Deferred Tax Liability					
	Depreciation	25.47	(25.47)	-	-	-
	Borrowing Cost	(0.00)	0.00	-	-	-
	Total Deferred Tax Liability	25.47	(25.47)	-	-	-
	Less : Deferred Tax Assets					
	Provision for gratuity	66.21	9.31	26.19	-	101.71
	Provision for bonus	8.21	0.51	-	-	8.71
		-	0.08	-	-	0.08
	Total Deferred Tax Assets	74.42	9.89	26.19	-	110.50
	Net Deferred Tax Assets	48.94	35.36	26.19	-	110.50

(Rs. in Lakhs)			
8	OTHER NON CURRENT ASSETS	As at March 31, 2026	As at March 31, 2025
	Other Trade receivables (disputed considered good) <i>The above receivables do not belong to any related party</i>	586.41	498.80
	TOTAL	586.41	498.80

(Rs. in Lakhs)			
9	INVENTORIES	As at March 31, 2026	As at March 31, 2025
	Raw materials	2,578.86	2,464.78
	Work in progress	615.28	754.42
	Finished Goods	1,143.08	1,325.18
	Traded Stock	170.32	45.41
	TOTAL	4,507.53	4,589.79

(Rs. in Lakhs)			
10	TRADE RECEIVABLES	As at March 31, 2026	As at March 31, 2025
	Trade receivables- Unsecured		
	Undisputed Trade receivables -considered good	3,924.96	3,479.71
	Receivables from related parties	-	-
	SUB- TOTAL	3,924.96	3,479.71
	Less: Expected credit loss allowance	-	-
	Sub Total 1	3,924.96	3,479.71
	TOTAL	3,924.96	3,479.71

A a. The above balance has no due o/s from related party

b. Expected Credit Loss

Based on the Company's assessment of the recoverability of its trade receivables, including evaluation of historical collection trends, ongoing communications with customers, subsequent recoveries and other available information, the expected credit loss has been assessed as Nil and accordingly no loss allowance has been recognised as at March 31, 2026.

Trade receivables outstanding for more than three years include export receivables aggregating to Rs. 114.89 lakhs. These receivables are under dispute and have been reported to the Reserve Bank of India in accordance with applicable regulatory requirements. Based on the current status of the matter and management's assessment of the likelihood of recovery, no impairment provision has been considered necessary as at the reporting date. The Company continues to monitor the matter and will reassess the recoverability of these receivables at each reporting date.

Further, in respect of receivables outstanding for more than two years, management has undertaken a customer-wise assessment on Mar 26 based on recent follow-ups, confirmations, ongoing business discussions and other relevant information available, management is of the opinion to continuously monitor these receivables and recognise impairment losses, if any, in upcoming year as and when required in accordance with the requirements of Ind AS 109.

Trade Receivables ageing schedule as at 31st March, 2026

(Rs. in Lakhs)						
	Particulars	Outstanding for following periods from due date of payment				
		Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years
(i)	Undisputed Trade receivables - considered good	3,397.27	527.69	191.14	-	-
(ii)	Undisputed Trade receivables - considered doubtful	-	-	-	-	-
(iii)	Disputed trade receivables considered good	-	-	-	118.09	277.17
(iv)	Disputed trade receivables considered doubtful	-	-	-	-	-
	TOTAL					



(Rs. in Lakhs)							
	Particulars	Outstanding for following periods from due date of payment					Total
		Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i)	Undisputed Trade receivables - considered good	3,134.83	344.88	190.02	25.78		3,695.50
(ii)	Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii)	Disputed trade receivables considered good	-	-	-	-	283.00	283.00
(iv)	Disputed trade receivables considered doubtful	-	-	-	-	-	-

(Rs. in Lakhs)			
11	CASH AND CASH EQUIVALENTS	As at March 31, 2026	As at March 31, 2025
	Cash and Cash equivalents:		
	Cash on hand	2.87	6.37
	Bank Balances :		
	- In Current accounts	348.76	408.83
	- In Margin Money deposit maturing within 3 month	-	-
	TOTAL	351.64	415.20

(Rs. in Lakhs)			
12	OTHER BANK BALANCES	As at March 31, 2026	As at March 31, 2025
	Deposits with banks (Maturity more than three months and upto twelve months)	-	-
	Earmarked balance with bank for unpaid dividend	31.12	25.92
	TOTAL	31.12	25.92

(Rs. in Lakhs)			
13	LOANS (CURRENT)	As at March 31, 2026	As at March 31, 2025
	(Unsecured, considered good)		
	Loan to employees and other advances	22.87	18.18
	TOTAL	22.87	18.18

Loans and advances to Directors, promoters, KMP's, related parties

Repayable on demands

		Current Period		Previous period	
14A	Type of Borrowers	Amt. Outstanding	% of total	Amt. Outstanding	% of total
(i)	Promoters	-	-	-	-
(ii)	Directors	-	-	-	-
(iii)	KMP's	-	-	-	-
(iv)	Related parties	-	-	-	-
	Total	-	-	-	-

Without specifying any terms or period of repayments

		Current Period		Previous period	
14B	Type of Borrowers	Amt. Outstanding	% of total	Amt. Outstanding	% of total
(i)	Promoters	-	-	-	-
(ii)	Directors	-	-	-	-
(iii)	KMP's	-	-	-	-
(iv)	Related parties	-	-	-	-
	Total	-	-	-	-

(Rs. in Lakhs)			
14	OTHER CURRENT ASSETS	As at March 31, 2026	As at March 31, 2025
	(Unsecured, considered good unless otherwise stated)		
	Deposits with government authorities towards matters in litigation	107.14	324.30
	Income Tax Assets(Net)	-	12.87
	Pre-paid expense	9.25	6.95
	TOTAL	116.39	344.12



		(Rs. in Lakhs)	
15	SHARE CAPITAL	As at March 31, 2026	As at March 31, 2025
	Authorised 1,60,00,000 (March 31, 2026 : 1,60,00,000) equity shares of Rs. 10/- each	1,600.00	1,600.00
		1,600.00	1,600.00
	Issued 1,31,71,750 (March 31, 2026 : 1,31,71,750) equity shares of Rs. 10/- each	1,317.18	1,317.18
	Subscribed and paid-up 1,31,71,750 (March 31, 2026 : 1,31,71,750) equity shares of Rs. 10/- each	1,317.18	1,317.18
	TOTAL	1,317.18	1,317.18

a) Reconciliation of the number of shares : Equity Shares

(Rs. in Lakhs)					
	Particulars	As at March 31, 2026		As at March 31, 2025	
		Number of Shares	Amount	Number of Shares	Amount
	Balance at the beginning of the year	131.72	1,317.18	131.72	1,317.18
	Add: Conversion of warrants into equity shares	-	-	-	-
	Add: Preferential Allotment	-	-	-	-
	Balance at the end of the year	131.72	1,317.18	131.72	1,317.18

b) Rights, preferences and restrictions attached to equity shares

The company has one class of equity shares having a par value of Rs. 10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amount, in proportion to their shareholding.

c) Details of shareholder holding more than of 5% of the aggregate shares in the company

Name of Shareholder	As at March 31, 2026		As at March 31, 2025	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
(i) Mahendra A Turakhia	21.21	16.10%	21.21	16.10%
(ii) Kishore A Turakhia	21.22	16.11%	21.22	16.11%
(iii) Rajesh A Turakhia	21.28	16.16%	21.28	16.16%
TOTAL	63.70	48.36%	63.70	48.36%

d) The company has converted 1390000 warrants of Rs 10 each at Rs. 183.15 per warrant into equity shares on March 7, 2024.

e) Disclosure of Shareholding of Promoters

Shares held by promoters at the end of the year 31st March 2026				
Sr. No.	Promoter Name	No. of Shares	% of total shares	% Change during the year
(i)	Rajesh A Turakhia	21.28	16.15%	0.00
(ii)	Kishore A Turakhia	21.22	16.11%	0.00
(iii)	Mahendra A Turakhia	21.21	16.10%	0.00
(iv)	Turakhia Rajesh Abhaychand HUF	3.57	2.71%	0.00
(v)	Turakhia Mahendra Abhaychand HUF	3.57	2.71%	0.00
(vi)	Turakhia Kishore Abhaychand HUF	3.07	2.33%	0.00
		73.93	56.12%	
Shares held by promoters at the end of the year 31st March 2025				
Sr. No.	Promoter Name	No. of Shares	% of total shares	% Change during the year
(i)	Rajesh A Turakhia	21.28	16.15%	0
(ii)	Kishore A Turakhia	21.22	16.11%	0
(iii)	Mahendra A Turakhia	21.21	16.10%	0
(iv)	Turakhia Rajesh Abhaychand HUF	3.57	2.71%	0
(v)	Turakhia Mahendra Abhaychand HUF	3.57	2.71%	0
(vi)	Turakhia Kishore Abhaychand HUF	3.07	2.33%	0
		73.92	56.12%	0

		(Rs. in Lakhs)	
16	BORROWINGS - NON-CURRENT	As at March 31, 2026	As at March 31, 2025
	Secured:		
	Vehicle Loan:		
	From Banks	17.82	30.92
	Less: Current maturities of long term debt	(11.33)	(13.09)
		6.49	17.82
	TOTAL	6.49	17.82

Details of loans and securities

Vehicle 1- Rs 4.53 Lakh O/s as on Mar 26, repayable in 60 months with 60 equal installment of Rs 22455 each till Jan'28

Vehicle 2- Rs 0.26 Lakh O/s as on Mar 26, repayable in 36 months with 36 equal installment of Rs 26556 each till April'26

Vehicle 3- Rs 8.01 Lakh O/s as on Mar 26, repayable in 60 months with 60 equal installment of Rs 41375 each till Dec'27

Vehicle 4- Rs 5.01 Lakh O/s as on Mar 26, repayable in 39 months with 39 equal installment of Rs 37887 each till May'27

Details of securities: Charge over vehicles financed and post dated cheques

There is no default in repayment of Loan Installment and interest thereon.



(Rs. in Lakhs)			
17	TRADE PAYABLE - NON-CURRENT	As at March 31, 2026	As at March 31, 2025
	Trade payables	195.12	227.97
	TOTAL	195.12	227.97

Ageing kindly refer below

(Rs. in Lakhs)			
18	EMPLOYEE BENEFIT OBLIGATIONS - NON-CURRENT	As at March 31, 2026	As at March 31, 2025
	Provision for employee benefits (Refer note no. 30A)		
	Provision for gratuity	272.30	268.43
	TOTAL	272.30	268.43


(Rs. in Lakhs)			
19	BORROWINGS - CURRENT	As at March 31, 2026	As at March 31, 2025
	Secured:		
	Working Capital loan from Bank (Refer note below)	546.89	512.75
	Current maturities of long term borrowings (Vehicle loan- details of security, kindly refer note 16)	11.33	13.09
	TOTAL	558.23	525.84

Details of securities

1. Exclusive charge on stock and receivables

(Rs. in Lakhs)			
20	TRADE PAYABLES	As at March 31, 2026	As at March 31, 2025
	a) total outstanding dues of micro enterprises and small enterprises	104.37	336.14
	b) total outstanding dues of creditors other than micro enterprises and small enterprises and dues to related parties	1,641.23	1,268.33
	c) total outstanding dues to related parties	14.85	34.40
	TOTAL	1,760.45	1,638.87

(Rs. in Lakhs)			
20A	DUES TO MICRO AND SMALL ENTERPRISES	As at March 31, 2026	As at March 31, 2025
	Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	104.37	335.02
	Principal amount over due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	1.07
	Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	0.05	0.05
	Principal amount paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
	Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
	Interest paid under section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
	Interest due and payable towards suppliers registered under MSMED Act, for payment already made.	-	-
	Further interest remaining due and payable for earlier years	-	-
	TOTAL	104.41	336.13



Trade Payables ageing schedule: As at 31st March, 2026

(Rs. in Lakhs)

20B	Particulars	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i)	MSME	104.37	-	-	-	104.37
(ii)	Others	1,656.08	55.85	2.76	136.52	1,851.20
(iii)	Disputed dues- MSME	-	-	-	-	-
(iv)	Disputed dues - Others	-	-	-	-	-

Trade Payables ageing schedule: As at 31st March, 2025

(Rs. in Lakhs)

20B	Particulars	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i)	MSME	336.14	-	-	-	336.14
(ii)	Others	1,302.73	67.31	3.53	157.12	1,530.70
(iii)	Disputed dues- MSME	-	-	-	-	-
(iv)	Disputed dues - Others	-	-	-	-	-

During the year no interest has been paid to such parties. This information has been determined to the extent such parties have been identified on the basis of information available with the Company and certificates provided by counterparties

(Rs. in Lakhs)

21	OTHER CURRENT FINANCIAL LIABILITIES	As at March 31, 2026	As at March 31, 2025
	Salaries payable	38.56	22.68
	Provision for Bonus	42.00	34.61
	Dividend distribution tax	-	-
	Unclaimed dividend	31.12	25.92
	TOTAL	111.68	83.22

(Rs. in Lakhs)

22	SHORT TERM PROVISIONS	As at March 31, 2026	As at March 31, 2025
	Provision for Income Tax		
	Movement in provision for income tax		
	Opening balance	(12.87)	5.65
	Less: Current tax payable for the year	388.09	451.44
	Add: Taxes Paid / (Refunded)	(342.86)	(469.96)
	Closing balance	32.36	(12.87)

(Rs. in Lakhs)


22A	TAX EXPENSE	As at March 31, 2026	As at March 31, 2025
	Current Tax :		
	Current Tax on Profits for the Year	365.69	465.64
	Total Current Tax Expense	365.69	465.64
	Deferred Tax :		
	Decrease/(Increase) in Deferred Tax Assets	(4.28)	(9.89)
	(Decrease)/increase in Deferred Tax Liabilities	2.24	(25.47)
	Total Deferred Tax Expense/(Benefit)	(2.04)	(35.36)
	Income Tax Expense	363.65	430.28
	Reconciliation of tax expense and accounting profit multiplied by statutory tax rate		
	Profit for the year	1,446.69	1,809.70
	Rate of tax	25.17%	25.17%
	Tax Expense at Applicable Tax Rate	364.13	455.50
	Tax Rate Difference	-	-
	CSR Expenses	-	-
	Interest on delayed payment of TDS and advance tax	-	-
	Deferred tax adjustment	-	-
	Others	(0.48)	(25.22)
	Income Tax Expense	363.65	430.28



(Rs. in Lakhs)			
23	EMPLOYEE BENEFIT OBLIGATIONS - CURRENT	As at March 31, 2026	As at March 31, 2025
	Provision for employee benefits		
	Provision for gratuity	141.70	135.65
	TOTAL	141.70	135.65


(Rs. in Lakhs)			
24	OTHER CURRENT LIABILITIES	As at March 31, 2026	As at March 31, 2025
	Statutory dues (including provident fund and tax deducted at source)	31.58	44.05
	TOTAL	31.58	44.05

(Rs. in Lakhs)							
25	CONTINGENT LIABILITIES					As at March 31, 2026	As at March 31, 2025
	Claim against the Company not acknowledged as debts						
	a) Demand contested by the Company						
	- Sales tax						71.34
	- Excise duty						
	- Income tax (Incl. TDS)						8.28
	Below id details of above demand						
	Name of the Statue	Nature of Dues	Original Demand	INTEREST	Amount paid	Amt Due	FY pertaining to demand
	Income Tax Act, 1961	80HHC/80IA/ MAT/Regular Demand	1.16	2.69		3.85	FY 2005-06
	Income Tax Act, 1961	80HHC/80IA/ MAT/Regular Demand	6.30	5.54		11.85	FY 2016-17
	Income Tax Act, 1961	80HHC/80IA/ MAT	0.00	0.12		0.12	FY 2017-18
	Income Tax Act, 1961	80HHC/80IA/ MAT	6.71	3.63		10.34	FY 2019-20
	Income Tax Act, 1961	80HHC/80IA/ MAT	0.77	0.26		1.03	FY 2021-22
	Income Tax Act, 1961	80HHC/80IA/ MAT	0.34	0.06		0.39	FY 2023-24
	Income Tax Act, 1961	80HHC/80IA/ MAT	19.39	0.31		19.70	FY 2024-25
	Name of the Statue	Nature of Dues	Original Demand	INTEREST	Amount paid	Amt Due	FY pertaining to demand
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	6.60	0.00	2.08	4.52	FY 2005-06
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	12.73	0.00	10.00	2.73	FY 2006-07
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	8.21	0.00	2.30	5.91	FY 2007-08
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	2.76	0.00	0.00	2.76	FY 2008-09
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	11.80	0.00	4.92	6.89	FY 2008-09
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	9.43	0.00	5.17	4.26	FY 2009-10
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	10.05	0.00	1.54	8.51	FY 2010-11
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	8.77	0.00	3.79	4.98	FY 2011-12
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	40.74	0.00	18.39	22.35	FY 2012-13
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	5.51	0.00	4.93	0.58	FY 2013-14
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	6.22	0.00	1.71	4.52	FY 2014-15
	Central Sales Tax & VAT	Sales Tax Interest & Penalty	4.43	0.00	1.11	3.32	FY 2016-17
	No provision has been recognised in respect of the above matters, as the amount of the obligation cannot be measured reliably. Based on the assessment of the facts and legal advice obtained, management believes that the likelihood of an outflow of economic resources is not probable and that the Company has a strong case in its favour. Accordingly, the matters have been disclosed as contingent liabilities.						


PANCHSHEEL ORGANICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026

(Rs in Lakhs)

26	REVENUE FROM OPERATIONS	Year ended March 31, 2026	Year ended March 31, 2025
	Sale of Products		
	Finished Goods		
	- Bulk Drug & Intermediate	8,399.86	8,896.39
	Stock in trade		
	- Bulk Drug & Intermediate	2,153.62	1,683.29
	- Formulations	115.07	129.50
	Total sale of products	10,668.55	10,709.18
	Other operating revenue		
	- D.E.P.B. License		
	- Others	9.71	8.66
	Total other operating income	9.71	8.66
	TOTAL	10,678.26	10,717.84
27	OTHER INCOME	Year ended March 31, 2026	Year ended March 31, 2025
	Interest Income from financial assets at amortised cost	257.29	307.29
	Wind Mill		-
	Other Income	94.70	-
	Commission Received		-
	TOTAL	351.99	307.29
28	COST OF MATERIAL CONSUMED	Year ended March 31, 2026	Year ended March 31, 2025
	Raw material consumed		
	Opening inventory	2,464.78	2,449.04
	Add: Purchases	7,021.82	7,394.16
	Less: Closing inventory	2,578.86	2,464.78
	Cost of raw material consumed during the year	6,907.74	7,378.42
	Packing material consumed		
	Opening inventory		
	Add: Purchases	62.07	62.25
	Less: Closing inventory		
	Cost of packing material consumed during the year	62.07	62.25
	TOTAL	6,969.81	7,440.67
29	CHANGES IN INVENTORIES OF FINISHED GOODS, WORK IN PROGRESS AND STOCK IN TRADE	Year ended March 31, 2026	Year ended March 31, 2025
	(Increase) / Decrease in stocks		
	Stock at the end of the year		
	Finished goods	1,143.08	1,325.18
	Work in progress	576.02	746.47
	Stock in trade	209.57	53.36
	TOTAL A	1,928.68	2,125.01
	Less: Stock at the beginning of the year		
	Finished goods	1,325.18	1,115.68
	Work in progress	746.47	232.68
	Stock in trade	53.36	154.85
	TOTAL B	2,125.01	1,503.21
	(Increase) / Decrease in stocks (B-A)	196.33	(621.80)
30	EMPLOYEE BENEFITS EXPENSES	Year ended March 31, 2026	Year ended March 31, 2025
	Salaries, wages and bonus	735.49	690.07
	Contribution to provident and other funds:		
	Provident fund [Refer note no. 30A(i)]	27.22	22.79
	Gratuity [Refer note no. 30A(ii)]	50.34	40.68
	ESIC	9.01	7.74
	Staff welfare expenses	34.25	33.32
	TOTAL	856.31	794.61



30A EMPLOYEE BENEFIT OBLIGATIONS:

i) Defined-contribution plans

The Company makes contribution to provident fund under the provision of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 and to superannuation fund for the qualifying employees as per the Company's policy.

Amount recognised in Statement of Profit and Loss	Year ended March 31, 2026	Year ended March 31, 2025
Provident fund	27.22	22.79

ii) Defined-Benefits Plans

The company provides for gratuity, a defined benefit retirement plan covering eligible employees. The Gratuity Plan provides a lump sum payments to vested employees at retirement, death, incapacitation or termination of employment, as per the company's policy. Vesting occurs on completion of 5 continuous years of service as per Indian law. However, no vesting condition applies in case of death. The gratuity payable to employees is based on the employee's service and last drawn salary at the time of leaving the services of the Company. The gratuity plan is an unfunded plan.

Profit & Loss account expenses:

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Current Service Cost	39.36	21.39
Past service Cost		
Interest on defined benefit obligation/(asset) (net)	10.98	19.29
Total expenses charged	50.34	40.68

Amount recorded in other comprehensive income:

Particulars	As at March 31, 2026	As at March 31, 2025
Opening balance recorded in OCI		
Remeasurement during the period due to:		
(Gain)/loss from change in financial assumptions		
(Gain)/loss from change in demographic assumptions		
Experience (gains)/losses	35.49	101.44
Actuarial (gains)/losses on plan assets		
Total amount recognised in OCI	35.49	101.44

Present value of defined benefit obligation:


Particulars	Gratuity (Unfunded Plan)	
	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year	404.08	265.36
Current service cost	39.36	21.39
Past service cost		
Interest on defined benefit obligation	10.98	19.29
Remeasurement due to:		
(Gain)/loss from change in financial assumptions	28.39	4.02
(Gain)/loss from change in demographic assumptions		
Experience (gains)/losses	(63.88)	95.11
Benefit paid	(4.93)	(1.10)
Balance at the close of the year	414.00	404.08

Fair value of plan assets:

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year		-
Contributions by employer		-
Interest income		-
Benefits paid		-
Actuarial gains/(losses) on plan assets		-
Balance at the close of the year		-

Assets and Liabilities recognised in the Balance Sheet:

Particulars	As at March 31, 2026	As at March 31, 2025
Present value of obligations	414.00	404.08
Fair value of plan assets		
Deficit of funded plan	414.00	404.08
Non-current (Note 18)	272.30	268.42
Current	141.70	135.65



Major Category of Plan Assets as a % of total Plan Assets:

Particulars	As at March 31, 2026	As at March 31, 2025
Government of India securities	0.00%	0.00%
Corporate bonds	0.00%	0.00%
Insurance managed fund	0.00%	0.00%
Others	0.00%	0.00%
	0.00%	0.00%

Actuarial Assumptions:

Particulars	As at March 31, 2026	As at March 31, 2025
Discount rate	7.98%	7.06%
Salary Growth rate	5%	5.00%

The discount rates reflects the prevailing market yields of Indian Government securities as at the Balance Sheet date for the estimated term of the obligations.

The estimates of future salary increases, considered in actuarial valuation, takes into account, inflation, seniority, promotions and other relevant factors, such as demand and supply in the employment market.

The expected rate of return of plan assets is the Company's expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations.

Sensitivity Analysis

The sensitivity of the defined benefit obligation to changes in the weighted principal assumptions by 0.5% is:

a) Impact of the change in discount rate	Rs in Lakhs
Present Value of Obligation at the end of the period	414
a) Impact due to increase of 0.50%	(8.43)
b) Impact due to decrease of 0.50 %	8.91
b) Impact of the change in salary increase	(Rs.)
Present Value of Obligation at the end of the period	414.00
a) Impact due to increase of 0.50%	9.13
b) Impact due to decrease of 0.50 %	(8.70)

The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied which has been used for calculating the defined benefit liability recognised in the Balance Sheet.

The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the prior period.

Expected Contribution to the Fund in the next year:

Particulars	As at March 31, 2026	As at March 31, 2025
Gratuity	51.41	47.93

iv) Risk Exposure

The Gratuity scheme is a final salary Defined Benefit Plan that provides for a lump sum payment made on exit either by way of retirement, death, disability or voluntary withdrawal. The benefits are defined on the basis of final salary and the period of service and paid as lump sum at exit. The risks commonly affecting the defined benefit plan are expected to be:

Demographic Risk: This is the risk of variability of results due to unsystematic nature of decrements that include mortality, withdrawal, disability and retirement. The effect of these decrements on the defined benefit obligation is not straight forward and depends upon the combination of salary increase, discount rate and vesting criteria. It is important not to overstate withdrawals because in the financial analysis the retirement benefit of a short career employee typically costs less per year as compared to a long service employee.

Salary Inflation Risk : Higher than expected increases in salary will increase the defined benefit obligation

Interest-Rate Risk: The defined benefit obligation calculated uses a discount rate based on government bonds. If bond yields fall, the defined benefit obligation will tend to increase.

v) Defined Benefit Liability and Employer Contributions

The company considers that the contribution rates set at the last valuation date are sufficient to eliminate the deficit over the agreed period and that regular contributions, which are based on service costs, will not increase significantly.



The expected maturity analysis of undiscounted gratuity is as follows:


Maturity Analysis of the Projected Benefit Obligations - Gratuity (Undiscounted)

Particulars	As at March 31, 2026	As at March 31, 2025
1st Following Year	141.70	135.65
2nd Following Year	11.67	7.40
3rd Following Year	8.49	10.03
4th Following Year	8.70	7.87
5th following year	94.37	8.10
Sum of 6th to 10th Following Year	149.08	235.03

31	FINANCE COSTS	Year ended March 31, 2026	Year ended March 31, 2025
	Interest on short term borrowings	5.42	4.54
	Interest on long term borrowings	2.30	3.32
	Other finance cost	16.63	29.56
	TOTAL	24.35	37.42

32	DEPRECIATION AND AMORTISATION EXPENSES	Year ended March 31, 2026	Year ended March 31, 2025
	Depreciation on property, plant and equipment	233.40	219.62
	TOTAL	233.40	219.62

33	OTHER EXPENSES	Year ended March 31, 2026	Year ended March 31, 2025
	Other Direct Expense		
	Consumables	18.76	21.22
	Quality control expenses	4.71	3.54
	Security Service	6.33	6.47
	Other operating expenses	85.76	64.46
	Freight, handling and other charges	48.47	39.87
	Processing Charges	681.86	839.61
	Loading Charges	16.67	14.10
	Other Indirect Expenses		
	Loss on sales of Assets	-	0.42
	Commission & Brokerage	32.90	39.17
	Advertisement and publicity expenses	8.09	8.18
	Outward Cartage, Hamali & Crain Charges	13.25	16.06
	Legal and professional fees	1.00	0.40
	Consolidation charges	3.03	2.46
	Conveyance	12.05	11.42
	CSR-CORPORATE SOCIAL RESPONSIBILITY	50.00	-
	Courier Charges	11.25	10.31
	Discount	14.15	-
	Export Clearing Charges	4.44	9.97
	Exhibition Expenses	24.22	28.67
	Fees & Subscription	13.19	17.84
	Freight Outward	3.55	2.86
	Interest on Income Tax	3.20	-
	Miscellaneous Expenses	11.65	4.17
	Printing & Stationary	4.34	5.83
	Rent	22.72	20.25
	Telephone Expenses & Charges	1.33	1.25
	Travelling Expenses	24.57	16.86
	Other Administrative Expenses	38.50	37.82
	Warehousing Charges	0.97	0.88
	Duties and taxes	18.23	0.38
	Donation Expenses	2.02	1.26
	Directors fees	0.23	0.30
	Consultancy Charges	27.89	18.00
	Net loss on foreign currency transactions and translations		
	Payment to auditors		
	As auditor:		
	Audit fees (Including limited review)	3.50	3.50
	Tax audit fees	1.00	0.50
	Certification Fees		
	TOTAL	1,213.83	1,248.03



33A Value of Imports on CIF basis in respect of :

	Year ended March 31, 2026	Year ended March 31, 2025
Raw Material	1,201.59	842.74
Componets and Spare Parts		
Capital Goods	10.61	
TOTAL	1,212.21	842.74

33B Expenditure in Foreign Currency on accout of:

	Year ended March 31, 2026	Year ended March 31, 2025
a) Royalty, know how, professional, consultation fees, interest and other matters	3.73	4.31
b) Travelling		
TOTAL	3.73	4.31

33C Value of Imported and Indigenous material consumed & percentage there of:


	Year ended March 31, 2026		Year ended March 31, 2025	
	Value	%	Value	%
Value of Imported material consumed	1,080.88	22.87%	1,030.27	13.93%
Value of Indigenous material consumed	3,644.66	77.13%	6,368.35	86.07%
TOTAL	4,725.55	100.00%	7,398.62	100.00%

33D

	Year ended March 31, 2026	Year ended March 31, 2025
Dividend Remitted in foreign currency		

33E Earning in foreign exchange

	Year ended March 31, 2026	Year ended March 31, 2025
FOB Value of Exports	105.43	207.37
Royalty, know how Professional and consultancy fees		
Interest and dividends		
Other Income		
TOTAL	105.43	207.37



PANCHSHEEL ORGANICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026

34 SEGMENT INFORMATION

The Company's chief operating decision maker (CODM) has identified one business segment viz. Manufacturing and Trading of Bulk Drug and Intermediate. There are no other reportable segment.

GEOGRAPHIC INFORMATION

PARTICULARS	Year ended March 31, 2026		Year ended March 31, 2025	
	Country of domicile (India)		Country of domicile (India)	
	Foreign countries		Foreign countries	
Revenue from External Customers	10,515.68	162.58	10,477.16	240.69

The Company does not hold any non-current assets in foreign countries.

There are no individual customers or a particular group contributing to more than 10% of revenue.

35 RELATED PARTY DISCLOSURES:

35a Names of the related parties and nature of relationship:

i) Enterprises over which KMP exercise significant influence

- Turakhia Brothers
- Invochem Laboratories
- Synodrug & Intermediates
- Panchsheel Bio Tech (Formerly Known as Suneeta Chemicals)
- Gene Biotech Private Limited
- Paramount Organics

ii) Key Management Personnel

- Mahendra A Turakhia- Managing Director
- Kishore A Turakhia- Executive Director
- Rajesh A Turakhia- Executive Director
- Deepak Shah- CFO
- Sonia Verma- CS

iii) Relatives of Key Management Personnel

- Arti K Turakhia- Wife of Director
- Devang R Turakhia- Son of Director
- Amisha M Turakhia- Daughter of Director
- Pallavi M Turakhia- Daughter of Director
- Harsh K Turakhia- Son of Director
- Chandan M Turakhia- Wife of Director
- Paresha R Turakhia- Wife of Director

35b Compensation of key managerial personnel


Related Parties	(Rs.)	
	Year ended March 31, 2026	Year ended March 31, 2025
Remuneration to CEO and Whole Time Director	204.60	192.60
Directors' sitting fees to independent directors	0.22	0.30
CFO	4.99	2.89
CS	7.41	6.84
Total	217.22	202.63

Key Management Personnel Compensation

Gratuity is computed for all the employees in aggregate, the amounts relating to the Key Managerial Personnel cannot be individually identified.

35c Details of Transactions with related Parties:

Particulars	(Rs.)	
	Year ended March 31, 2026	Year ended March 31, 2025
Sales		
Turakhia Brothers	212.88	168.23
Synodrug & Intermediates	-	-
Panchsheel Bio Tech (Formerly Known as Suneeta Chemicals)	86.81	61.78
Invochem Laboratories	0.01	-
Gene Biotech Private Limited	-	-
Purchases		
Turakhia Brothers	10.81	4.01
Synodrug & Intermediates	-	-
Panchsheel Bio Tech (Formerly Known as Suneeta Chemicals)	402.11	276.36
Gene Biotech Private Limited	3.44	0.01
Rent		
Turakhia Brothers	18.59	17.70
Testing Charges		
Invochem Laboratories	15.70	10.15
Turakhia Brothers	-	-
Processing Charges		
Panchsheel Bio Tech (Formerly Known as Suneeta Chemicals)	640.03	809.74
Purchase of Fixed Asset		
Invochem Laboratories	-	-
Gene Biotech Private Limited	73.00	263.89



Salary		
Devang R Turakhia	18.00	18.00
Harsh Turakhia	18.00	18.00
Pallavi M Turakhia	-	-
Amisha M Turakhia	-	-
Chandan M Turakhia	18.00	18.00
Advance		
Panchsheel Bio Agritech Pvt Ltd.	-	73.05

35d Details of outstanding balances with related Parties:

(Rs.)

Related Parties	Year ended March 31,2026	Year ended March 31,2025
Trade Receivables		
Panchsheel Bio Agritech Pvt Ltd.	-	-
Panchsheel Bio Tech (Formerly Known as Suneeta Chemicals)	-	-
Gene Biotech Private Limited	0.01	0.18
Paramount Organics	-	0.15
TOTAL	0.01	0.33
Trade Payables		
Invochem Laboratory	-	-
Gene Biotech Private Limited	-	-
Turakhia Brothers	-	- 0.46
Paramount Organics	0.18	-
Panchsheel Bio Tech (Formerly Known as Suneeta Chemicals)	14.67	33.94
TOTAL	14.85	34.40

Terms and conditions:

All the transactions with the related parties during the year are based on the arms length price and terms that would be available to/from third parties
All outstanding balances are unsecured and repayable on demand

36 FAIR VALUE MEASUREMENTS

(i) Financial instruments by category

There are no financial assets/liabilities that are measured at fair value through other comprehensive income. Category wise break up of financial assets/liabilities measured at amortised cost and fair value through statement of profit and loss account are given below:

(Rs.)

Particulars	As at March 31, 2026		As at March 31, 2025	
	Amortised Cost	FVPL	Amortised Cost	FVPL
Financial Assets				
Investments	0.05	0.01	0.05	0.01
Security deposits (Level 3)	-	-	-	-
Other Advances	-	-	-	-
Deposit with bank and other deposit	3,807.95	-	3,572.09	-
Trade receivables	3,924.96	-	3,479.70	-
Cash and cash equivalents	382.76	-	441.12	-
Loans to employee	22.87	-	18.18	-
Total Financial Assets	8,138.58	0.01	7,511.15	0.01
Financial Liabilities				
Borrowings	564.72	-	543.67	-
Trade payables	1,955.57	-	1,866.84	-
Other current financial liabilities	111.69	-	83.22	-
Total Financial Liabilities	2,631.98	-	2,493.73	-

(ii) Fair value hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level is as follows.

Level 1 : Level 1 hierarchy includes financial instruments measured using quoted prices.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

iii) Fair value of financial assets and liabilities measured at amortised cost

The carrying amounts of Investments, deposits with banks and interest there on, trade receivables, cash and cash equivalents, loans to employees, borrowings, trade payables and other current financial liabilities are considered to be the same as their fair values due to their short-term nature.


The fair values of security deposits and other advances are based on discounted cash flows. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk. Fair value of the security deposit and other advances are considered to be the same as their carrying value.

37 FINANCIAL RISK MANAGEMENT

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk. The Company's focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance. The market risk to the Company is foreign exchange risk and interest rate. The Company's exposure to credit risk is influenced mainly by the individual characteristic of each customer end.

37A CREDIT RISK

Credit risk comprises of direct risk of default, the risk of deterioration of creditworthiness as well as concentration risks. It mainly arises from trade receivables, cash and cash equivalents (excluding cash on hand) and bank deposits.



(i) Credit risk management

a) Trade receivables

The carrying amount of trade receivables represent the maximum credit exposure net of provision for impairment. The maximum exposure to credit risk was Rs. 4511.37 lakhs as of March 31, 2026 (March 31, 2025 : Rs. 3978.58 lakhs).

Trade receivables are derived from revenue earned from customers. Credit risk for trade receivable is managed by the company through credit approvals, establishing credit limits and periodic monitoring of the creditworthiness of its customers to which the company grants credit terms in the normal course of business. The Company's credit period generally ranges from 90-180 days.

The company does not have a high concentration of credit risk to a single customer. Single largest customer have the total exposure in receivables Rs. 266.18 lakhs as of March 31, 2026 (March 31, 2025 : Rs. 742.40 lakhs).

As per simplified approach, the company uses a provision matrix to compute the expected credit loss allowance for trade receivables. The provision matrix takes into account a continuing credit evaluation of company's customers' financial condition; aging of trade accounts receivable and the company's historical loss experience. The company defines default as an event when there is no reasonable expectation of recovery. The company has not made any provision for loss allowance in any of the years presented. Further, alongwith matrix, the company also does individual debtor assessment to compute ECL.

Trade receivables are written off when there is no reasonable expectation of recovery.

b) Cash & cash equivalent and bank deposits

Credit risk on cash and cash equivalents and bank deposits is generally low as the said deposits have been made with banks having good reputation, good past track record and high quality credit rating and company also reviews their credit-worthiness on an on-going basis.

c) Other financial assets

Credit risk on other financial assets is generally considered to be low

37B MARKET RISK

(i) Foreign currency risk

Foreign exchange risk arises on financial instruments being denominated in a currency that is not the functional currency of the entity and that are monetary in nature. The Company is exposed to foreign exchange risk mainly arising from Trade Payables denominated in United States Dollar ('USD') and European Union Currency ('EURO') and Trade receivables in United States Dollar ('USD').

(a) Foreign currency risk exposure:

The Company has not entered into any derivative transactions during the year and there were no derivative transactions outstanding as on March 31, 2026

The Company's exposure to foreign currency risk at the end of the reporting period are as follows

PARTICULARS	As at March 31, 2026			As at March 31, 2025		
	Amount	Foreign currency	Foreign Currency Amount	Amount	Foreign currency	Foreign Currency
(i) Financial assets						
Trade receivables	147.51	USD	1.58	118.77	USD	1.39
(ii) Financial liabilities						
Trade payable	374.42	USD	4.00	76.72	USD	0.90

(b) Sensitivity:

The sensitivity of profit or loss to changes in the exchange rates arises mainly from foreign currency denominated financial instruments is as follows:

PARTICULARS	Impact on Profit after Tax positive/(negative)	
	Year ended March 31, 2026	Year ended March 31, 2025
USD - Sensitivity		
Rs./USD -Increase by 10.15% (March 31, 2026: 0.32%)	(23.03)	0.13
Rs./USD -Decrease by 10.15% (March 31, 2026=: 0.32%)	23.03	(0.13)
#Holding all other variables constant		

(ii) Interest rate exposure

The exposure of the company's borrowing to interest rate changes at the end of the reporting period are as follows :

PARTICULARS	As at March 31, 2026	As at March 31, 2025
Variable rate borrowings	546.89	512.75
Fixed rate borrowings	17.82	30.92
Total borrowings	564.71	543.67

An analysis by maturities is provided in Note 39(C) liquidity risk below.

PARTICULARS	Impact on Profit after Tax positive/(negative)	
	As at March 31, 2026	As at March 31, 2025
Interest rate - increase by 50 basis points	(2.73)	(2.56)
Interest rate - decrease by 50 basis points	2.73	2.56



37C LIQUIDITY RISK

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities (comprising the undrawn borrowing facilities below), by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The liquidity risk is managed by means of the ultimate parent company's Liquidity and Financial Indebtedness Management Policy, which aims to ensure the availability of sufficient net funds to meet the Company's financial commitments with minimal additional cost. One of the main liquidity monitoring measurement instruments is the cash flow projection, using a minimum projection period of 12 months from the benchmark date.

(i) Financing arrangements

The Company has undrawn borrowing facilities of Rs. 103.11 lakhs as at March 31, 2026 (Rs. 137.24 lakhs as at March 31, 2025) which is renewable on yearly basis by mutual consent. Undrawn credit facilities comprises of fund based and non-fund based.

(ii) Maturities of financial liabilities

The following table shows the maturity analysis of the companies financial liabilities based on the contractually agreed undiscounted cash flows as at the Balance Sheet date.


(Rs.)				
CONTRACTUAL MATURITIES OF FINANCIAL LIABILITIES	Less than 6 months	6 months to 1 year	Above 1 Year	Total
March 31, 2026				
Borrowings	279.11	279.11	6.49	564.71
Trade payables	1,760.49	-	195.12	1,955.61
Other financial liabilities	111.68	-	-	111.68
Total Liabilities	2,151.28	279.11	201.61	2,632.00

(Rs.)				
CONTRACTUAL MATURITIES OF FINANCIAL LIABILITIES	Less than 6 months	6 months to 1 year	Above 1 Year	Total
March 31, 2025				
Borrowings	262.92	262.92	17.82	543.66
Trade payables	1,638.87	-	227.96	1,866.83
Other financial liabilities	83.22	-	-	83.22
Total Liabilities	1,985.01	262.92	245.78	2,493.71

38 Security of current assets against borrowings

Disclosure when borrowings have been availed based on security of current assets

Quarter	Name of Bank	Particular of security provided	Amount as per Books of accounts	Amount as reported in quarterly report statement	Difference in amounts	Reason
Quarter 1	Yes Bank Ltd	Inventory	4,474.95	4,473.83	1.12	No major difference
Quarter 2	Yes Bank Ltd	Inventory	4,680.29	4,679.17	1.12	No major difference
Quarter 3	Yes Bank Ltd	Inventory	4,499.87	4,498.75	1.12	No major difference
Quarter 4	Yes Bank Ltd	Inventory	4,507.53	4,507.53	-	No difference

**PANCHSHEEL ORGANICS LIMITED****NOTES TO THE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2026****39 CAPITAL MANAGEMENT**

The company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure of the Company, management can make, or may propose to the stockholders when their approval is required, adjustments to the amount of dividends paid to stockholders, return capital to stockholders, issue new shares or sell assets to reduce, for example, debt.

The Company considers total equity reported in the financial statements to be managed as part of capital.

The Company does not have any borrowing which is subject to the capital requirements.

40 EARNINGS PER SHARE**Rs In Lakhs**

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Profit after tax (Rs. in lakhs)	1,083.04	1,379.45
Weighted average number of shares outstanding for basic EPS (In lakhs)	131.72	131.72
Weighted average number of shares outstanding for diluted EPS (In lakhs)	131.72	131.72
Nominal value per share (In Rs.)	10.00	10.00
Basic earning per Share (In Rs.)	8.22	10.47
Diluted earning per Share (In Rs.)	8.22	10.47

41 LEASES

As a lessee: Operating lease


The Company has operating leases for land and premises. Most of the leases are renewable for further period on mutually agreeable terms.

Rs in Lakhs

With respect to all operating leases:	Year ended March 31, 2026	Year ended March 31, 2025
Lease payments recognised in the Statement of Profit and Loss during the year	22.72	20.25

Transition to New Standards

The Company has elected not to recognise right-of-use assets and lease liabilities for short term leases that have a lease term of less than or equal to 12 months with no purchase option and assets with low value leases. The Company recognises the lease payments associated with these leases as an expense in statement of profit and loss over the lease term. The related cash flows are classified as operating activities.

**42 EXPENDITURE TOWARDS CORPORATE SOCIAL RESPONSIBILITY**

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. The areas for CSR activities are eradication of hunger and malnutrition, promoting education, art and culture, healthcare, destitute care and rehabilitation, environment sustainability, disaster relief, COVID-19 relief and rural development projects. A CSR committee has been formed by the Company as per the Act. The funds were primarily allocated to a corpus and utilized through the year on these activities which are specified in Schedule VII of the Companies Act, 2013:

Particulars	Rs in Lakhs	
	Year ended March 31, 2026	Year ended March 31, 2025
Opening Balance yet to spend	43.89	9.82
Gross amount required to be spent by the Company during the year (Provision)	38.28	34.07
Total amount to spend	82.17	43.89
Amount spent during the year on:		
i) Construction / acquisition of asset	-	-
ii) On purposes other than (i) above	50.00	-
Total amount spent	50.00	-
Amount yet to spend	32.17	43.89

Consequent to the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021, the Company intends to transfer its unspent CSR fund to a designated bank account opened with Yes Bank Limited during previous year.

- 43 Figures for the corresponding previous years have been regrouped/ rearranged, wherever necessary, to conform to the classification of the current year.

For Panchsheel Organics Limited

For Jayesh R Shah & Co
Chartered Accountants
Firm Registration No. : 104182W

Mahendra Turakhia
Chairman &
DIN: 00006222

Kishore Turakhia
Director
DIN: 00006236

Kruti H Doshi
Partner
Membership No.: 605915
Place: Mumbai
Date: May 30, 2026

Rajesh Turakhia
Director
DIN: 00006246

Deepak Shah
Chief Financial Officer

Sonia Verma
Company Secretary

Place: Mumbai
Date: May 30, 2026



PANCHSHEEL ORGANICS LIMITED

Note 44

Sr no	Ratio Analysis	Numerator	Denominator	25-26		24-25		Ratio		% Changes
				Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	25-26	24-25	
1	Current Ratio	Current assets	Current Liabilities	8954.51	2636.00	8872.92	2427.64	3.40	3.65	-7%
2	Debt Equity Ratio	Total Liabilities	Shareholder's Equity	564.72	14083.22	543.67	13386.19	0.04	0.04	-1%
3	Debt Service Coverage Ratio	EBITDA	Interest+Principal	1704.44	589.07	2066.75	581.09	2.89	3.56	-19%
4	Return on Equity Ratio (in %) ^a	Profit for the period	Avg. Shareholders Equity	1118.53	13734.70	1304.20	12944.83	0.08	0.10	-19%
5	Inventory Turnover Ratio	Cost of Goods sold	Average Inventory	7166.14	2026.84	6818.87	1814.11	3.54	3.76	-6%
6	Trade Receivables Turnover Ratio	Net Credit Sales	Average Trade Receivable	10678.26	3702.33	10717.84	3534.95	2.88	3.03	-5%
7	Trade Payables Turnover Ratio	Total Purchases	Average Trade Payables	9204.01	1911.20	8978.60	2124.29	4.82	4.23	14%
8	Net Capital Turnover Ratio	Net Sales	Average Working Capital	10678.26	6381.90	10717.84	6886.03	1.67	1.56	8%
9	Net Profit Ratio (in %)	Net Profit	Net Sales	1118.53	10678.26	1304.20	10717.84	0.10	0.12	-14%
10	Return on Capital employed	EBIT	Capital Employed*	1448.99	14557.14	1813.02	13900.42	0.10	0.13	-24%
11	Return on Investments	Return/Profit/Earnings	Investment	257.29	3690.08	307.29	3227.25	0.07	0.10	-27%

* Capital Employed is equal to Total assets - Current Liabilities

Return on investment has reduced due to fluctuation in market rates

In terms of our report of even date

For Panchsheel Organics Limited

For Jayesh R Shah & Co
Chartered Accountants
Firm Registration No. : 104182W

Mahendra Turakhia
Chairman &
Managing Director
DIN: 00006222

Kishore Turakhia
Director
DIN: 00006236


Kruti H Doshi
Partner
Membership No.: 605915
Place: Mumbai
Date: May 30, 2026

Rajesh Turakhia
Director
DIN: 00006246

Deepak Shah
Chief Financial Officer

Sonia Verma
Company Secretary

Place: Mumbai
Date: May 30, 2026

[illegible]

